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PSyChodeRMaTology
Chronic skin conditions are very common and are reported to be one of the leading 
causes of nonfatal disease burden [1–4]. As there is no permanent cure, patients have 
to cope with the consequences of their chronic skin condition for the rest of their lives. 
Chronic inflammatory skin conditions such as acne, atopic dermatitis, and psoriasis are 
known for their large impact on daily life, and lowered levels of physical and psychologi-
cal functioning [2, 5, 6]. One of the most common chronic inflammatory skin conditions 
is psoriasis, with an estimated prevalence of 1.6% in the Netherlands [4], and worldwide 
prevalence rates ranging from 0.5% to 11.4% [7]. Psoriasis is a chronic, immune-mediated 
inflammatory skin condition typically characterized by red and scaly plaques on the skin 
[8]. Its severity can range from just a few marks to plaques covering almost the entire 
body surface. One of the most frequent complaints in psoriasis is itch, which is experi-
enced by an estimated 60-80% of patients [9–11]. Other frequently occurring symptoms 
include fatigue, experienced by over half of all patients [10], and pain, experienced by 
25-43% of patients [10, 12]. The condition can occur at any age, and its cause is still not 
fully understood. While psoriasis used to be viewed as a condition limited to the skin 
and joints, accumulating evidence shows that psoriasis is a systemic condition associ-
ated with increased risk for comorbidity such as cardiovascular conditions, stroke, and 
diabetes mellitus [13–15]. Moreover, the psychosocial impact of chronic skin conditions 
is substantial.
Psychodermatology refers to the field of research and medicine that involves the 
complex interaction between psychological factors and the skin [16]. Although the field 
has been in existence for several decades [e.g., 17], research to date has been relatively 
limited and psychodermatology is still considered ‘upcoming’ [18]. One of the most fre-
quent topics that psychodermatological research has focused on to date is the increased 
risk for psychological problems in patients with chronic skin conditions. Given that the 
skin is the largest organ of the body and one of the first things we notice about another 
person, having a visible skin condition such as psoriasis can have a major impact on 
psychological and social functioning. Aspects of the psychosocial burden of chronic skin 
conditions include impairments in psychological functioning [5, 19], social functioning 
[20], quality of life [21, 22], work productivity [23, 24], body image [25], sleep quality [14, 
26], sexual functioning [27], and perceived stigmatization [28–31]. An estimated 30-40% 
of patients with chronic skin conditions are at risk for long-term adjustment problems, 
such as symptoms of anxiety or depression [32, 33]. For example, in a recent large-scale 
study across 13 European countries, a significantly higher prevalence for clinical depres-
sion, anxiety, and suicidal ideation was found in patients with psoriasis than in controls 
[5]. The burden of the condition is often not limited to the patients themselves, but may 
also affect their significant others. In one study, relatives of patients reported social 
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disruptions (55%) limitations to holiday plans and leisure activities such as sports and 
evenings out (44%), and negatively affected close relationships (37%) [34].
The psychosocial impact of chronic skin conditions, and particularly psychosocial 
distress, are not only consequences of living with a chronic skin condition such as 
psoriasis; they also play a significant role in its exacerbation. Psychosocial distress has 
been indicated as a trigger in various inflammatory skin conditions, including psoriasis 
[35–38], atopic dermatitis [39], and acne vulgaris [40, 41]. This relationship between 
distress and disease exacerbation has been demonstrated in prospective studies, which 
showed that peak levels of psychological distress could predict increased disease sever-
ity a month later [35–38]. Individual cognitive and behavioral reactivity factors may play 
a role in the impact of psychosocial distress on disease severity, as patients with high 
levels of worrying and scratching seem particularly vulnerable to the influence of daily 
stressors at moments of high stress [37]. Similarly, excessive worrying has been related 
to impaired dermatological treatment success [42]. The mechanisms underlying the 
influence of distress on inflammatory disease processes in chronic skin conditions such 
as psoriasis remain largely unknown, but are likely to involve an altered functioning of 
the Hypothalamic-Pituitary-Adrenal (HPA) axis and the Sympathetic Adrenal Medullary 
(SAM) system, combined with the release of nerve-related factors from peripheral sen-
sory nerves [43]. The typically symmetrical pattern of psoriasis lesions provide further 
indications that the nervous system may be involved [44]. There may also be behavioral 
pathways contributing to disease severity. For example, psychological factors such as 
depressed mood have been found to be related to impaired dermatological treatment 
adherence [45] and unhealthy lifestyle behavior [46, 47]. Given that patients with psoria-
sis are already at increased risk for unhealthy lifestyle behavior such as excessive drink-
ing, smoking, and overeating [48–50], psychological distress may additionally enhance 
these behavioral patterns and negatively impact patients’ overall health.
To summarize, having a visible chronic skin condition such as psoriasis may result in 
significant distress and psychosocial burden for patients, and this distress and burden 
in itself may be an exacerbating factor in chronic inflammatory skin conditions, increas-
ing flare-ups and the length of time until disease clearance. This process can over 
time become a vicious, self-perpetuating cycle. In order to help break this cycle, it is 
important to advance research in the field of dermatology by examining new concepts 
of relevance to disease management of these conditions, by developing new methods 
to assess relevant aspects of the psychosocial impact of chronic skin conditions, and by 
examining the (cost-)effectiveness of new treatments to reduce the impact of chronic 
skin conditions on daily life.
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PSyChodeRMaTology 2.0: TowaRdS BReakIng The VICIouS CyCle
There are several areas that have remained relatively unexplored in previous research 
in psychodermatology. First, new concepts of relevance to disease management should 
be examined. Disease management, such as dermatological treatment adherence, is 
generally suboptimal in chronic skin conditions [51–53], despite the fact that adequate 
adherence and self-care is of utmost importance to ensure that patients benefit 
optimally from their treatment. Therefore, in Part I of this thesis, we will examine new 
concepts in psychodermatology that may play a role in patients’ adherence and self-
care behavior, namely aspects of body awareness. Second, new assessment methods 
in psychodermatology are needed to examine relatively unexplored implicit aspects of 
the psychosocial impact of chronic skin conditions, such as perceived stigmatization. 
Therefore, in Part II of this thesis, both direct and indirect assessment methods will be 
used to assess stigmatization-related implicit bias, as well as predictors of perceived 
stigmatization, in patients with chronic skin conditions. Third, new evidence-based 
interventions are needed to target the overall impact of chronic skin conditions in daily 
life. This is important not only to improve patients’ psychological functioning, but also 
to prevent disease exacerbation, as illustrated above. Therefore, in Part III of this thesis, 
the effectiveness and cost-effectiveness of therapist-guided internet-based cognitive 
behavioral treatment (ICBT) will be examined in patients with psoriasis.
ConCePTS 2.0: The Role of Body awaReneSS In ChRonIC SkIn CondITIonS
Disease management of chronic skin conditions such as psoriasis often relies heavily on 
self-care, as the majority of patients have to apply topical treatments on a regular basis 
to prevent deterioration of their skin lesions. This can take up a considerable amount 
of patients’ time each day [54, 55] and can have a substantial impact on their daily lives 
[56]. While adherence to dermatological treatment and adequate self-care behavior 
(e.g., applying topical treatments) is essential for effective disease management, adher-
ence is often found to be poor [51–53]. A prerequisite for adequate self-care may be that 
the patient is sufficiently aware of bodily signals (e.g., dry or itchy skin) that indicate that 
self-care is required. Therefore the concept of body awareness, which can be defined as 
an attentional focus on, and awareness of, bodily signals [57], may be especially relevant 
in patients with psoriasis. Theoretically, a distinction needs to be made between body 
awareness and concepts such as somatosensory amplification, in which individuals 
show a hypervigilance toward bodily signals, and a catastrophizing interpretation of 
these signals [58]. This concept differs from body awareness with regard to the focus-
ing style involved: body awareness encompasses a non-evaluative focusing style, while 
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somatosensory amplification clearly has an evaluative (typically negative) component 
consisting of attributing threatening characteristics to regular bodily signals [58, 59]. In 
contrast to somatosensory amplification, body awareness is considered to be an adap-
tive characteristic (e.g., enhancing alertness and recognition of bodily signals that are 
relevant for disease management in chronic skin conditions).
Despite the potential relevance of body awareness for chronic skin conditions, no stud-
ies to date have assessed body awareness in a dermatological population, nor have its 
associations with physical and psychological functioning been examined in this group. 
Given that body awareness may be an important prerequisite for adequate self-care, 
patients who show impaired body awareness (such as not recognizing bodily signals, or 
ignoring them) may be at risk for impaired physical and psychological functioning. For 
this reason, the assessment of aspects of body awareness in chronic skin conditions, and 
their associations with physical and psychological functioning, are studied in Part I of 
this thesis.
MeThodS 2.0: exPlICIT and IMPlICIT MeaSuReS of PeRCeIVed STIgMaTIzaTIon
An important aspect that differentiates the psychosocial impact of skin conditions from 
that of many other chronic somatic conditions is the effect that skin conditions can 
have on patients’ appearance. A chronic skin condition such as psoriasis, for instance, 
can cause thick, red, scaly marks, and the visibility of these lesions can have a profound 
effect on the way patients experience social interactions. Patients with skin conditions 
commonly report negative social experiences, for example people staring at them, mak-
ing negative remarks, avoiding contact with them, or even requesting them to leave 
public places [29, 60, 61]. These accounts are examples of stigmatization, which can be 
defined as an awareness of social disapproval, discrediting, or devaluation based on an 
attribute or physical mark [62]. These experiences likely originate from common miscon-
ceptions and negative prejudices due to a lack of knowledge about the condition, such 
as believing that the condition is contagious [63]. A recent study demonstrated that 50% 
of participants from the general population reported discriminatory behavior towards 
people with the chronic skin condition psoriasis, including a reluctance to shake hands 
or kiss on the cheek in greetings, to maintain friendships or to have sexual relations 
with individuals with the condition [63]. Perceived stigmatization is increasingly recog-
nized as a common and disabling disease-related stressor in chronic skin conditions. 
Stigmatizing experiences, or the anticipation of such experiences, can lead to feelings 
of shame, social anxiety, and avoidance of social situations [31, 64–67]. Furthermore, 
stigmatization has been found to have a substantial impact on patients’ daily lives and 
to contribute significantly to disability and depression [31, 65, 68]. Although research is 
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accumulating, little is known about vulnerability factors for stigmatization in patients 
with chronic skin conditions. More knowledge about the intra-individual characteristics 
associated with higher levels of perceived stigmatization could provide important input 
for the development of screening and intervention procedures.
Another topic that warrants further attention is whether the stigmatization experience 
is also reflected in implicit processes, and how these potential stigmatization-related 
implicit biases may be assessed in patients with chronic skin conditions. Perceived stig-
matization is traditionally measured using self-report questionnaires. When patients fill 
out a questionnaire to self-assess perceived stigmatization, this is a conscious, direct, and 
reflective process: patients have an idea of what is being assessed and provide answers 
based on their conscious experiences. Although this type of direct assessment can pro-
vide valuable information about patients’ experiences, it can also lead to socially desir-
able responses [69]. Furthermore, there may be aspects of the stigmatization experience 
that cannot be assessed by questionnaires, such as more or less automatic reactions that 
occur reflexively. Such automatic reactions can be assessed by indirect tasks that provide 
implicit measures of stigmatization-related bias. Dual-process models and related re-
search in other conditions suggest that these automatic reactions influence information 
processing and social behavior at least as strongly as conscious and reflective processes 
[70]. Furthermore, previous studies have shown that implicit biases can be found in vari-
ous physical conditions [71–73], and retraining these biases may be a promising way to 
enhance the effectiveness of current psychological interventions [73–76].
Although research on implicit processes in chronic skin conditions is scarce, there 
are indications that patients with psoriasis show an attentional bias to words related 
to skin symptoms and social threat [77]. Similarly, increased attentional focus on skin 
symptoms has been found in people with acne: an eye tracking study showed that, 
when presented with pictures of faces with acne lesions, people with acne gazed more 
at these lesions than did healthy controls [78]. A skin-related behavioral bias has also 
been found in people suffering from chronic skin picking: they displayed greater distrac-
tion and avoidance of pictures of skin irregularities than did controls [79]. Indications of 
biases for stimuli related to social threat and disgust have also been found, for example 
in a previous study demonstrating an attentional bias to social threat in patients with 
psoriasis [77]. Furthermore, a functional magnetic resonance imaging (fMRI) study 
showed that patients with psoriasis had diminished insular cortex activity in response 
to pictures of disgusted faces, possibly due to an avoidance-based coping mechanism 
[80]. Taken together, these preliminary findings of skin-related and social threat-related 
biases suggest that the impact of having a skin condition may be reflected in reflexive, 
more or less automatic, cognitive and behavioral reactions.
Studies examining methods for assessing implicit biases in chronic skin conditions 
can establish whether implicit biases in chronic skin conditions are present. These 
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methods that assess stigmatization-related cognitive and behavioral bias in chronic 
skin conditions may also provide promising starting points for innovative interventions 
that comprehensively target the problem from different angles by incorporating both 
explicit and implicit aspects of stigmatization. Furthermore, examining implicit biases 
in several chronic skin conditions will enable us to compare potential differences and 
similarities in implicit biases across conditions. Lastly, chronic skin conditions may also 
have a substantial impact on the lives of patients’ significant others [34], and the stigma 
of chronic skin conditions may extend to these significant others due to a process called 
courtesy stigma [62, 81], making it worthwhile to examine whether implicit stigmatiza-
tion-related biases are also present in patients’ significant others.
Part II of this thesis will examine the concept of perceived stigmatization using both 
explicit and implicit measures. First, we study predictors of perceived stigmatization; 
such predictors can assist in screening and in developing interventions. Second, we 
examine whether implicit stigmatization-related biases are present in patients with 
chronic skin conditions. To enable us to compare differences and similarities in implicit 
stigmatization-related biases across conditions, we performed this study in two groups 
of patients with chronic skin conditions, patients with psoriasis and patients with 
alopecia, and compared both groups with healthy controls. Furthermore, significant 
others of both patient groups also participated in the study, allowing us to examine 
whether stigmatization-related biases can also be identified in patients’ significant 
others.
TReaTMenT 2.0: InTeRneT-BaSed CognITIVe BehaVIoRal TReaTMenT
Although previous research in psychodermatology clearly underlines the substantial 
psychosocial impact and increased risk for psychological problems in patients with 
chronic skin conditions, there is still a relative lack of studies on the effectiveness of 
psychological interventions to target these problems. The studies that have been con-
ducted show that there is currently very limited evidence for the effectiveness of purely 
educational interventions in patients with chronic skin conditions [82]. Psychological 
interventions with components of cognitive behavioral therapy (CBT) and habit reversal 
seem more promising, as in a meta-analysis of psychological interventions for chronic 
skin conditions the largest effects were found for these types of interventions. In this 
meta-analysis, based on relatively few studies, overall moderate effects were found for 
the impact of psychological interventions on disease severity, itching/scratching, and 
psychosocial outcomes [83]. When we examine the evidence specifically for psoriasis, 
CBT-based interventions currently show the most promising effects on psychosocial 
functioning and disease severity [84, 85].
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In order to increase access to CBT-based interventions and potentially decrease 
societal costs, interventions are increasingly being offered online (internet-based CBT; 
ICBT). There are several potential benefits to these online treatments, for patients as 
well as for care providers. For patients, ICBT may offer advantages in terms of flexibil-
ity and time/cost reductions: there is no need to travel for face-to-face consultations, 
which saves both time and costs, and no need for face-to-face consultations during 
working hours: patients can determine for themselves when and where they would 
like to invest time in their treatment [86–88]. In addition, it may be easier for patients 
to implement what they have learned from ICBT in their own environment, considering 
that the intervention already takes place in their own personal environment and not 
in a doctor’s office. Furthermore, some patients may find it easier to share personal 
matters from the comfort of their home as a safe environment [89]. Last, ICBT may 
save a considerable amount of therapist time. Therapist guidance in ICBT is often less 
time-intensive than in face-to-face consultations [86–88], and therapists can be more 
flexible in the way they allocate their time, which makes it a promising treatment in 
terms of cost-effectiveness.
While systematic reviews and meta-analyses have shown the effectiveness of ICBT in 
patients with chronic somatic conditions [90–93], there is a lack of a disease-transcending 
overview and meta-analysis of the overall effects of ICBT on different relevant outcomes 
in patients with chronic somatic conditions. Furthermore, to date no studies have been 
published on the effects of therapist-guided ICBT in patients with chronic skin condi-
tions. To our knowledge only one randomized controlled trial has examined the effects 
of unguided ICBT in psoriasis, with promising effects on anxiety and quality of life [94].
Therapist guidance and personalized care have both been shown to be possibly 
relevant to optimize ICBT treatment effects. Previous research has shown that increased 
therapist guidance is associated with increased effects and decreased dropout rates 
[95–97]. The effects of tailoring ICBT interventions are currently less established, al-
though initial studies are promising [98–101]. Internet-based interventions have often 
adopted a standardized ‘one-size-fits-all’ approach, in which all participants receive the 
same intervention, usually based largely on self-help and including minimal therapist 
support [87]. These types of interventions may serve well for patients with relatively 
minor complaints and have advantages from a societal perspective, as they can be dis-
seminated to large numbers of people at relatively low cost. However, the effects of these 
programs are often quite modest and adherence can be low [e.g., 102]. Furthermore, 
they may not be suitable for patients with more complex complaints and co-morbidity.
In order to offer each patient the best fitting care, internet-based interventions could 
be organized in a stepped care model, offering less intensive self-help interventions to 
patients with minimal adjustment problems or for prevention of future problems [103]. 
For patients with more moderate to severe adjustment problems, offering tailored in-
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terventions with therapist guidance could increase intervention effectiveness by taking 
into account the large inter-individual differences in disease characteristics, personal 
characteristics, and psychological comorbidity [103]. Furthermore, internet-based in-
terventions may be a cost-effective approach from a societal perspective; they have 
previously been shown to be cost-effective for a range of conditions, when compared 
with, for example, wait-list, care as usual, unguided interventions, and face to face CBT 
[104]. However, the effectiveness and cost-effectiveness of internet-based therapist-
guided ICBT for patients with chronic skin conditions have not been examined to date 
for patients with chronic skin conditions. Therefore, in Part III of this thesis, we examine 
the overall effectiveness of guided ICBT for patients with chronic somatic conditions, as 
well as the effectiveness and cost-effectiveness of an individually tailored and therapist-
guided ICBT approach in patients with psoriasis.
aIMS and ouTlIne of The TheSIS
To summarize, this thesis aims to expand the current literature in psychodermatology, by 
examining 1) new concepts in psychodermatology, specifically aspects of body aware-
ness that may be related to physical and psychological functioning; 2) new methods 
in psychodermatology, specifically both explicit and implicit methods to assess the 
stigmatization experience; and 3) new psychological treatment methods in psychoder-
matology, specifically the (cost-)effectiveness of ICBT for patients with psoriasis.
In Part I (Concepts 2.0), we examine the assessment of aspects of body awareness in 
patients with psoriasis, as well as the relationship between impairments in body aware-
ness and reduced physical and psychological functioning (Chapter 2).
In Part II (Methods 2.0), we investigate predictors of self-reported perceived stigma-
tization in a large cross-sectional study in patients with psoriasis in Chapter 3. Further-
more, in Chapter 4, we examine the use of implicit measures to assess attentional and 
behavioral bias to stigmatization-related stimuli in patients with psoriasis and alopecia, 
as well as in their significant others.
In Part III (Treatment 2.0), we assess the effectiveness of internet-based interventions 
in reducing the impact of chronic conditions in daily life. First, we establish the state of 
the art in guided internet-based cognitive behavioral treatment (ICBT) for patients with 
chronic somatic conditions by conducting a meta-analytic review of randomized con-
trolled trials (Chapter 5). Next, we present the results of a randomized controlled trial 
on the effectiveness, for patients with psoriasis, of individually tailored therapist-guided 
ICBT in comparison with regular dermatological care (Chapter 6). Last, we undertake a 
cost-effectiveness analysis to examine whether the clinical benefits of this intervention 
outweigh the costs to society (Chapter 7).
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To conclude this thesis, a summary of results is provided in Chapter 8, and the 
theoretical and clinical implications of our findings and directions for future research 
are discussed in the context of current knowledge in Chapter 9.
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aBSTRaCT
A certain level of attention to bodily signals may be adaptive in the management of 
chronic skin conditions, as a lack of attention may lead to inadequate self-care behavior 
and, consequently, may affect functioning and treatment outcomes. The purpose of this 
study was to develop a body awareness questionnaire and to investigate its psycho-
metric properties and physical and psychological correlates in a cross-sectional study in 
patients with psoriasis (n = 475). The 16-item Body Attention, Ignorance and Awareness 
Scale demonstrated a 3-factor structure that could be interpreted as body ignorance, 
body attention, and body awareness (Cronbach’s α of .73, .74, and .68, respectively). 
Higher body ignorance was significantly related to more physical symptoms and worse 
psychological functioning. Body attention and body awareness showed small significant 
correlations with coping and personality. Given the negative influence of impaired psy-
chological functioning on treatment outcomes, it may be clinically important to screen 
for these constructs of body awareness in chronic skin conditions.
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InTRoduCTIon
Having a chronic skin condition can have negative consequences for physical as well as 
psychological wellbeing [1–4]. One of the major problems that patients have to cope 
with is itch, which accompanies the majority of dermatological diseases [5–10]. The 
prevalence of itch ranges from 50% up to 92% in patients with chronic skin conditions 
[6–10]. Physical symptoms such as itch are known to significantly affect patients’ quality 
of life [5–7] and are associated with emotional distress [5, 7, 9, 10]. In order to manage 
their chronic skin condition, patients are often required to take an active role in their 
treatment; the majority of patients need to use topical treatments on a regular basis 
to prevent deterioration. As better treatment adherence generally results in greater 
improvement, adequate self-care behavior is very relevant in these patients [11]. In 
order to respond to symptoms of the skin condition with appropriate self-care behavior, 
patients should be aware of the bodily signals that indicate that self-care is required. 
Thus, the way in which people pay attention to and interpret bodily signals, which is 
an important aspects of body awareness, may be relevant, especially in patients with 
chronic skin conditions.
Body awareness can be defined as an attentional focus on, and awareness of, body 
sensations [12]. In previous research, heightened body awareness has been viewed 
mainly as a mechanism that may be detrimental to health and wellbeing [13, 14] as 
it may lead to excessive worrying about physical symptoms and somatizing thoughts. 
These findings originated partly from findings regarding health anxiety [excessive con-
cern about one’s health; 15] and hypervigilance [heightened attention; e.g., 16] to bodily 
symptoms, both of which are associated with an increased attention to bodily signals, 
high levels of symptom reporting, and negative health outcomes [e.g., 17]. Recently, 
however, an alternative view has emerged that perceives body awareness as an adaptive 
process that may be useful in the management of chronic conditions, as long as body 
awareness involves mindful attentiveness to the present moment and not excessive 
worrying about symptoms [12, 13, 18, 19].
Even though they are different constructs, both alexithymia, which is characterized 
by the inability to identify and verbalize emotions [20], and body awareness show simi-
larities, in the sense that they share a focus on internal awareness processes. Previous 
research has found moderately negative associations between alexithymia and body 
awareness [21–23], suggesting that a lack of ability to identify and verbalize emotions 
may be related to a lack of awareness of physical sensations.
In samples of dermatological patients, a certain level of body awareness may lead to 
patients paying adequate attention to bodily symptoms such as dry skin and, resultantly, 
to taking appropriate action, such as using moisturizing ointments. Subsequently, the 
lack of body awareness, especially, could be detrimental for patients with a chronic 
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skin condition. For instance, patients who do not pick up subtle bodily signals, such 
as dry skin or itch, may not take care of their skin accordingly and thus are less able to 
control their skin condition through adequate skin care. Finally, there are some indirect 
indications that body awareness interventions may have positive effects on wellbeing 
for chronic skin conditions. For instance mindful awareness, which includes elements 
of body awareness, may be of relevance for chronic skin conditions; a brief attention 
intervention focusing on mindful meditation has shown to accelerate the rate of clear-
ance in psoriasis patients undergoing photo(chemo)therapy [24, 25]. Although these 
results are based on a small study in need of replication, they indicate that (mindful) 
aspects of body awareness may play a role in alleviating physical symptoms in chronic 
skin conditions such as psoriasis.
A systematic review examined existing self-report measures for body awareness and 
concluded that they often lacked adequate psychometric properties and were often uni-
dimensional, leaving out key aspects of body awareness [12]. The authors of this review 
recently constructed a new, relatively elaborate measure of body awareness consisting 
of 8 subscales as an alternative [18, 26]. However, this measure does not include items 
regarding a specific lack of attention to, or ignorance of, bodily signals, which is hypoth-
esized to be important in dermatological patient samples. The current study aims to: 
(i) assess a conceptualization of body awareness including ignorance of bodily signals 
in psoriasis patients by means of a new brief scale suitable for dermatological patient 
groups; and (ii) examine its psychometric properties and correlations with measures of 
physical and psychological functioning, personality characteristics, coping, and illness 
cognitions.
MaTeRIalS and MeThodS
Participants and procedure
In order to prevent selection bias, patients were recruited from both academic (Radboud 
university medical center, Nijmegen, the Netherlands) and non-academic (Canisius-
Wilhelmina Hospital, Nijmegen; Rijnstate Hospital, Velp; Ziekenhuis Groep Twente, 
Almelo, the Netherlands) hospitals, as well as from the Dutch Psoriasis Association. 
Inclusion criteria were: a minimum age of 18 years and a dermatologist-confirmed 
psoriasis diagnosis. Exclusion criteria were: illiteracy, pregnancy, presence of other 
physical conditions that had a larger perceived impact on the daily life than psoriasis, 
presence of psychiatric comorbidity [according to the Diagnostic and Statistical Manual 
of Mental Disorders; 27] and/or current psychological treatment. The study protocol was 
approved by the regional medical ethics committee and written informed consent was 
obtained from each participant. The current study was part of a larger study examining 
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the effectiveness of E-health cognitive behavioral therapy for patients with psoriasis, 
and made use of questionnaires that were assessed as part of the screening procedure. 
All participants who completed questionnaires in the period March 2010 - May 2013 
were included. The resulting sample size of 475 can be considered (highly) sufficient ac-
cording to often-cited sample size guidelines for factor analysis [28]. Sociodemographic 
characteristics of participants are shown in Table 1. Participants’ mean ± SD age was 
52 ± 13 years and gender was approximately evenly distributed (56% male). Disease 
severity was mild to moderate [29]. Approximately half of our sample (46%) reported 
medical conditions in addition to psoriasis, of which 32% indicated more than one other 
medical condition. Most commonly reported conditions were: rheumatic disease (100 of 
220 patients; 45%), high blood pressure (n = 27; 12%), heart disease (n = 28; 13%), lung 
disease (n = 26; 12%), diabetes (n = 26; 12%), chronic back/muscle/tendon pain (n = 21; 
9.5%), skin disease besides psoriasis (n = 20; 9%), and thyroid disease (n = 14; 6%).
Table 1. Sociodemographic characteristics of the study population (n = 475)
Characteristics
Sex, n (%)
Male 266 (56)
Female 209 (44)
Age, (years), mean ± SD (range) 52.08 ± 13.06 (18-84)
Marital status, n (%)
Single 56 (12)
Married/ living together 380 (80)
Divorced 22 (5)
Widowed 17 (4)
Educational level, n (%)
Primary education 72 (15)
Secondary education 226 (48)
Tertiary education 175 (37)
Missing 2 (0.4)
Disease severity (SAPASI), mean ± SD (range) 5.12 ± 4.03 (0-33)
Disease duration (years), mean ± SD (range) 16.00 ± 14.95 (0-64)
Note. SAPASI = Self-Administered Psoriasis Area and Severity Index.
Item generation and scale construction
Based on a review of the literature, an item pool was generated with (adjusted) items 
of the following questionnaires: Bermond-Vorst Alexithymia Questionnaire [BVAQ; 
20], Toronto Alexithymia Scale [TAS-20; 30], Body Awareness Questionnaire [BAQ; 31], 
Kentucky Inventory of Mindfulness Skills [KIMS; 32], Mindful Attention Awareness Scale 
[MAAS; 33] and Amplification Questionnaire [APQ; 34]. Items were adjusted to suit the 
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revised conceptualization of body attention and ignorance [12]. For instance, suitable 
items from the identifying, analyzing, and verbalizing dimensions of the alexithymia 
questionnaires were rephrased to reflect (a lack of ) body awareness instead of a lack 
of emotional awareness (e.g., “I don’t know what’s going on inside my body” instead 
of “I don’t know what’s going on inside me” [TAS-20]). In four cases, original items 
were used. Initial item selection was conducted by three medical psychologists with a 
research and/or clinical focus on psychodermatology. The resulting item pool was sent 
to five other clinicians and researchers involved in the field of psychodermatology and 
to three patients involved in patient participation for dermatological research, with the 
instruction to evaluate the items on relevance, clarity and readability. This process led 
Table 2. Rotated factor loadings of the 3-factor solution for the Body Attention, Ignorance and Awareness 
Scale (BAIAS)
Items Body
Ignorance
Body
attention
Body
awareness
factor I
1. I do not know what is happening inside my bodya 0.68 -0.05 0.00
2. When I am not feeling well physically, I do not know the reasonb 0.64 0.17 0.10
3. I have physical sensations that I can’t quite identifya 0.63 -0.22 0.02
4. I do not know what is going on in my bodyb 0.62 0.16 -0.16
5. I am often confused about what I observe in my bodya 0.62 -0.11 -0.14
6. I find it difficult to describe my physical sensationsb 0.59 0.23 0.09
7. I tend not to notice feelings of physical tension or discomfort until 
they really grab my attentionc
0.55 0.19 0.17
factor II
8. I notice changes in my body, such as whether my breathing slows 
down or speeds upd
-0.04 0.72 0.12
9. I notice when my physical sensations are beginning to changed 0.17 0.69 0.17
10. I pay attention to whether my muscles are tensed or relaxedd 0.03 0.67 0.19
11. I know in advance when I am getting the flue 0.02 0.66 0.10
12. I know I am running a fever without taking my temperaturee 0.08 0.65 0.09
factor III
13. I think that you should pay attention to your bodyb 0.01 0.05 0.76
14. When my body feels tense, I want to know where this feeling 
comes fromb
-0.11 0.08 0.68
15. In general I pay attention to my physical sensationsd 0.21 0.31 0.68
16. It is important that you are aware of your bodya 0.01 0.28 0.64
% of variance explained 23.0 16.0 8.4
Note. Item adapted from: aTAS-20 (Toronto Alexithymia Scale), bBVAQ (Bermond-Vorst Alexithymia Ques-
tionnaire), cMAAS (Mindful Attention Awareness Scale), dKIMS-obs (Kentucky Inventory of Mindfulness 
Skills – observe subscale), eBAQ (Body Awareness Questionnaire). Factor loadings ≥ 0.55 printed in bold.
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to a 23-item scale comprising 14 indicative (positively formulated) and nine contra-
indicative (negatively formulated) items (Table 2). Respondents were asked to indicate 
on a 4-point Likert scale to what extent they agree with each statement (1 = not at all, 2 
= somewhat, 3 = to a large extent, 4 = completely).
Measures of physical and psychological functioning
The following commonly-used and well-validated self-report questionnaires were used 
to examine correlations of body awareness with physical and psychological functioning 
and provide first indications of construct validity:
Physical and psychological wellbeing
The Impact of Chronic Skin Disease on Daily Life [ISDL; 35] was used to measure physi-
cal functioning (itch, pain, and scratching behavior). Symptoms of itch were assessed 
by means of a 4-item subscale measuring the intensity and duration of itch during 
the past 4 weeks (Cronbach’s α in current study = .92). The answers are indicated on a 
4-point Likert scale (ranging from “not at all” to “completely”) and higher scores indicate 
higher levels of itch. Pain was assessed on a 10-point VAS scale (0 = no pain, 10 = worst 
pain ever experienced). Scratching behavior was assessed with 2 subscales: a 3-item 
conscious scratching subscale that assesses the frequency and duration of scratching 
behavior (Cronbach’s α = .79) and a 3-item automatic scratching subscale that evalu-
ates scratching behavior to non-itching stimuli and scratching in the absence of itch or 
without being aware of it (Cronbach’s α = .71). In both scales, higher scores reflect more 
scratching behavior.
The 8-item fatigue subscale of the Checklist Individual Strength [CIS; 36] was used 
to assess fatigue. The subscale consists of 8 items that are responded to on a 7-point 
Likert scale (ranging from “yes, that is true” to “no, that is not true”), with higher scores 
reflecting more fatigue (Cronbach’s α = .94).
The Self-Administered Psoriasis Area and Severity Index [SAPASI; 37] was used to as-
sess disease severity. On anterior and posterior silhouettes, patients mark the areas that 
are currently affected by psoriasis. Below the silhouettes, patients can note the redness, 
thickness, and scaliness of their psoriasis on 3 analogue scales. Scores on the SAPASI can 
range from 0 (complete remission) to 72 (most severe psoriasis). The SAPASI has shown 
good reliability and validity [37, 38].
The Dermatology Life Quality Index [DLQI; 39] is a dermatology-specific instrument 
used to measure quality of life. The questionnaire assesses the impact of chronic skin 
conditions on several physical, psychological, and social aspects of daily life. It consists 
of 10 items that are responded to on a 4-point scale (ranging from “very much” to “not at 
all”). Higher scores reflect poorer quality of life (Cronbach’s α = .85).
34 Chapter 2
The Hospital Anxiety and Depression Scale [HADS; 40] was used to assess anxiety (7 
items; Cronbach’s α = .82) and depression (7 items; Cronbach’s α = .80). The questions 
refer to the mood in the last week and they are responded to on a 4-point scale. Higher 
scores reflect higher levels of anxiety and depression.
Coping
Two subscales of the Utrecht Coping List [UCL; 41] were used to assess active coping 
(problem-focused coping, 7 items, Cronbach’s α = .83) and passive coping (avoidance 
strategies, 8 items, Cronbach’s α = .71) related to handling everyday stressful events. 
Respondents answer on a 4-point Likert scale (from “seldom or almost never” to “very 
often/ frequently”). Higher scores reflect a stronger tendency to use that specific coping 
strategy.
Illness cognitions
The Illness Cognition Questionnaire [ICQ; 42] was used to measure illness cognitions 
related to chronic diseases: helplessness (concentration on aversive aspects of the dis-
ease), acceptance (positive adaptation to chronic illness with emphasis on decreasing its 
negative aspects), and perceived benefits (assigning positive meaning to illness). Each 
subscale consists of 6 statements answered on a 4-point Likert scale (from “not at all” to 
“completely”), with higher scores indicating higher levels of the illness cognition. The 
ICQ was found to be highly reliable in the current sample (Cronbach’s α = .88 for each 
scale).
Personality traits
The Eysenck Personality Questionnaire [EPQ; 43] was used to evaluate the personality 
traits neuroticism (Cronbach’s α = .92) and extraversion (Cronbach’s α = .87). It consists 
of 41 items with a dichotomous response format (yes/no), with higher scores reflecting 
higher levels of the personality trait.
Statistical analysis
Exploratory factor analysis (EFA) with Varimax rotation and Kaiser normalization was 
performed to assess the underlying structure of the new questionnaire [44]. Selection of 
the number of factors for the most optimal solution was based on conjunctive criteria 
requiring the eigenvalue of a factor being at least 1.0 and a clear bend in Cattell’s scree 
test [45]. To assess the reliability of the new questionnaire, Cronbach’s α were computed 
for the three scales. To examine associations between body awareness and measures of 
physical and psychological functioning and sociodemographic characteristics, Pearson 
correlation coefficients were computed for measures of physical and psychological 
wellbeing, personality characteristics, coping, illness cognitions, and sociodemographic 
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characteristics. Statistical significance was accepted at p < .05 in two-tailed tests. All 
analyses were performed using Statistical Packages for the Social Sciences version 20.0 
[46].
ReSulTS
The newly developed 23-item questionnaire was sent to 682 psoriasis patients, 475 of 
whom returned the questionnaire (70% response rate). Missing values on this question-
naire were present in 1% of data and were randomly distributed. Missing values were 
present in 1.6% of data in the entire dataset of included questionnaires (excluding the 
DLQI, as this scale was not distributed to the entire sample). Due to their low percent-
age and random distribution, the impact of these missing values is considered to be 
negligible. No cases with extreme values on one or more variables were observed; all 
values were within 3 standard deviations of the mean and all variables were normally 
distributed (skewness and kurtosis < 1.1).
exploratory factor analysis of the Body attention, Ignorance and awareness 
Scale
The 23 items of the original questionnaire were reduced to 16, based on examination 
of item loadings and cross-loadings (i.e. primary factor loadings > 0.50 and at least 0.20 
difference in cross-loadings; six items removed based on these criteria), meaningfulness 
and usefulness for the corresponding factor (one additional item removed). Based on 
these 16 items, three factors were extracted, explaining a total of 47.4% of the variance. 
The resulting questionnaire was termed the Body Attention, Ignorance and Awareness 
Scale (BAIAS). The first component, “Body Ignorance” (not recognizing and/or ignoring 
bodily signals), explained 23.0% of the variance, the second component, “Body Atten-
tion” (being aware of and paying mindful attention to bodily signals), added 16.0% 
and the third component, “Body Awareness” (self-perceived importance of and general 
attitude towards body awareness), added 8.4%.
Body attention, Ignorance and awareness scale: means and associations with 
sociodemographic variables
Based on the above-mentioned components, mean scores on the three scales were 
calculated by adding the scores of the items and dividing them by the total number 
of items of that scale. If more than one-third of the items on one particular scale were 
missing, the mean score of the scale was not calculated. Mean scores on BAIAS scales for 
the total sample, and stratified by age, gender, educational level, and marital status are 
shown in Table 3. Women scored slightly higher than men on Body Awareness (t(469) 
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= –2.61, p < .01), no gender differences were found for the other 2 scales. Patients with 
a higher educational level scored lower on Body Ignorance (F(2,452) = 13.98, p < .001) 
and higher on Body Attention (F(2,452) = 8.78, p < .001) and Body Awareness (F(2,453) = 
3.78, p = .02). No differences according to age group or marital status were found for any 
of the three scales, nor were the subscales of the BAIAS significantly correlated with age 
(continuous scores; p-values ≥ .36).
Table 3. Mean scores on the Body Attention, Ignorance and Awareness Scale (BAIAS), stratified by age, 
gender, education, and marital status
Body Ignorance
(mean ± SD)
Body attention
(mean ± SD)
Body awareness
(mean ± SD)
Total sample 13.59 ± 3.51
(n = 470)
12.32 ± 3.31
(n = 470)
11.61 ± 2.26
(n = 471)
Stratified by age
18-44 13.40 ± 3.45
(n = 127)
12.02 ± 3.35
(n = 127)
11.67 ± 2.17
(n = 126)
45-64 13.49 ± 3.61
(n = 261)
12.52 ± 3.31
(n = 260)
11.54 ± 2.30
(n = 262)
65-84 14.18 ± 3.27
(n = 82)
12.15 ± 3.23
(n = 83)
11.74 ± 2.28
(n = 83)
Stratified by gender
Male 13.76 ± 3.67
(n = 262)
12.35 ± 3.28
(n = 261)
11.37 ± 2.24**
(n = 263)
Female 13.37 ± 3.30
(n = 208)
12.28 ± 3.35
(n = 209)
11.91 ± 2.25**
(n = 208)
Stratified by education
Primary 15.00 ± 2.93***
(n = 71)
10.85 ± 3.42***
(n = 72)
10.93 ± 2.43*
(n = 72)
Secondary 13.82 ± 3.32***
(n = 219)
12.61 ± 3.26***
(n = 218)
11.69 ± 2.29*
(n = 219)
Tertiary 12.59 ± 3.61***
(n = 165)
12.58 ± 3.16***
(n = 165)
11.75 ± 2.13*
(n = 165)
Stratified by marital status
Married /long-term relationship 13.51± 3.53
(n = 398)
12.24 ± 3.21
(n = 399)
11.61 ± 2.22
(n = 400)
Single 14.07 ± 3.42
(n = 71)
12.67 ± 3.79
(n = 70)
11.61 ± 2.52
(n = 70)
*p < .05, **p < .01, ***p < .001.
Reliability and intercorrelations of the Body attention, Ignorance and 
awareness Scale
The internal consistency was satisfactory for the Body Ignorance (α = .73), Body Attention 
(α = .74) and Body Awareness (α = .68) scales of the BAIAS. The subscale Body Attention 
showed a moderate correlation with the subscale Body Awareness (r = .43, p < .001), 
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and the Body Ignorance and Body Attention subscales were slightly, but significantly, 
negatively correlated (r = –.16, p < .001). No significant correlation was found between 
the Body Awareness and Body Ignorance subscales (r = –.08, p = .09).
As reported in Table 4, higher levels of Body Ignorance were associated with higher 
levels of itch, pain, and fatigue, more scratching, a decreased quality of life, higher levels 
of anxious and depressive symptoms, more avoidant coping, less active coping, higher 
levels of neuroticism and helplessness, and lower levels of extraversion and acceptance. 
Correlations between the Body Attention subscale and measures of physical and 
psychological wellbeing were mostly non-significant, with the exception of small cor-
relations of higher Body Attention with higher levels of active coping, acceptance, and 
extraversion. Similarly, small correlations were found for higher Body Awareness, with 
higher levels of active coping and higher levels of anxiety, neuroticism and extraversion.
Table 4. Correlations between the Body Attention, Ignorance and Awareness Scale (BAIAS) and measures 
of physical and psychological functioning
Measure Body Ignorance Body attention Body awareness
r n r n r n
Physical and psychological wellbeing
Itch 0.20*** 466 0.00 465 0.06 466
Pain 0.24*** 461 -0.05 461 0.03 462
Fatigue 0.32*** 468 0.04 468 0.01 469
Conscious scratching 0.18*** 451 -0.05 451 0.03 452
Automatic scratching 0.12* 451 -0.05 451 0.06 451
Quality of life 0.25*** 362a 0.02 362a 0.03 362a
Disease severity 0.06 448 0.00 449 0.05 449
Depression 0.33*** 467 -0.04 467 -0.07 469
Anxiety 0.34*** 468 0.01 468 0.11* 469
Coping
Active -0.24*** 465 0.27*** 465 0.18*** 466
Passive 0.29*** 466 -0.07 466 -0.06 467
Illness cognitions
Helplessness 0.30*** 467 0.04 466 0.02 467
Acceptance -0.24*** 467 0.10* 466 0.02 467
Perceived benefits 0.10* 464 0.07 463 0.07 464
Personality traits
Neuroticism 0.33*** 469 -0.05 469 0.12** 470
Extraversion -0.23*** 468 0.12** 468 0.14** 469
Note.aQuality of life was not assessed in the whole study sample.
*p < .05 **p < .01 ***p < .001.
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dISCuSSIon
The aims of the current study were to develop a measure to assess body awareness and 
to examine its physical and psychological correlates in patients with psoriasis. The results 
showed that body awareness can be measured adequately in patients with psoriasis by 
means of the BAIAS. In addition, body ignorance and, to a lesser extent, body aware-
ness and attention were related to physical and psychological functioning. In particular, 
patients who do not recognize and/or ignore their bodily signals experience lower levels 
of physical and psychological wellbeing.
The BAIAS showed a 3-factor structure, with three reliable scales: body ignorance (not 
recognizing and/or ignoring bodily signals), body attention (being aware of and paying 
mindful attention to specific internal bodily signals) and body awareness (self-perceived 
importance of and general attitude towards body awareness). In line with our hypoth-
esis, the aspect of the BAIAS reflecting a low level of body awareness demonstrated 
associations with poorer physical and psychological wellbeing. Higher levels of body 
attention and body awareness were not related to physical and psychological wellbeing, 
but slightly to aspects of coping and personality that are generally perceived as adaptive 
(active coping and extraversion). We explicitly added items in the BAIAS that assess the 
failure to recognize bodily signals, which was shown to be only slightly negatively corre-
lated with body attention. Results suggest that body awareness is not a unidimensional 
construct, but rather consists of multiple aspects that may be independently associated 
with physical and psychological functioning.
The concepts of body awareness and body ignorance seem to have inherently different 
meanings. While body awareness refers to the general tendency to be aware of and pay at-
tention to bodily signals, body ignorance is related more to not recognizing or to actively ig-
noring bodily signals. Several mechanisms can be suggested to play a role in both concepts. 
For example, parallels can be drawn between body ignorance and the emotion regulation 
strategies of avoidance and suppression, which were found to be related to psychopathol-
ogy in meta-analysis with moderate to large effect sizes [47]. Body ignorance may also be 
related to the maladaptive emotion regulation construct of “experiental avoidance”; the 
suppression or avoidance of a broader range of psychological experiences, including bodily 
signals, but also, for instance, cognitions, emotions, memories and sensations [48, 49]. Body 
ignorance might be related to problems with adherence; bodily signals often have a certain 
threat value due to signals of disease, and are therefore potentially avoided or ignored in 
patients who score high on body ignorance. In contrast, the construct body attention is 
hypothesized and operationalized to be more related to mindfulness and perhaps a broad 
awareness of, or sensitivity to, signals in general. When this sensitivity is accompanied by 
excessive worrying about bodily signals, this process may become maladaptive, as in health 
anxiety [15]. Future research should examine these hypotheses and constructs further.
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The body ignorance subscale was found to be associated with more physical symp-
toms of itch, pain, and fatigue, as well as more scratching behavior. Because treatment 
of chronic skin conditions relies heavily on adequate self-care behavior and treatment 
compliance [11], being aware of bodily sensations and taking appropriate action may 
be especially important in this population. In addition, not being conscious of bodily 
sensations such as itch could also lead to unaware, automatic ways of dealing with these 
sensations, for instance through more frequent automatic scratching behavior. Scratch-
ing may cause further damage to the skin and lead to more itch, a process called the 
itch-scratch cycle.
Body ignorance was also found to be correlated with psychological wellbeing; pa-
tients who do not recognize or ignore bodily signals were found to be more anxious 
and depressed. In addition, they scored higher on generally maladaptive personality 
traits and coping styles. These findings may suggest that patients who do not recognize 
or pay attention to their bodily signals may be at risk for psychological problems. This 
may be relevant not only for patient wellbeing, but also for dermatological treatment 
outcomes, as it is known that psychological distress plays a significant role in the exac-
erbation of psoriasis [50]. An alternative explanation could be that patients with high 
levels of psychological distress may be less aware of their bodily signals as they are fo-
cused on exaggerated worries of, for example, health anxiety. Further research is needed 
on the association between body awareness in its current conceptualization and these 
distress-related constructs of health anxiety and hypervigilance, which are known to be 
associated with both increased symptom reporting and increased attention to bodily 
signals [e.g., 17].
The BAIAS was also found to be correlated with sociodemographic variables; women 
scored slightly higher than men on the body awareness subscale, and a higher educa-
tional level was slightly associated with lower levels of body ignorance and higher levels 
of body attention and awareness. These results correspond with the notion that women 
[51] and individuals with a higher educational level [52] have also been found to score 
lower on the related emotion regulation construct alexithymia.
The findings of this study should be considered in light of its limitations, which may 
be addressed in future research. Firstly, as this is the first study on this newly developed 
questionnaire, the BAIAS should be further validated based on these results. Also, this 
study was conducted in a sample of psoriasis patients with relatively mild to moderate 
disease severity from various hospitals, which raises the issue of representativeness and 
possible floor effects in the development of the questionnaire. However, all three body 
awareness subscales showed a normal distribution and few participants scored the high-
est or lowest possible values, indicating that floor effects were not likely to be a problem. 
Moreover, none of the three body awareness scales correlated with disease severity. In 
addition, disease severity in psoriasis is known to be, on average, mild to moderate in 
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general practice [e.g., 6, 53]. However, in order to generalize beyond this group, studies 
need to be conducted that replicate these results in patients with more severe disease 
activity, other chronic conditions, such as atopic dermatitis, and healthy participants. 
The developed questionnaire should also be administered to other independent 
samples to confirm its factor structure and further test its psychometric properties, such 
as test-retest reliability and sensitivity to change. In addition, it would be informative to 
perform a qualitative assessment on comprehension of the scale for respondents with 
diverse educational levels and cultural backgrounds, in order to examine whether the 
scale is equally comprehensible for all respondents.
Secondly, a substantial part of our sample had a comorbid medical condition. As 
research clearly suggests that psoriasis patients are at an increased risk for several other 
chronic somatic conditions, such as diabetes and cardiovascular conditions [see for 
an overview: 54], excluding these patients would leave us with a sample that would 
probably not be very clinically representative. However, this leaves the possibility that 
differences in body awareness according to medical conditions may have influenced 
our results. For example, diabetics are taught to be attuned to physiological sensations 
as they need to detect possible hypoglycemia in an early stage. Even though in the cur-
rent study no differences in body awareness between patients with and without these 
medical conditions were observed, future studies should shed more light on this matter.
Thirdly, while correlations between the body ignorance scale and psychological and 
physical functioning were consistently in the same direction, the magnitude of the cor-
relations was generally small to moderate. This corresponds with the knowledge that a 
multitude of factors can contribute to poor physical and psychological wellbeing, with 
body awareness being one of these factors. Lastly, the cross-sectional nature of this 
study precludes causal conclusions. While it could be hypothesized that a low awareness 
of bodily signals leads to poorer self-care behavior and, therefore, poorer skin status 
and lower physical and psychological wellbeing, alternative hypotheses cannot be ruled 
out. Future prospective studies should disentangle the causal pathways between body 
awareness and wellbeing.
In conclusion, the current study provided new insights into the potential relevance of 
body ignorance, body attention, and body awareness, which can be reliably measured 
with the BAIAS. Body ignorance was found to be associated with worse physical and 
psychological functioning. If it is proven that body ignorance is predictive of worse func-
tioning in longitudinal studies, the BAIAS may be useful in assessment and screening for 
body ignorance in patients with psoriasis. Subsequently, psychological interventions, 
such as mindfulness or body awareness training, may be helpful in reducing body ig-
norance and improving body attention and awareness in an adequate manner [55–59].
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aBSTRaCT
Background: The physical appearance of psoriasis can be cosmetically disfiguring, 
resulting in a substantial social burden for patients. An important aspect of this burden 
is the experience of stigmatization. While stigmatization is known to be disabling and 
stressful for patients, little is known about its correlates and effective interventions are 
lacking.
objectives: To examine predictor variables for perceived stigmatization in psoriasis.
Methods: Questionnaires were administered to 514 patients with psoriasis in a cross-
sectional study. Zero-order correlation and multiple regression analyses were conducted 
including sociodemographic, disease-related, personality, illness cognitions, and social 
support predictor variables.
Results: Stigmatization was experienced by 73% of patients to some degree, and cor-
related with all five categories of predictor variables. In multiple regression analyses, 
stigmatization was associated with higher impact on daily life; lower education; higher 
disease visibility, severity, and duration; higher levels of social inhibition; having a type 
D personality; and not having a partner.
Conclusions: Results indicate that perceived stigmatization is common in psoriasis, 
and can be predicted by sociodemographic, disease-related, and personality variables. 
These predictor variables provide indications on which patients are especially vulner-
able regarding perceived stigmatization, which might be used in treatment.
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InTRoduCTIon
It has long been theorized that humans have a fundamental need to be accepted by oth-
ers and included in social interactions [1]. Social relationships are important for health 
and wellbeing, and social rejection can lead to physical, behavioral, and emotional 
problems [1]. Social rejection is central to the experience of stigmatization, which can 
be defined as an awareness of social disapproval, discrediting, or devaluation based on 
an attribute or physical mark [2–3].
In psoriasis, a chronic skin condition characterized by red plaques on the skin [4], 
the experience of stigmatization is commonly mentioned as one of its more troubling 
characteristics [5–9]. Patients often experience felt or perceived stigma, referring to the 
negative attitudes and responses that they perceive to be present in society and the 
sense of shame and fear of being discriminated against because of being ‘flawed’ due to 
their illness [10–11]. Actual experiences of stigmatization (i.e. enacted stigma) are also 
reported, for instance reactions of disgust or aversion, negative comments, or avoidance 
of contact [7, 9]. Stigmatization contributes considerably to disability, depression, and 
reduced quality of life in psoriasis [12–14], and can be considered a stressor. As distress 
can be a trigger for psoriasis exacerbation, this can become a vicious self-perpetuating 
cycle [15–17].
Despite these detrimental consequences, relatively few studies have studied interven-
tions targeting stigmatization-related problems, and thus far no compelling evidence 
has been found for any type of intervention [18–19]. Firstly, it is important to recognize 
that stigmatization is a societal problem, and therefore societal educational interven-
tions including contact between patients and the general population are called for to al-
ter the public view [20]. Furthermore, interventions with a more inter- and intrapersonal 
focus are needed to improve patients’ ability to cope with perceived stigmatization. In 
order to aid intervention development, a broad understanding of associated risk factors 
is needed, to be able to identify risk populations and focus points for interventions.
The literature suggests several potential sociodemographic predictors of perceived 
stigmatization in psoriasis, such as lower age [7], being female [5], and lower education 
[7]. Secondly, disease-related variables such as higher disease severity, longer disease 
duration, greater cosmetic involvement, and greater impact of the condition on daily 
life may be relevant [7–9, 13, 21, 22]. General ways in which patients deal with a chronic 
condition, such as heightened helplessness regarding the disease and its consequences, 
and lower disease acceptance have also been found to be predictive [7]. Additionally, 
social support and a large social network may serve a protective function against experi-
ences of stigmatization [7].
While several studies have examined the abovementioned variables as predictors, 
the role of personality has hardly been studied [7, 9]. A possibly relevant personality 
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construct is type D, which is defined as a tendency to inhibit the expression of emotions 
or behavior to avoid negative reactions of others (social inhibition; SI), in combination 
with the stable tendency to experience negative affect (negative affectivity; NA [23]). 
Type D personality has been associated with increased risk of cardiovascular morbid-
ity and mortality [24] and impaired health behavior [25], which are both frequently 
reported in psoriasis [26, 27]. The two main features − SI and NA − may both increase 
the impact of perceived stigmatization. Being socially inhibited implies being sensitive 
to negative reactions of others, which may cause stigmatization experiences to be espe-
cially detrimental. Additionally, having a stable tendency to experience negative affect 
may worsen psychological distress, which in turn may increase disease severity and 
resultantly visibility [15–17], and thereby vulnerability to stigmatization experiences. 
Furthermore, individuals with high levels of NA may be more likely to perceive social 
interactions as negative, due to the associated cognitive bias to negative information 
[28]. The specific combination of heightened SI and NA, type D, has mainly been related 
to adverse outcomes in cardiovascular patients [24, 29–31], but also to poorer physi-
cal, psychological and social functioning in other healthy and patient samples [32, 33], 
including two studies in psoriasis [34, 35].
This study aims to examine the relative contributions of a broad range of concepts, 
including never examined variables such as type D personality, to perceived stigmati-
zation in a large sample of patients with psoriasis. It was hypothesized that perceived 
stigmatization would be related to the sociodemographic variables age, educational 
level, and being single; the disease-related variables severity, duration, visibility, and im-
pact; type D personality; the illness cognitions acceptance and helplessness; and social 
support. This broad approach may provide indications for screening and interventions 
for reducing stigmatization-related problems.
MaTeRIalS and MeThodS
Participants
Psoriasis patients were recruited from one academic and three non-academic hospitals, 
and the Dutch Psoriasis Association. Inclusion criteria were a minimum age of 18 years 
and a dermatologist-confirmed psoriasis diagnosis. Exclusion criteria were illiteracy, 
pregnancy, and severe physical and mental comorbid conditions. This study made use 
of questionnaires that were administered between 2010 and 2013 to determine partici-
pant eligibility for a study on the effectiveness of internet-based cognitive behavioral 
treatment for psoriasis [36]. Parts of these data have been used in a previous paper [37]. 
All questionnaires were assessed prior to the intervention. The study was approved by 
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the regional medical ethics committee and carried out in accordance with the declara-
tion of Helsinki [38]. All participants provided informed consent.
Measures
Perceived stigmatization was measured with a six-item subscale of the Impact of Chronic 
Skin Disease on Daily Life questionnaire (ISDL [39]; Cronbach’s α in this study = .88). 
This assesses to what extent the patient feels stigmatized as a result of the skin condi-
tion. Items are assessed on a four-point Likert scale, with higher scores reflecting higher 
levels of perceived stigmatization (theoretical range 6-24). Example items are “others 
feel uncomfortable touching me due to my skin disease” or “other people sometimes 
make annoying comments about my skin disease”.
Measures used for assessment of predictor variables
Sociodemographic variables
Sociodemographic variables were assessed with a general checklist that assessed pa-
tients’ sex, age, educational level and marital status. Educational level was categorized 
into primary (i.e. lower education, elementary school), secondary (i.e. middle school and 
high school, including vocational training) and tertiary (i.e. higher professional educa-
tion and university-level education).
Disease-related variables
Self-assessed disease severity was measured with the Self-Administered Psoriasis Area 
and Severity Index (SAPASI [40, 41], theoretical range 0-72). Self-assessed disease vis-
ibility was measured with a four-item ISDL subscale [39] asking about the extent of in-
volvement of the face, scalp, neck, and hands (theoretical range 4-16). Disease duration 
was assessed by asking how old the patient was when diagnosed, and subtracting this 
number from their current age (range 0-64 years). Impact of the disease on daily life was 
assessed with a 10-item ISDL subscale [39], assessing the extent that the skin condition 
affects daily life activities (theoretical range 10-40, α = .89).
Personality
The Type D scale 14 [23] was used to assess type D personality. It consist of two seven-
item subscales: SI (α = .88, example item: “I often feel inhibited in social interactions”, 
theoretical range 0-28) and NA (α = .89, example item: “I often feel unhappy”, theoretical 
range 0-28). A cutoff score of ≥ 10 on both scales is used to classify type D personality. 
Using these cutoff scores, one in four participants in this study (25.1%) had a type D 
personality. As previous studies indicate that type D is best represented as a continuous 
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variable [42, 43] the interaction term between the NA and SI subscales was used as a 
measure of type D.
Illness cognitions
The Illness Cognition Questionnaire [44] was used to measure two illness cognitions: 
acceptance, assessing the extent of positive adaptation to chronic illness with emphasis 
on decreasing its negative aspects (six items, α = .88, theoretical range 6-24) and help-
lessness, assessing the extent to which patients concentrate on aversive aspects of the 
disease (six items, α = .88, theoretical range 6-24).
Social support
Social support was assessed with a five-item ISDL subscale [39], assessing the qualitative 
aspect of social support (α = .86, theoretical range 5-20), and the quantitative aspect, 
asking patients about the actual size of their social network (range 0-25). This score was 
categorized according to norm groups [39].
Statistical analysis
All variables were checked for outliers, normality and normal distribution of residuals, 
and logarithmic transformations were successfully applied in case of non-normal dis-
tribution of variables (i.e. perceived stigmatization, helplessness and disease severity). 
Winsorizing was applied in outlying SAPASI scores prior to log-transformation, limiting 
the influence of extreme values. Zero-order correlations between perceived stigmati-
zation and predictor variables were examined by Pearson correlation coefficients for 
continuous variables, and t-tests and ANOVAs for categorical variables. Zero-order 
correlations were interpreted as small (r = .10 - .29), moderate (r = .30 - .49), or large (r ≥ 
.50) [45]. Only study variables showing significant zero-order correlations with perceived 
stigmatization were entered in regression analyses. To study the relative contribution 
of five categories of variables (sociodemographic, disease-related, personality, illness 
cognitions, and social support), each category was entered in a consecutive step with 
perceived stigmatization as the dependent variable. Only statistically significant individ-
ual predictor variables (p < .05) were retained in further models. For type D personality, 
the main effects of mean-centered NA and SI were first examined and in a second block 
their interaction term was added. All regression analyses were conducted with SPSS 21.0 
(IBM, Armonk, NY, USA) on a dataset without missing values (n = 433).
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ReSulTS
Sample characteristics
The sociodemographic characteristics of the study sample (n = 514) and means and SDs 
of the study variables can be found in Tables 1 and 2. Disease severity was generally mild 
to moderate, with 6.7% of patients having severe psoriasis (SAPASI >10) [46]. The mean 
values of perceived stigmatization, impact on daily life, social support and illness cogni-
tions were similar to those found in previous research in psoriasis [39], and scores on 
type D personality were comparable with those found in the general population [33, 47].
Table 1. Sociodemographic characteristics of study sample (n = 514)
Patient characteristics
age (years), mean ± SD; range 52.21 ± 13.0; 18-84
Sex
Male 286 (55.6)
Female 228 (44.4)
Marital status
Unmarried 62 (12.1)
Married/living together 410 (79.8)
Divorced 24 (4.7)
Widowed 18 (3.5)
educational status
Primary 16 (3.1)
Secondary 306 (59.5)
Tertiary 190 (37.0)
 Missing 2 (0.4)
Note. Values are n (%) unless stated otherwise.
Perceived stigmatization
Seventy-three percent of our sample perceived at least some stigmatization, as indicated 
by a positive score on at least one of the six items, as reported in previous studies [7, 8]. 
The feeling of being stared at was reported most often (in 61.9% of patients), followed 
by other people thinking their condition was contageous (44.9%), finding them unat-
tractive because of their skin condition (38.1%), avoiding to touch them (32.3%), and 
making negative comments (27.7%).
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Table 2. Means and standard deviations of study variables
Characteristic Mean ± Sd Range
Perceived stigmatization 9.02 ± 3.48 6-24
disease-related
Disease severitya 5.09 ± 4.02 0-33
Disease visibility 1.85 ± 0.57 1.0-3.5
Disease duration (years)b 15.72 ± 14.75 0-62
Impact on daily life 16.06 ± 6.06 10-40
Type d, (n, %) 129 (25.1)
Negative affectivity (NA) 8.45 ± 6.02 0-26
Social inhibition (SI) 9.13 ± 6.01 0-27
Illness cognitions
Helplessness 9.38 ± 3.74 6-24
Acceptance 17.19 ± 4.46 6-24
Social support
Perceived support 15.80 ± 3.60 5-20
Actual support 8.12 ± 5.33 0-25
Note.an = 489, bn = 498.
Individual associations with perceived stigmatization
Zero-order correlations of study variables are reported in Table 3. Higher perceived 
stigmatization showed a large correlation with a greater impact of the skin condition 
on daily life; moderate correlations with higher disease severity, helplessness, NA, and 
lower levels of acceptance; and small correlations with lower age, longer disease dura-
tion, greater visibility, higher levels of SI, and less perceived social support. Furthermore, 
higher perceived stigmatization scores were associated with a smaller social network (p 
= 0.001), not having a partner (p < 0.001), and a lower educational level (p = 0.01), but 
not with sex (p = 1.00).
Table 3. Zero-order correlation matrix of continuous study variables
Variable 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
1. Stigmatization -
2. Age -.28*** -
3. Disease severity .34*** -.14** -
4. Disease visibility .26*** -.12** .29*** -
5. Disease duration .13** .22*** .11* -.03 -
6. Disease impact .61*** -.17*** .32*** .26*** .11* -
7. Type D: NA .30*** -.23*** .20*** .12* -.05 .36*** -
8. Type D: SI .22*** -.11* .05 .07 -.03 .17*** .41*** -
9. Helplessness .49*** -.09# .28*** .19*** .10* .67*** .39*** .17*** -
10. Acceptance -.34*** .10* -.19*** -.23*** .10* -.48*** -.42*** -.20*** -.52*** -
11. Perceived support -.16*** -.02 .02 .00 .00 -.18*** -.36*** -.27*** -.17*** .26*** -
Note. NA = Negative Affectivity; SI = Social Inhibition.
*p < .05 **p < .01 ***p < .001 #p < .10.
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Relative impact on perceived stigmatization
Table 4 presents the results of multiple regression analyses that were performed to 
examine the relative impact of predictors on perceived stigmatization.
Table 4. Predictors of stigmatization: multiple regression analyses
Predictors Standardized regression coefficients (β)
Block 1 Block 2 Block 3 Block 4 Block 5
Sociodemographic
Age -.27*** -.19*** -.19*** -.19*** -.18***
Education (primarya) .06 .03 .03 .03 .02
Education (secondarya) .15** .12*** .12** .11** .11**
Married / With partnerb -.13** -.07* -.07# -.07# -.06
disease-related
Disease severity .10** .10** .10* .11**
Disease visibility .12** .12** .12** .12**
Disease duration .11** .11** .11** .09*
Impact on daily life .51*** .50*** .46*** .50***
Personality
Negative affectivity (NA) .00 -.01 -.02
Social inhibition (SI) .10** .10* .09*
Type D personality
(interaction NA*SI)
.08* .08* .07*
Illness cognitions
Helplessness .05
Acceptance -.01
Social support
Perceived support -.03
Actual support (1-4c) -.15
Actual support (5-14c) -.17
Actual support (15-25c) -.13
F-change 16.78*** 76.16*** 4.31** 0.44 0.63
R2 .12 .48 .50 .50 .50
Note.aReference group = tertiary education, bReference group = no partner, cNumber of friends, reference 
group = no friends.
***p < .001, **p < .01, *p < .05, #p < .10.
In block 1, sociodemographic variables explained 11.9% of the variance in perceived 
stigmatization, with lower age, lower education, and being singe being predictive of 
higher levels of perceived stigmatization. In block 2, adding the disease-related vari-
ables explained a total of 48.3% of the variance, with greater disease severity and vis-
ibility, longer disease duration, and a higher disease impact predicting more perceived 
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stigmatization. In block 3, adding the personality variables resulted in a total of 49.7% 
explained variance, with the main effect of SI (but not NA) and the type D interaction 
effect being predictive of perceived stigmatization. Patients scoring both high on SI and 
NA, indicating a type D personality, had higher levels of perceived stigmatization (Figure 
1). In blocks 4 and 5, illness cognitions of helplessness and acceptance, and perceived 
and actual social support did not significantly add to the model.
The final model, including only the significant predictors, explained a total of 49.7% of 
the variance in perceived stigmatization (Table 5). Predictors, from highest to lowest 
standardized regression coefficients, were higher disease impact, lower age, lower 
education and greater disease visibility, longer disease duration, higher disease severity 
and higher levels of SI, having a type D personality, and being single. A model excluding 
multivariate outliers (n = 16; critical Mahalanobis Distance value = 32.91, degrees of 
freedom = 12, p = .001) yielded similar results, with the exception of two predictors that 
became marginally significant (type D personality, p = .08) or non-significant (marital 
status, p = .11).
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figure 1. Interaction effect of negative affectivity (na) and social inhibition (SI) on perceived stig-
matization. Predicted values of perceived stigmatization are displayed for high and low levels of NA and 
SI (i.e. 1 SD above/below the mean). For all other variables included in the model, mean scores were used 
to calculate the regression outcome. In this figure, the degree of SI was not associated with perceived stig-
matization when patients had low NA. For patients high on NA, specifically the combination with high SI, 
indicating a type D personality, was related to higher levels of perceived stigmatization.
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Table 5. Predictors of stigmatization: final model
Predictors β B Se
Sociodemographic
Age -.19*** -.00*** (.00)
Married / With partnera -.07# -.02# (.01)
Education (primary)b .04 .03 (.03)
Education (secondary)b .12** .03** (.01)
disease-related
Disease severity .10* .02* (.01)
Disease visibility .12** .03** (.01)
Disease duration .11** .00** (.00)
Impact on daily life .50*** .01*** (.00)
Personality
Negative affectivity .00 .00 (.01)
Social inhibition .10** .01** (.00)
Type D .08* .01* (.00)
F-change 37.80***
R2 .50
Note. β = standardized coefficients, B = unstandardized coefficients, SE = standard error of B.
aReference group = no partner, bReference group = tertiary education.
***p < .001, **p < .01, *p < .05, #p < .10.
dISCuSSIon
This study examined perceived stigmatization and its potential sociodemographic, 
disease-related, and psychosocial predictors in a large sample of patients with psoriasis. 
The vast majority of our sample experienced perceived stigmatization to some degree, 
corresponding with previous studies [7, 8]. Higher levels of perceived stigmatization 
were found to be correlated with sociodemographic and disease-related variables, 
personality, illness cognitions and social support. Perceived stigmatization was found 
to be particularly predicted by disease impact, as well as by lower age, lower education, 
greater disease visibility and lower education, longer disease duration, greater disease 
severity and higher levels of SI, having a type D personality, and being single.
Greater severity and visibility and longer disease duration were predictive of perceived 
stigmatization, underlining the importance of early dermatological treatment; patients 
whose psoriasis is not adequately controlled may be more affected by stigmatization. 
However, the impact of the condition was a much stronger predictor, corresponding 
with the notion that the subjective experience of impact is generally more important 
than disease severity [48, 49]. In contrast with an earlier study [7], the impact of the 
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condition was also a stronger predictor than the illness cognition of helplessness. The 
relative and different contribution of both variables may be explained by the high 
correlation between these variables in the current study and in previous research [48]. 
It seems likely that patients with psoriasis who are prone to feelings of helplessness 
regarding the disease may also experience a larger impact of psoriasis and magnify 
negative reactions of others.
Type D personality and its subcomponent SI were found to be significant predictors of 
perceived stigmatization. The fear of disapproval that leads individuals to inhibit emo-
tions or behavior in SI [23] may explain its relation to perceived stigmatization; socially 
inhibited individuals may be more sensitive to the reactions of others and may therefore 
perceive themselves to be stigmatized more readily. Not only SI in itself, but also the 
combination of higher levels of SI and NA (type D personality) was a significant predic-
tor of perceived stigmatization. This corresponds with studies suggesting that type D is 
associated with social impairments [50, 51]. These results extend preliminary evidence 
indicating that type D may be a risk factor for worse outcomes in psoriasis [34, 35], by 
showing for the first time that it is associated with increased perceived stigmatization. 
However, these results should be replicated in further research, as the effect of type 
D became marginally significant when excluding multivariate outliers. In the current 
study, NA was not a significant predictor of perceived stigmatization. It seems that, while 
the shared variance with NA can also be explained by other variables, SI contains more 
unique information relevant for perceived stigmatization.
Regarding sociodemographic variables, the significant predictors lower age, lower 
educational level and being single were in line with previous research indicating that the 
negative psychosocial influence of psoriasis is particularly strong in younger patients [7, 
52].
To develop a comprehensive model of factors influencing perceived stigmatization, 
both potential risk factors (e.g., social fears and inhibition) and protective factors (e.g., 
social support) need to be taken into account. While the current study provides evidence 
for the former, results of the latter (social support) were inconsistent with previous 
research [7], possibly due to the inclusion of predictor variables not previously studied. 
Furthermore, while the current study examined self-perceived support, a more objec-
tive measure may lead to different results. Nonetheless, current results suggest that it 
is not so much the experienced social support that plays a significant role in perceived 
stigmatization, but more the extent to which patients may experience social anxiety 
and want to avoid negative reactions, as captured in SI. Future research should further 
explore the role of protective factors in perceived stigmatization.
Strengths of the current study include the large sample size, simultaneous assessment 
of relevant variables to control for shared variance, including personality variables never 
before studied, and inclusion of patients from a variety of settings. Limitations include 
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the cross-sectional design, precluding conclusions about cause and effect, and the rela-
tively mild disease severity of our sample, which may limit generalizability. In addition, 
self-report measures were used to assess disease severity. However, self-assessed PASI 
scores correlate reasonably well with clinician-assessed PASI scores [40, 53] and modest 
relationships with stigmatization have also been found in studies using the clinician-
assessed PASI [54, 55]. Lastly, some predictor variables showed high intercorrelations, 
but none of them were above the multicollinearity cutoff point of .80 [56].
In conclusion, perceived stigmatization was found to be common in patients with 
psoriasis and was predicted by specific sociodemographic, disease-related, and per-
sonality variables. This provides several possible focus points for individual screening 
and interventions, in addition to the societal interventions that are needed to target the 
overarching problem. Firstly, the predictors found in this study provide clinicians with 
an understanding of which patients may be especially vulnerable to stigmatization-
related problems, which may warrant special attention during consultations. Type D and 
especially its social inhibition component may be screened for, when further evidence 
confirms our preliminary results indicating that individuals with this personality subtype 
are especially vulnerable to stigmatization-related problems. Stigmatization-related 
problems may be screened using validated instruments [39], followed by targeted inter-
ventions that may focus on the impact of the condition on daily life, considering that this 
was the largest predictor. Cognitive behavioral treatment, including social skills training, 
seems promising as an intervention framework. Previous research indicates that it can 
decrease perceived stigmatization in skin conditions [57], improve psychological and 
disease-related outcomes in psoriasis [58, 59], and decrease helplessness, which shows 
high correlations with disease impact [60–62]. In order to target the social inhibition 
aspect of type D personality, social skills training and evidence-based interventions for 
social fears, such as cognitive behavioral therapy and/or exposure therapy, may be an 
additional treatment approach [63, 64].
The current study provides a framework of characteristics of patients who are at greater 
risk to perceive stigmatization, which has been shown to have detrimental psychological 
consequences in psoriasis. Future research should expand upon these findings in order 
to examine interplays between predictors in prospective studies. Further development 
of screening and intervention procedures are needed in order to facilitate implementa-
tion of tailored evidence-based treatment to reduce the psychosocial burden of chronic 
skin conditions.
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aBSTRaCT
objective: Stigmatization is common in people with chronic skin conditions and 
may also affect their significant others (SOs). The fast and implicit processing of stig-
matization-related stimuli has received little attention in these populations; however, 
such knowledge may offer indications for new treatment methods. This study aimed 
to investigate implicit processing of stigmatization-related stimuli in people with skin 
conditions and their SOs.
Method: A modified Stroop task and 2 approach-avoidance tasks were administered to 
participants with chronic skin conditions (alopecia: n = 50 and psoriasis: n = 50); their 
significant others (alopecia SOs: n = 47 and psoriasis SOs: n = 50); and controls (n = 50). 
The aim was to examine attentional and behavioral biases toward disease-related and 
social threat-related stigmatization stimuli.
Results: An attentional bias to disease-related stimuli was found in participants with 
alopecia and their SOs, compared with controls (p < .001). This effect was not found for 
participants with psoriasis and their SOs. Increased behavioral avoidance of disgusted 
faces was found in participants with psoriasis and their SOs, compared with controls (p 
= .047). This effect was not found in participants with alopecia and their SOs.
Conclusions: These results provide support for the idea that individuals with skin 
conditions and their SOs are characterized by a stigmatization-related stimulus bias 
regarding implicit cognitive and behavioral reactions, in comparison to healthy indi-
viduals. Furthermore, preliminary results suggest that these processes may differ across 
skin conditions, with people with psoriasis being more affected by social reactions (i.e. 
disgusted faces) and people with alopecia by disease-related cues possibly related to 
internalized self-stigma.
Implicit processes in chronic skin conditions 67
4
InTRoduCTIon
The visible marks of a skin condition can have substantial social consequences. In 
alopecia, people experience hair loss, ranging from minor patches to loss of all scalp 
and body hair. This may have negative consequences for social interactions, body im-
age, and self-esteem [e.g., 1]. Psoriasis is characterized by red patches of skin covered 
with silvery scales, that may be unjustly viewed as “unclean” and likely to be contagious 
[e.g., 2, 3], resulting in negative social reactions. People with chronic skin conditions 
frequently experience stigmatization [e.g., 4], which can be defined as an awareness of 
social disapproval, discrediting, or devaluation based on an attribute or physical mark 
[5]. In self-stigma, stigmatization becomes internalized, as the stigmatized individual 
endorses stereotypes about the discreditable attribute that he or she has and applies 
them to him/herself [6]. Self-stigma has been associated with negative psychological 
and physical health outcomes [e.g., 7, 8].
Stigmatization and self-stigma are usually assessed by questionnaires [9]. However, 
dual-process models suggest that information processing and behavior are influenced 
not only by the relatively slow, reflective processes assessed by questionnaires, but 
perhaps even more by the fast, reflexive reactions assessed by indirect tasks [10]. The ex-
perience of stigmatization in people with skin conditions may also be reflected in these 
implicit processes. Biases could then be expected regarding (a) social threat-related 
stimuli (perceived stigma) and (b) disease-related stimuli to assess the individual’s re-
sponse to his or her own condition (self-stigma). While disease-related and social threat-
related attentional biases were previously found in individuals with psoriasis [11], it is 
unknown whether they also occur on a behavioral level (e.g., in avoidance responses) 
and/or in other skin conditions.
As theorized in disease-avoidance models [12], visible cues of disease, such as skin 
lesions, may activate disgust reactions and motivate behavioral avoidance. Disgust-
related brain regions were found to be activated in healthy participants when they were 
shown pictures of stigmatized groups [e.g., 13]. Given that people with skin conditions 
may experience and/or anticipate these disgust reactions, they may develop a behav-
ioral avoidance bias to social threat-related information (e.g., disgusted faces), similar to 
the biases seen in social anxiety [e.g., 14]. In line with this, a reduced ability to identify 
disgusted faces, and diminished associated brain activity, was found in psoriasis; this 
suggests an avoidance-based coping mechanism [15]. In addition to social threat-
related stimuli, biases may also be present for disease-related stimuli. An eye-tracking 
study showed that people with acne automatically gazed more at acne lesions than 
did controls, which suggests an attentional bias [16]. Also, in pathological skin picking, 
greater behavioral avoidance of pictures of skin irregularities was found compared to 
controls [17].
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Social threat-related and disease-related biases may also occur in significant others 
(SOs), because they often experience increased distress and a substantial burden be-
cause of the chronic skin condition [e.g., 18]. No research has yet focused on these biases 
in significant others of individuals with chronic skin conditions. However, indications of 
a larger implicit preference for clear skin were found in people from the general popula-
tion who knew someone with a skin condition than in people who did not. The authors 
explained this finding by suggesting that these individuals attempted to suppress their 
stereotypical reaction, which required cognitive effort [19]. The current study explores 
whether social threat-related and disease-related biases also occur in SOs.
This study examines attentional bias and approach-avoidance tendencies in relation 
to disease-related and social threat-related stigmatization stimuli using reaction time 
(RT) tasks, to gain new insights into the concept of stigmatization, which has previously 
only been examined using questionnaires. It was hypothesized that, compared with 
controls, people with chronic skin conditions and their SOs would show an attentional 
bias and an increased avoidance reaction toward both stimulus categories. The two skin 
conditions were exploratively compared, with the expectation that both conditions 
would show similar biases.
MeThodS
This section provides a condensed summary of the methods used. For detailed informa-
tion, we refer to the supplemental material. This study included 247 participants: people 
with chronic skin conditions, their SOs, and controls from the general population (see 
Table S1, supplemental material). Attentional bias to disease-related and social threat-
related words was assessed with a modified Stroop task ([20]; Table S3). Approach-
avoidance tendencies regarding disease-related and social threat-related pictures were 
assessed with two approach-avoidance tasks (AATs; [21]). Last, questionnaires were 
administered regarding disease severity, self-perceived visibility, psychological distress, 
social anxiety, and fear of negative evaluation. For all picture (AATs) or word (modified 
Stroop task) categories, repeated-measures ANOVAs were conducted to compare the 
RTs of individuals with each chronic skin condition and their SOs with those of controls.
ReSulTS
This section summarizes the main results. For more details, see supplemental material.
Implicit processes in chronic skin conditions 69
4
attentional bias: modifi ed Stroop task
Mean RTs for the modifi ed Stroop task are presented in Figure 1 and Table S4. People 
with alopecia, their SOs, and controls diff ered in their RTs to specifi c word categories 
(p = .002), ηp2 = .09): people with alopecia and their SOs were slower than controls to 
name colors of hair-related words compared with neutral words (p = .001, ηp2 ≥ .10). No 
diff erences were found between people with psoriasis, their SOs, and controls regarding 
the RTs for skin-related words compared with neutral words (p = .43). Last, no diff er-
ences were found between individuals with either chronic skin condition, their SOs, and 
controls regarding social threat-related words (p ≥ .40).
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figure 1. Modifi ed Stroop task: average color-naming reaction times in seconds (±SEM) for (a) alopecia, 
signifi cant others, and controls, and (b) psoriasis, signifi cant others, and controls. Note. SO = signifi cant 
others.
Behavioral bias: approach-avoidance tasks
Mean RTs and AAT-eff ects for the disease-related and social threat-related AATs can be 
found in Figure 2 and Tables S5 and S6, respectively. In the disease-related AAT, people 
with psoriasis and their SOs did not diff er from controls regarding their approach-
avoidance reactions to psoriasis-related and neutral pictures (p ≤ .73). In the social 
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threat-related AAT, people with alopecia and their SOs did not diff er from controls 
regarding their approach-avoidance reactions to emotional faces (p ≤ .68). Similarly, no 
diff erences in approach-avoidance reactions to emotional faces were found between 
people with psoriasis, their SOs, and controls (p ≤ .46). In the case of disgusted faces, 
specifi cally, participants with psoriasis and their SOs were quicker than controls to avoid 
than approach disgusted faces (p = .047, ηp2 = .03), while participants with alopecia and 
their SOs did not diff er from controls (p = .71).
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figure 2. Approach-Avoidance Tasks: average approach-avoidance task (AAT) eff ects (push-pull) in mil-
liseconds (±SEM), depending on group and picture type, for (a) social threat-related AAT, and (b) disease-
related AAT. Note. SO = signifi cant others.
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dISCuSSIon
This study examined implicit bias to social threat-related and disease-related stimuli in 
relation to two chronic skin conditions. In people with alopecia and their SOs, compared 
with controls, an attentional bias to disease-related words was found, but no behavioral 
avoidance bias for social threat-related pictures. The opposite was found in people with 
psoriasis and their SOs (again compared with controls): no attentional bias, but indica-
tions of a behavioral avoidance bias. These results provide preliminary support for the 
idea that people with skin conditions and their significant others differ from healthy 
controls regarding their implicit reactions to stigmatization-related stimuli. Further-
more, in contrast to what was initially expected, these processes may differ between 
specific skin conditions.
In contrast to a previous study [11], an attentional bias was found in individuals with 
alopecia, but not with psoriasis. This may be because of the relatively mild disease 
severity and lower levels of fear of negative evaluation (FNE) in psoriasis compared 
with alopecia, and the lower levels of disease severity, anxiety, and depression among 
participants than in the previous study [11]. It may also be because of inherent differ-
ences between the two skin conditions. Skin lesions in psoriasis may provoke social 
avoidance responses because of these being viewed as “unclean” or “contagious” [3]. In 
contrast, hair loss in alopecia may provoke fewer direct social responses, as the majority 
of patients tend to hide their condition. However, the significant disease-related distress 
and illness-related cognitive preoccupation reported in this patient group suggest that 
alopecia patients are psychologically affected by their condition [22], and these psy-
chological effects may be reflected in an attentional bias to disease-related words. The 
markedly higher levels of FNE further underline the concerns that these people have 
about being unfavorably evaluated by others, which may be the result of their “hidden 
stigma”. No attentional biases to social threat-related words were found for any of the 
groups. In a pilot validation study, these words were selected based on their high ratings 
of stigmatization combined with their negative emotional valence. However, as words 
were not specifically selected on ratings of individual threat, they may have been insuf-
ficiently threatening in comparison to words used in previous research [11].
Behavioral avoidance bias was examined using social threat-related and disease-relat-
ed stimuli. In the disease-related AAT, no differences were found between people with 
psoriasis, their SOs, and controls. Instead, for people with psoriasis, the stigmatization 
experience seems to be better captured by their fear and avoidance of disgust reac-
tions of others. Indications toward a social threat-related bias were found in psoriasis, 
but not in alopecia. This is in line with the idea that disgust reactions are more relevant 
in psoriasis and with the finding that the neural response of people with psoriasis to 
disgusted faces is consistent with an avoidance-based coping mechanism [15]. The fact 
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that biases were also observed in SOs corresponds with a study showing increased bias 
to skin irregularities in people who knew someone with a skin condition [2]. Equally, 
however, this could reflect the burden of chronic conditions on SOs [18].
Limitations of this study include the differences between groups in certain sociode-
mographic and psychological characteristics; this limits the comparability of the groups 
and calls for a cautious interpretation of results. In contrast with previous research [e.g., 
23], relatively low distress levels were found in participants with chronic skin conditions. 
As this study was the first of its kind, further studies are needed to examine the psycho-
metric properties of the implicit measures used. While the reliability of the AATs was 
good, the validity of these and other implicit measures should be further established 
[e.g., 24]. Another possible limitation was that this study used several stimulus catego-
ries in each task. As responses on each stimulus may influence subsequent responses, 
we cannot exclude the possibility that this confounded the results. A simpler design, 
for instance only including disgusted and neutral faces in an AAT, could perhaps be 
considered to examine specific hypotheses in future research.
To conclude, an attentional bias for disease-related stimuli was found in people 
with alopecia and their SOs, while indications of a behavioral avoidance bias for dis-
gusted faces were found in people with psoriasis and their SOs. These results provide 
preliminary support for the idea that, compared with healthy individuals, people with 
chronic skin conditions show different implicit cognitive and behavioral reactions to 
stigmatization-provoking stimuli. Furthermore, these processes may differ between skin 
conditions, with people with psoriasis being more affected by reactions of others, and 
those with alopecia being more affected by disease-related cues relating to self-stigma. 
Future research should focus on extending these results in other samples (e.g., people 
with other skin conditions, other somatic conditions, or elevated levels of social anxiety), 
to help unravel the underlying mechanisms and to examine their clinical relevance.
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SuPPleMenTal MaTeRIal: SuPPleMenTal MeThodS
Participant recruitment and inclusion criteria
People with skin conditions were recruited through two patient associations, the Dutch 
Alopecia Association and the Dutch Psoriasis Association, and by contacting partici-
pants from previous studies on alopecia and psoriasis who had given permission to be 
approached for future studies. People with alopecia and psoriasis were asked to invite 
a significant other (partner, family member, or friend) to participate. Study participants 
from the general population were recruited by contacting a subsample of the Nijmegen 
Biomedical Study, a population-based survey (www.nijmegenbiomedischestudie.nl). 
Inclusion criteria for patients were a diagnosis of alopecia or psoriasis, age ≥ 18 years, 
and a sufficient understanding of the Dutch language. Exclusion criteria for patients 
were psychiatric conditions, current psychological treatment, and co-morbid medical 
conditions that had a larger self-perceived impact on patients’ daily lives than their skin 
condition. Exclusion criteria for SOs and controls were having a chronic skin condition. 
All participants had normal or corrected-to-normal vision. The regional medical ethics 
committee indicated that the study did not need formal approval due to its non-invasive 
nature. Written informed consent was obtained from each participant.
Materials & procedure
In this study, several implicit tasks and self-report questionnaires were administered in a 
laboratory setting. Table S2 shows the order in which the tasks and questionnaires were 
administered.
Attentional bias: modified Stroop task
To assess attentional bias for word stimuli, a modified Stroop task [20] was used. Partici-
pants are instructed to name aloud the print color of the words presented, as quickly 
and accurately as possible. The assumption of the task is that the saliency of words 
interferes with the color-naming task and results in longer response latencies, indicating 
an attentional bias. In the current modified Stroop task, disease-related words (i.e. hair-
related words for alopecia and skin-related words for psoriasis) and social threat-related 
stigmatization words were administered, along with three word categories taken from 
the Dutch Emotional Word list [25]. The aim was to assess processing of words without 
emotional or disease-related content (neutral), threatening emotional words (negative), 
and non-threatening emotional words (positive; see Table S3). Disease-related words 
were chosen as self-stigma stimuli as they most closely relate to the participants’ skin 
conditions. The individual’s reaction times to these stimuli are therefore indicative of 
the individual’s implicit reaction to skin conditions. People with skin conditions may 
show longer reaction times to disease-related words, which would indicate an implicit 
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emotional reaction. This ‘negative reaction to the self’ closely relates to the concept of 
self-stigma, in which an individual endorses stereotypes about a discreditable attribute 
(e.g., damaged or flawed skin) that he or she has and applies these stereotypes to him/
herself.
Disease-related and social threat-related stigmatization words were validated in a 
pilot study consisting of 43 people with skin conditions, healthy individuals, and medi-
cal psychology professionals. The pilot study examined both the extent to which stimuli 
reflected the underlying constructs and their emotional valence. Words were presented 
against a black background, in random order, in a blocked design: 1 screen per word 
category, containing 8 words repeated 5 times. The distribution of word colors was the 
same for each category. The experimenter, who was blind to word category, recorded re-
sponse latencies (automated via mouse click at start and end of category), and number 
of errors (hand-scored) per category.
Behavioral bias: approach-avoidance tasks
To assess approach-avoidance tendencies regarding disease-related and social threat-
related stimuli, two irrelevant-feature zooming approach-avoidance tasks (AATs) were 
used [21]. Disease-related pictures were chosen as self-stigma stimuli. The reasoning 
behind this was similar to that for disease-related words, as presented above (see ‘At-
tentional bias: modified Stroop task’). Social threat-related pictures showed disgusted 
faces (for rationale, see ‘Introduction’). For these tasks, participants were seated behind 
a 19-inch computer screen (resolution: 1024x786 pixels) and instructed to respond to 
each picture on the screen, as quickly and accurately as possible, with a joystick that 
was tightly fastened to the table. Depending on an irrelevant stimulus feature, partici-
pants had to either push the joystick away (avoidance, picture size decreases) or pull it 
towards them (approach, picture size increases). Whether participants had to push or 
pull in response to the irrelevant feature was determined randomly. If the participant 
responded correctly, the picture disappeared when the joystick was pushed or pulled 
by approximately 30 degrees.
For the disease-related AAT, stimuli were pictures of psoriasis and neutral control pic-
tures of structured fabric resembling skin. The pictures of psoriasis had been previously 
validated in the pilot study described above; the neutral control pictures had been used 
in previous research [17]. Participants had to respond with push or pull according to 
whether the picture was tilted to the left or to the right. The task was introduced by 10 
practice trials (pictures of empty frames), followed by 200 experimental trials distributed 
across two blocks. The reliability of each picture category and the response direction 
of the disease-related AAT was found to be good (Cronbach’s alpha = .88 - .91). Due to 
the specific nature of the picture stimuli, this AAT was only administered to people with 
psoriasis, their SOs, and controls.
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For the social threat-related AAT, the stimuli were pictures of emotional facial expres-
sions: disgusted (main hypothesis), sad (bias to other negative emotional stimuli), smil-
ing (bias to positive emotional stimuli), and neutral faces (as comparison). The pictures 
were selected from the Radboud Faces Database [26]. Participants now had to respond 
with push or pull according to whether the picture color was grey or sepia. The task was 
introduced by 10 practice trials (checkerboard pictures), followed by 324 experimental 
trials distributed across two blocks. The reliability of each picture category and the 
response direction of the social threat-related AAT was found to be good (Cronbach’s 
alpha = .85-.91).
Questionnaires
Self-reported questionnaires were administered regarding disease severity, self-per-
ceived visibility, psychological distress, social anxiety, and fear of negative evaluation. 
In addition, a general checklist was used to assess participants’ gender, age, educational 
level, and marital status.
People with alopecia indicated their degree of hair loss as alopecia areata (circular 
patches of hair loss), androgenetica (female pattern baldness), totalis (total loss of 
hair on scalp), or universalis (total loss of hair on scalp and body). Disease severity in 
psoriasis was assessed with the commonly-used, valid, and reliable Self-Administered 
Psoriasis Area and Severity Index [SAPASI; 27]. This consists of an anterior and posterior 
silhouette on which people mark their affected areas, and three scales on which patients 
score the redness, thickness, and scaliness of their affected areas (range = 0 [complete 
remission] - 72 [most severe psoriasis]). Self-perceived visibility was assessed verbally, by 
asking: “To what extent do you think that your condition is generally visible to other 
people?” (range = 0 [never] - 4 [almost always]). To assess psychological distress, social 
anxiety, and fear of negative evaluation, three questionnaires were administered: the 
Hospital Anxiety and Depression Scale, the Liebowitz Social Anxiety Scale, and the Fear of 
Negative Evaluation Scale. The Hospital Anxiety and Depression Scale [HADS; 28] contains 
seven items measuring anxious symptoms and seven measuring depressive symptoms, 
rated on a 4-point scale. The total HADS score (range = 0-42, α = .80 in the current study) 
was used as a global measure of psychological distress, with higher scores reflecting 
higher distress. Previous research indicates that the HADS is valid and reliable [e.g., 29] 
The Liebowitz Social Anxiety Scale [LSAS; 30] is a measure of social anxiety that assesses 
fear and avoidance across different social situations. On a 4-point scale, participants rate 
their levels of anxiety (from none to severe) and avoidance (from never to always) of 24 
social situations. The total LSAS score (range = 0 - 144, α = .94) was used, with higher 
scores indicating higher levels of social anxiety. The brief version of the Fear of Negative 
Evaluation scale [BFNE; 31, 32] is a 12-item questionnaire that assesses fear of negative 
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evaluation (FNE) on a scale from 0 to 4, with higher scores reflecting higher levels of FNE 
(range = 0 - 48, α = .89). Research supports its validity and reliability [33].
Data preparation
In the preparation of Stroop data, data of one participant in the Alopecia SO group were 
excluded as an extreme outlier (participants’ mean reaction time [RT] across Stroop cat-
egories was 83.4 seconds, compared to the group mean RT of 28.8 ± 4.9). All other par-
ticipants were included in the analyses, to provide the most accurate description of un-
altered data. Repeating analyses on log-transformed variables, and on log-transformed 
variables in which outlying cases were given the value of the next-highest score, did not 
alter levels of significance. In the preparation of AAT data, individual trials with extreme 
RTs (< 300ms or > 2000ms, < 2% of trials) were removed before aggregating the data, 
in line with previous studies [e.g., 34]. Participants’ median RTs were then calculated for 
all categories, to prevent outlier effects, and the mean of these median RTs (dependent 
variable) was calculated for each group [e.g., 21]. In addition, AAT-effects were calcu-
lated by subtracting participants’ pull RTs (approach) from their push RTs (avoidance) for 
each picture category; a positive AAT-effect indicated relatively stronger approach than 
avoidance, while a negative AAT-effect indicated relatively stronger avoidance than ap-
proach [e.g., 21]. In the psychological questionnaires, one person with alopecia showed 
outlying scores on two of the questionnaires (mean LSAS score = 129, HADS = 31, > 4 
SD from group mean). These results were reported unaltered to provide an accurate 
description of the sample used for analyses. The same individual did not show outlying 
scores in Stroop or AAT data, and excluding this person from between-group analyses 
on questionnaire data did not alter levels of significance.
Statistical analysis
To examine whether people with chronic skin conditions and their SOs showed implicit 
biases as compared with controls, repeated-measures ANOVAs were conducted. These 
compared the reaction times (RTs) of the chronic skin condition groups and their SOs 
with those of controls with regard to all picture categories (AATs) or word categories 
(modified Stroop task). In the modified Stroop task, if the participants with chronic skin 
conditions and their SOs showed a slower reaction time to hair-related or stigmatization-
relation words than to neutral words, as compared with controls (i.e. a significant word 
category*group effect, followed by post-hoc analyses showing slower reaction times to 
hair-related and/or stigmatization-related words than to neutral words in these groups), 
this was taken as indicative of larger attentional bias in these groups. In the two AATs, 
significant picture category*response direction*group interactions, with quicker avoid-
ance reactions to disease-related or disgust-related pictures in chronic skin conditions 
and SOs compared with controls, were taken as indicative of larger behavioral bias in 
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those groups. If significant effects emerged, post-hoc tests were conducted to examine 
for which specific groups and/or conditions the effects were significant. In the case of 
significant between-group differences on sociodemographic variables or self-report 
questionnaires regarding psychological variables, these variables were controlled for in 
secondary analyses.
SuPPleMenTal MaTeRIal: SuPPleMenTal ReSulTS
Sample characteristics
Table S1 shows further details on the characteristics of the sample. Of the people with 
alopecia, 54% had alopecia universalis, 18% alopecia totalis, 26% alopecia areata, and 
2% alopecia androgenetica. People with psoriasis had a relatively mild disease severity 
(SAPASI mean ± SD = 4.56 ± 2.31). More females were present in the alopecia group than 
in the alopecia SO, psoriasis, and control groups (p ≤ .04), and the alopecia group scored 
higher on FNE than the control group (p = .001). Furthermore, the psoriasis group was 
less highly educated than the alopecia group and the healthy controls (p ≤ .008).
attentional bias: modified Stroop task
Mean reaction times for the modified Stroop task are presented in Table S4. In people 
with alopecia, groups differed in their RTs to specific word categories (F(8,262) = 3.13, p 
= .002, η2p = .09). Both people with alopecia (F(1,97) = 13.24, p < .001, η2p =.12) and their 
SOs (F(1,86) = 9.73, p < .001, η2p = .10) were slower than controls to name colors of hair-
related words compared to neutral words, while people with alopecia and their SOs did 
not differ from one another (p = .61). A main effect of word category (F(4,131) = 20.02, 
p < .001, η2p= .38) indicated that RTs differed across word categories, with participants 
overall being slower on hair-related words (F(1,134) = 74.88, p < .001, η2p =.36) and nega-
tive words (F(1,134) = 5.04, p = .03, η2p = .04) than on neutral words.
In people with psoriasis, groups differed in their RTs across word types (F(8,280) = 2.21, 
p = .03, η2p =.06); people with psoriasis were significantly faster to name the colors of 
negative words than of neutral words, compared with both SOs and controls (F(2,143) = 
3.67, p = .03, η2p =.05), but no differences were found for skin-related words (p = .43). In 
addition, RTs tended to differ between word categories across groups (F(4,140) = 2.23, p 
= .07, η2p =.06), with marginally slower RTs on skin-related words than on neutral words 
(p = .054).
No differences were found regarding social threat-related stigmatization words for 
participants with either skin condition, SOs, or controls (p ≥ .40).
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Behavioral bias: approach-avoidance tasks
Mean RTs and AAT-effects for the disease-related and social threat-related AAT can be 
found in Tables S5 and S6, respectively.
Disease-related behavioral bias
When people with psoriasis, their SOs, and controls were compared, the groups did not 
differ regarding their approach-avoidance reactions to psoriasis-related and neutral 
pictures (p ≤ .73). Participants’ RTs were generally slower on psoriasis-related pictures 
than on neutral pictures (F(1,145) = 25.78, p < .001, η2p =.15), and quicker to push (avoid) 
pictures than to pull (approach) them (F(1,145) = 14.79, p < .001, η2p = .09). AAT-effects 
(i.e. pull RTs - push RTs) were less pronounced in psoriasis-related than in neutral pic-
tures, possibly due to the near-zero AAT-effect in controls (F(1,145) = 14.64, p < .001, 
η2p =.09). Due to the specific nature of the picture stimuli, this skin-related AAT was not 
administered to people with alopecia and their SOs.
Social threat-related behavioral bias
When people with alopecia, their SOs, and controls were compared, the groups did not 
differ in their approach-avoidance reactions to pictures of emotional faces (p ≤ .68). 
Participants were generally slower to respond to neutral faces than to the other faces 
(F(3,140) = 13.88, p < .001, η2p = .23), and quicker to push (avoid) pictures than to pull 
(approach) them (F(1,142) = 26.59, p < .001, η2p = .16), with this effect being statistically 
significant for disgusted, smiling, and neutral faces (all p-values < .001), but not for sad 
faces (p = .89). The push/pull response differed across picture categories (F(3,140) = 
12.16, p < .001, η2p = .21); the avoidance tendency towards disgusted faces was more 
pronounced than towards sad faces (p < .001), less pronounced than towards neutral 
faces (p = .04), and did not differ from smiling faces (p = .25).
When people with psoriasis, their SOs, and controls were compared, groups did not 
differ in their approach-avoidance reactions to pictures of emotional faces (p ≤ .46). 
Similarly to the alopecia group, participants were generally slower to respond to neutral 
faces than to other faces (F(3,142) = 11.21, p < .001, η2p = .19), and quicker to push (avoid) 
pictures than to pull (approach) them (F(1,144) = 50.13, p < .001, η2p = .26). Participants 
showed relatively more avoidance of disgusted and neutral faces than of sad and smil-
ing faces (F(3,142) = 12.77, p < .001, η2p = .21).
Regarding the specific hypothesis for disgusted faces, explorative tests were per-
formed specifically comparing people with skin conditions and their SOs to controls with 
regard to their RTs in pushing and pulling disgusted faces. In line with the hypothesis, 
people with psoriasis and their SOs were found to be quicker to avoid (push) than to 
approach (pull) pictures of disgusted faces, compared with controls (F(1,146) = 4.01, p = 
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.047, η2p = .03). People with alopecia and their SOs did not differ from controls (F(1,142) 
= 0.14, p = .71).
Confounder analyses
In the modified Stroop task, the significantly slower RTs to hair-related words than neutral 
words in people with alopecia and their SOs, compared with controls, remained sig-
nificant when controlling for gender, education, and fear of negative evaluation. In the 
social threat-related AAT, the significantly faster avoidance than approach of pictures of 
disgusted faces in people with psoriasis and their SOs, compared with controls, remained 
significant when controlling for fear of negative evaluation (p = .04), and became mar-
ginally significant when controlling for gender (p = .051) and education (p = .06).
SuPPleMenTal MaTeRIal: SuPPleMenTal TaBleS
Table S1. Sociodemographic and psychological characteristics
Characteristic group
Alopecia
(n = 50)
SOs Alopecia
(n = 47)
Psoriasis
(n = 50)
SOs Psoriasis
(n = 50)
Control
(n = 50)
age (M (SD)) 52.20 (14.25) 49.66 (15.55) 56.88 (12.91) 53.28 (15.47) 56.84 (12.08)
gender (f (%)) 42 (84) 31 (66) 23 (46) 27 (54) 23 (46)
education (n (%))
Primary 0 (0)a 1 (2) 1 (2)a 1 (2) 0 (0)a
Secondary 22 (44)a 16 (34) 36 (72)a 29 (58) 18 (36)a
Tertiary 28 (56)a 29 (62) 12 (24)a 20 (40) 29 (58)a
Missing 0 (0)a 1 (2) 1 (2)a 0 (0) 3 (6)a
disease duration 20 (16) n.a. 22 (16) n.a. n.a.
disease visibility 1.69 (1.58)b n.a. 2.48 (1.29)b n.a. n.a.
hadS (M (SD)) 7.53 (5.70) 8.26 (4.15) 7.33 (4.96) 8.71 (4.17) 6.73 (4.56)
lSaS (M (SD)) 28.10 (21.57) 28.00 (14.95) 21.50 (16.06) 24.42 (14.58) 21.26 (13.19)
Bfne (M (SD)) 22.54 (11.69)c 19.56 (8.37) 16.80 (7.69)c 17.48 (7.70)c 16.20 (6.91)c
Note. f = number of females, BFNE = Fear of Negative Evaluation scale - brief version, HADS = Hospital 
Anxiety and Depression Scale, LSAS = Liebowitz Social Anxiety Scale, M = mean, SD = standard deviation, 
SOs = significant others.
aLower educational level in psoriasis than in alopecia and healthy controls, p ≤ .008
bGreater visibility in psoriasis than in alopecia, p < .01
cHigher BFNE scores in alopecia than in all other groups, except for SOs alopecia, p ≤ .01.
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Table S2. Order of administering tasks and questionnaires
alopecia, Sos alopecia Psoriasis, Sos Psoriasis, Control
Social threat-related AATa Disease-related or Social threat-related AAT (random)a
Name Letter Task (NLT)a,b Name Letter Task (NLT)a,b
Implicit Association Test (IAT)a,c Disease-related or Social threat-related AAT (random)a
Modified Stroop task1 Modified Stroop taska
Questionnaires Questionnaires
Note. AAT = approach-avoidance task, SOs = significant others.
aThe NLT, IAT, two additional categories of words in the modified Stroop task (acceptance-related and itch-
related), and four additional picture categories in the AATs (pictures of itch, ambiguous skin conditions, and 
empty frames in disease-related AAT, checkerboards in social threat-related AAT) were administered for 
research questions unrelated to this paper.
b [35], c [19].
Table S3. English translation of the word stimuli used in the modified Stroop task
Social threat haira Skinb negative Positive neutral
Insecure Alopecia Skin disorder Bombs Good-humored Mug
Shame Hair loss Rash War Friendly Kettle
Inferior Downy hair Scaling Fight Honest Nutcracker
Bullying Hair growth Eczema Grenade Helpful Refrigerator
Unhappy Scalp hair Flaking Pistol Funny Kitchen
Secluded Baldness Psoriasis Murder Polite Tablecloth
Not understood Hair falling out Blisters Violent Nice Light bulb
Vulnerable Wig Bumps Explosion Cheerful Doorknob
Note. All words were single words in Dutch and matched in length between categories.
aThis category was not administered to people with psoriasis and their significant others.
bThis category was not administered to people with alopecia and their significant others.
Table S4. Modified Stroop task: average color-naming reaction times in seconds (with standard devia-
tions) for each group and word category
word category group
Alopecia SOs Alopecia Psoriasis SOs Psoriasis Control
Social threat 28.17 (5.32) 27.84 (4.82) 28.72 (7.17) 29.36 (6.63) 28.35 (6.04)
Hair 32.06 (6.10) 31.99 (5.74) n.a. n.a. 29.29 (7.05)
Skin n.a. n.a. 29.73 (7.40) 30.90 (7.49) 28.34 (5.58)
Neutral 27.66 (4.40) 28.08 (4.76) 29.14 (8.39) 29.60 (6.99) 28.16 (5.32)
Negative 28.57 (5.73) 28.69 (4.67) 28.10 (6.97) 30.33 (8.82) 28.47 (5.87)
Positive 28.18 (4.50) 28.95 (4.98) 29.27 (7.72) 30.41 (7.19) 27.84 (5.52)
Note. SOs = significant others, n.a. = not applicable.
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Table S5. Disease-related AAT: Means of median reaction times (and standard deviations) in milliseconds 
depending on group, picture type, and response direction, including AAT-effects
Picture type Response
direction
group
Psoriasis SOs Psoriasis Control
Psoriasis-related Pull 971 (448) 975 (391) 872 (244)
Push 910 (344) 955 (388) 871 (279)
aaT-effect -61 (196) -20 (189) 0 (108)
Neutral Pull 946 (404) 908 (300) 861 (251)
Push 847 (313) 840 (276) 797 (199)
aaT-effect -99 (237) -69 (204) -64 (136)
Note. AAT-effects were calculated by subtracting participants’ pull RTs from their push RTs for each pic-
ture category, with a negative AAT-effect indicating relatively stronger avoidance than approach. AAT = 
approach-avoidance task; SOs = significant others.
Table S6. Social threat-related AAT: Means of median reaction times (and standard deviations) in millisec-
onds depending on group, picture type, and response direction, including AAT-effects
Picture type Response
direction
group
Alopecia SOs Alopecia Psoriasis SOs Psoriasis Control
Sad Pull 700 (135) 699 (120) 687 (109) 721 (151) 713 (94)
Push 703 (135) 699 (122) 682 (96) 697 (118) 708 (102)
aaT-effect 3 (45) 1 (41) -5 (50) -24 (70) -5 (52)
Disgusted Pull 705 (143) 704 (118) 702 (107) 720 (142) 717 (92)
Push 691 (150) 678 (119) 667 (100) 685 (126) 699 (109)
aaT-effect -14 (48) -26 (50) -37 (44) -35 (59) -18 (54)
Smiling Pull 708 (142) 702 (126) 700 (111) 719 (139) 716 (90)
Push 692 (130) 689 (117) 680 (103) 699 (126) 702 (100)
aaT-effect -16 (51) -13 (42) -20 (44) -20 (44) -14 (44)
Neutral Pull 723 (139) 716 (124) 714 (112) 734 (144) 737 (90)
Push 704 (159) 686 (118) 680 (101) 692 (133) 701 (103)
aaT-effect -19 (67) -30 (42) -41 (72) -42 (62) -37 (50)
Note. AAT-effects were calculated by subtracting participants’ pull RTs from their push RTs for each pic-
ture category, with a negative AAT-effect indicating relatively stronger avoidance than approach. AAT = 
approach-avoidance task; SOs = significant others.
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aBSTRaCT
Background: Patients with chronic somatic conditions face unique challenges access-
ing mental health care outside of their homes due to symptoms and physical limitations. 
Internet-based cognitive behavioral therapy (ICBT) has shown to be effective for various 
psychological conditions. The increasing number of recent trials needs to be systemati-
cally evaluated and quantitatively analyzed to determine whether ICBT is also effective 
for chronic somatic conditions and to gain insight into the types of problems that could 
be targeted.
objective: Our goal was to describe and evaluate the effectiveness of guided ICBT in-
terventions for chronic somatic conditions on general psychological outcomes, disease-
related physical outcomes, and disease-related impact on daily life outcomes. The role 
of treatment length was also examined.
Methods: PubMed, PsycINFO, and Embase were searched from inception until February 
2012, by combining search terms indicative of effect studies, internet, and cognitive 
behavioral therapy. Studies were included if they fulfilled the following six criteria: (1) 
randomized controlled trial, (2) internet-based interventions, (3) based on cognitive 
behavioral therapy, (4) therapist-guided, (5) adult (≥ 18 years old) patients with an exist-
ing chronic somatic condition, and (6) published in English. Twenty-three randomized 
controlled trials of guided ICBT were selected by two independent raters after reviewing 
4848 abstracts. Demographic, clinical, and methodological variables were extracted. 
Standardized mean differences were calculated between intervention and control con-
ditions for each outcome and pooled using random effects models when appropriate.
Results: Guided ICBT was shown to improve all outcome categories with small effect 
sizes for general psychological outcomes (effect size range 0.17 to 0.21) and occasionally 
larger effects for disease-specific physical outcomes (effect size range -0.04 to 1.19) and 
disease-related impact outcomes (effect size range 0.17 to 1.11). Interventions with a 
longer treatment duration (> 6 weeks) led to more consistent effects on depression.
Conclusions: Guided ICBT appears to be a promising and effective treatment for chronic 
somatic conditions to improve psychological and physical functioning and reduce 
disease-related impact. The most consistent improvements were found for disease-
specific outcomes, which supports the possible relevance of tailoring interventions 
to specific patient groups. Explorative analyses revealed that longer treatment length 
holds the promise of larger treatment effects for the specific outcome of depression. 
While the current meta-analysis focused on several chronic somatic conditions, future 
meta-analyses for separate chronic somatic conditions can further consolidate these 
results, also in terms of cost-effectiveness.
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InTRoduCTIon
Cognitive behavioral therapy (CBT) focuses on challenging cognitive distortions and 
dysfunctional underlying beliefs, and on teaching coping and problem solving skills [1]. 
A variety of techniques are combined to achieve this, including cognitive restructuring, 
relaxation, problem solving, and stress management. The central idea of CBT is that the 
way people make sense of their environment affects their feelings and behavior. CBT is 
an extensively researched and widely used form of treatment for a variety of psychologi-
cal conditions [1] and is increasingly used to help a growing number of patients suffering 
from chronic somatic conditions cope with the consequences of their condition [1–5]. 
CBT models can, for instance, be applied to improve patients’ adjustment to receiving a 
diagnosis of a chronic somatic condition and coping with it, to improve comorbid mood 
problems such as anxiety and depression, to alter disease-specific beliefs and attitudes, 
and to teach pain/symptom management strategies [6, 7].
Although studies indicate that CBT may be an effective treatment for chronic somatic 
conditions, it has not been implemented on a large scale, partly due to the lack of CBT 
therapists specializing in patients with chronic somatic conditions. Furthermore, chroni-
cally ill patients may have physical limitations that make it difficult to travel to a clinic 
for face-to-face CBT. A possible solution is to offer CBT online: Internet-based cognitive 
behavioral therapy (ICBT). Generally, ICBT takes the form of an online self-help program, 
guided by a therapist who gives feedback and answers questions [8]. Advantages of 
ICBT over offline computerized CBT and over bibliotherapy include the possibility of 
the patient connecting with a therapist or with peers who cope with similar problems, 
and the ability to log on and use the intervention anytime and anywhere they would 
like. ICBT may be beneficial to both patients and therapists: it is more convenient, flex-
ible, and reduces traveling time, costs, and waiting lists, enabling more patients to be 
reached and treated [9]. In addition, providing CBT online may reduce the stigma of 
needing psychological help. Recently, first indications have been reported for the cost-
effectiveness of ICBT [10–12].
Internet interventions are generally found to be effective for a variety of psychological 
conditions [13–16]. Preliminary evidence is also emerging for its effect on psychological 
and physical outcomes in various health problems [17–21] and in promoting health 
behavior change [22, 23]. In order to determine whether ICBT is effective for chronic so-
matic conditions, the results of the increasing number of recent randomized controlled 
trials (RCTs) need to be systematically evaluated and quantitatively analyzed. Moreover, 
knowledge of which types of outcomes are specifically improved by ICBT will provide 
insight into the types of problems that could be targeted with ICBT.
An additional focus on which elements of interventions are effective for which patients 
at what disease stage will aid development of effective tailored interventions. Scarce 
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evidence suggests that the amount of therapist contact is related to effectiveness [16]. 
An aspect of ICBT that has not been examined is whether the duration of ICBT influences 
treatment outcomes. For traditional face-to-face CBT for chronic somatic conditions, an 
average treatment of 12–16 sessions given once a week is suggested [24]. Although 
there are indications in patients with depressive symptoms that a longer ICBT treatment 
duration yields better outcomes [25], the role of treatment duration has not yet been 
examined for chronic somatic conditions.
The current review aims to describe and evaluate the effectiveness of guided ICBT in-
terventions in randomized controlled trials, for three specific outcome categories −gen-
eral psychological outcomes, disease-related physical outcomes, and disease-related 
impact outcomes− and to explore the role of treatment duration. The review focused on 
guided ICBT interventions, in order to optimize comparability with face-to-face CBT and 
decrease heterogeneity, as it is known that guided ICBT interventions generally lead to 
different (larger) effects than non-guided self-help interventions [16]. This review has a 
broad focus, including a large population of chronic somatic conditions. Because the 
literature on ICBT in different chronic somatic conditions is rather limited at this time, 
it is not yet possible to meaningfully summarize the evidence for efficacy of ICBT for 
these separate categories of chronic somatic conditions. Because the main elements of 
CBT are generic in scope and can be applied to a large variety of problems, combining 
these different chronic somatic conditions in this meta-analysis provides a first overall 
indication of the efficacy of ICBT interventions in the large population of chronic somatic 
conditions. In addition, the separate outcomes for different somatic conditions can also 
be deduced from the paper.
MeThodS
Search strategy and inclusion criteria
PubMed, PsycINFO, and Embase were searched from inception until February 2012, by 
combining index terms indicative of effect studies, internet, and cognitive behavior 
therapy, and including the following Medical Subject Heading (MeSH) terms: internet, 
electronic mail, behavior therapy, psychotherapy, rehabilitation, counseling, and self-
care (see Multimedia Appendix 1 for search strategies). Only studies investigating guided 
ICBT, which is comparable to face-to-face CBT, were included. All retrieved references 
were loaded into Endnote, and two raters (SvB, MSc Psychology, HvM, PhD Psychology) 
independently screened titles and abstracts without blinding to authorship or journal. 
The full text of potentially relevant studies was examined. Discrepancies between re-
viewers were resolved by discussion. The kappa statistic was calculated to determine 
consistency among raters. Inclusion criteria were (1) RCT or equivalence trial, (2) therapy 
Meta-analytic review of internet-based treatment 91
5
provided with the internet (not face-to-face, telephone, onsite computerized therapy, 
videoconferencing, or personal digital assistants) as the main way of communication 
(e.g., patient spends > 50% of total intervention time spent on an Internet-based inter-
vention), (3) therapy based on CBT principles (in which at least some forms of cognitive 
and behavioral techniques are used), (4) therapy guided by contact with a therapist, 
with at least one episode of personalized patient contact (either through asynchronous 
messages, telephone, or another mode of contact), and (5) adult study sample (age ≥ 18 
years) with an existing chronic somatic condition (i.e. a condition expected to last a year 
or longer, limit what a patient can do, and/or may require ongoing medical care) [26]. 
Aetiology was not an inclusion criterion; both functional and structural disorders were 
included. Conditions that may have physical consequences but do not have physical 
illness as its primary feature, such as eating disorders, insomnia, addiction problems, 
fertility problems, and sexual dysfunction, were also excluded. Papers not published in 
English were also excluded. Studies were excluded when the main focus of the interven-
tion was focused on lifestyle change, such as increasing levels of exercise or improving 
diet. Publications of the same intervention were included if each study was based on a 
new patient sample. Papers were excluded based on a hierarchical approach, in which 
articles were not further assessed for remaining reasons if they were excluded based on 
a previous reason. The hierarchy of reasons for exclusion were that (1) the study does 
not examine ICBT for chronic somatic conditions, (2) the study is not an RCT, (3) the 
ICBT intervention is not guided by a therapist, and (4) the study does not examine adult 
patient populations (see Figure 1).
data extraction
The following information was gathered per study: publication year, chronic somatic 
condition, country of data collection, number of patients included, completers, drop-
outs, dropout reasons, age, gender, type of CBT intervention, therapist contact, control 
condition, outcome measures, intervention length, completer or intent-to-treat analy-
ses, post-treatment results, and follow-up results. A large variety of outcome measures 
were reported across studies. To enable general conclusions, these were grouped 
together into three main outcome categories that are of relevance to patients with 
chronic somatic conditions: (1) general psychological outcomes of depression, anxiety, 
and distress, (2) disease-related physical outcomes related to symptom severity, such as 
pain, fatigue, and headache, and (3) disease-related outcomes concerning the impact of 
a chronic somatic condition on daily life (i.e. disease-specific distress and disease-specific 
quality of life) (see Multimedia Appendix 2). To improve homogeneity and narrow the 
scope of the review, outcome measures that did not fit these categories (e.g., coping or 
behavior) or that were not suitable for pooling in meta-analysis (i.e. because of being 
assessed infrequently (e.g., general quality of life) or by means of different measures 
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(e.g., disability) were excluded. When more than one outcome was used to measure the 
same construct, results for the outcome that was most generic (e.g., total scale score 
versus subscale scores), most validated (e.g., Beck Depression Inventory (BDI [27]) versus 
Modified Beck Depression Inventory (mBDI [28]), or most comparable to other studies 
(e.g., visual analogue scale [VAS] of distress versus therapist-rated distress) was used, to 
prevent separate studies having too much influence on the analysis.
figure 1. PRISMA flow diagram of study selection.
assessment of risk of bias in included studies
Two independent authors (SvB, MSc Psychology; MF, MSc Psychology) assessed each 
study using the Cochrane risk of bias tool, including selection bias (randomization pro-
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cess), performance bias (blinding of subjects and personnel), detection bias (blinding 
of outcome assessment), reporting bias (handling of missing data), and attrition bias 
(reasons for withdrawal in all conditions) [29]. A third rater (MR, professor of evidence-
based surgery) was consulted to reach consensus when two raters were in disagreement. 
Risk of bias was assessed based on the information of original publications and on trial 
registrations on the ClinicalTrials website.
Reporting study results
Only between-group results were taken into account to examine the effect of ICBT as 
compared to a passive control condition. Passive control conditions were defined as 
conditions in which participants do not receive a therapeutic program and instead are 
placed on a waiting list, or receive only treatment as usual or treatment that is theorized 
to not lead to changes in therapeutic outcomes (e.g., patient education) (see Multimedia 
Appendix 2). For equivalence trials, in which patients receive an intervention that is 
theorized to lead to clinically relevant changes in outcomes as an active comparison 
condition, and for studies with a three-arm design, both between-group effects and 
main effects are reported (see Multimedia Appendices 3 and 4). Intent-to-treat analyses 
(ITT), in which all randomized patients are analyzed regardless of adherence to study 
protocol [30], were used wherever possible. When two active ICBT interventions were 
compared to a passive control condition in a three-arm RCT design, both comparisons 
are reported. Two types of dropout rates were calculated: (1) intervention dropouts by 
dividing the number of patients reported to have stopped the intervention (or did not 
return post-intervention questionnaires) by the number randomized to the intervention 
group, and (2) measurement dropouts by dividing the number of patients from both the 
intervention and control groups who did not return post-intervention questionnaires 
by the total number of patients randomized. As between-group follow-up results were 
not consistently and uniformly reported across studies, pooling was not feasible. There-
fore, only post-intervention study results are reported and the number of studies that 
included follow-up results is briefly summarized.
data analyses and synthesis
Standardized mean difference of effect sizes (SMDs) were calculated by subtracting the 
difference in means in the ICBT group from the difference in means in the control group 
and dividing the outcome by their pooled standard deviation [31]. Effect sizes of 0.2, 
0.5, and 0.8 can be considered as small, moderate, and large, respectively [32]. When 
a study contained multiple eligible ICBT treatment groups, these were combined in a 
single pairwise comparison, according to recommendations and calculation methods 
from the Cochrane handbook [29]. If mean values and SDs were not reported, authors 
were contacted to obtain original trial data. When not provided, alternative methods 
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were used (i.e. using reported mean change scores and associated SDs). To decide 
whether meta-analytic pooling of data was justified, we computed I2, which describes 
the percentage of total variation between studies due to heterogeneity rather than 
chance [33]. An I2 of 25%, 50%, and 75% can tentatively be considered as low, moderate, 
and high heterogeneity, respectively [33]. High heterogeneity indicates that the effects 
are not the same for all studies and that there may be other variables that explain this 
heterogeneity. As significant heterogeneity is to be expected, SMDs were calculated in 
random effects models, using Cochrane Collaboration software Review Manager, ver-
sion 5.1. These models assume that there is no one ‘true effect size’, but rather the effect 
sizes are sampled from a population of varying effect sizes [34]. Subgroup differences in 
intervention duration were analyzed using the chi-square test, with p < .05 indicating 
statistically significant differences.
ReSulTS
Search results and study characteristics
The literature search identified 4848 unique studies, 23 of which met the inclusion cri-
teria (see Figure 1) [35–57]. Interrater reliability of study selection was kappa = .805. The 
included studies involved 4340 subjects (2299 ICBT and 2041 control); 59% of subjects 
participated in three large studies by Lorig and colleagues [52–54].
In 74% (17/23) of studies, subjects were randomized to one of two conditions, 15 of 
which compared ICBT with a passive control condition: waiting-list (12 studies), care-
as-usual (2 studies), and information-based psycho-education (1 study) (Multimedia 
Appendix 2). Three studies compared ICBT with an active CBT control condition: face-
to-face group therapy, online stress management without CBT, and ICBT with added 
telephone contact (Multimedia Appendix 3). Five studies used a three-arm design, two 
of which reported results of the two joint intervention groups compared to a passive 
control condition (Multimedia Appendix 2), and three compared each of the three con-
ditions (Multimedia Appendix 4).
A total of 70% (16/23) of studies were published between 2008 and 2011, and 52% 
(12/23) were carried out in Sweden. Eleven studies (48%) used intent-to-treat (ITT) 
analyses. The majority of these studies (6/11) used the last observation carried forward 
(LOCF) method, in which a participant’s missing values after dropout are replaced with 
the last available measurement [58]. Four of the 11 studies used mixed models ap-
proaches [59], and one used multiple imputation by chained equations [60]. 74% (17/23) 
included some form of follow-up assessment ranging from 1-18 months: 10 (43%) used 
a between-group follow-up and 7 (30%) included a within-group or completers-only 
follow-up, ranging from 2 months to 1 year. Dropout rates differed widely but were over-
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all relatively high (median 18%, range 2-57%), particularly in the intervention groups 
(median 29%, range 1-72%) (Multimedia Appendix 2). Of the 5 studies that reported 
reasons for dropout, the most common reason mentioned was lack of time.
Patient populations
Patient populations included chronic pain (5/23 studies, 21%), headache or migraine 
(4/23 studies, 17%), tinnitus (4/23 studies, 17%), irritable bowel syndrome (IBS, 4/23 
studies, 17%), diabetes (2/23 studies, 8%), breast cancer (1/23 studies, 4%), epilepsy 
(1/23 studies, 4%), fatigue in patients with chronic neurological disorders (1/23 studies, 
4%), and a heterogeneous patient population (1/23 studies, 4%) (Multimedia Appendix 
2). Twenty studies of 23 (87%) involved community-based samples. The mean age range 
of subjects within studies varied between 34 and 66 years; most studies included more 
female than male subjects.
Intervention content and duration
Interventions consisted of a variety of generic CBT-based techniques, often supple-
mented with specific approaches appropriate for the chronic condition under study. 
Interventions focusing on relaxation and psycho-education were included only when 
combined with other CBT techniques, that is, some form of cognitive reappraisal or re-
structuring [61]. Treatment content was categorized into well-known CBT elements such 
as cognitive therapy, behavioral therapy, applied relaxation, and psycho-education (see 
Multimedia Appendix 2). The vast majority of studies described the interventions as self-
help programs with structured modules, which were typically completed in a rate of one 
module per week, with minimal therapist guidance. The most commonly mentioned 
intervention components were cognitive therapy techniques, (applied) relaxation, 
psycho-education, and improving coping skills. These components were mentioned in 
74-100% of interventions. Stress management and behavioral therapy techniques were 
also mentioned in over half of included interventions. Other therapy components, in-
corporated in 26-35% of interventions, were problem solving techniques, mindfulness-
based techniques, exposure, and physical exercise. The majority of interventions were 
labelled as CBT and/or self-management interventions, while some interventions were 
based on acceptance and commitment therapy (ACT) [46], exposure-based treatment 
in combination with mindfulness techniques [49–51], or mindfulness-based cognitive 
therapy (MBCT) [56].
Interventions were generally broad and multifaceted, targeting various aspects of 
chronic somatic conditions within one intervention (e.g., comorbid mental health 
problems, coping with the chronic somatic condition, and reducing physical symptoms). 
Incidentally, studies indicated that there was a specific primary aim, for example, to 
reduce depressive symptoms [56–57], distress associated with the condition [35, 37], 
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or severity of the chronic somatic condition [41, 43, 50]. However, also in the interven-
tions with a more specific aim, components were generally included to fit other aims as 
well. Therefore, it was not possible to meaningfully categorize interventions according 
to the intervention aim (e.g., physical, mental, prevention). When analysing the results, 
the SMDs in each meta-analysis generally did not meaningfully differ from one another, 
indicating that there are no differences in SMDs according to intervention aim.
Therapist contact and peer contact
All studies incorporated treatment-related contact options, usually in the form of 
(weekly) email contact with (psychology master students supervised by) licensed 
clinical psychologists. One study was based solely on therapist-patient contact via email 
without additional treatment components. Most studies did not report, or not in detail, 
the average time therapists spent on patients. The main mode of therapist contact was 
through asynchronous (email) messages, but in three of 23 studies (13%) telephone was 
the main contact option. Five studies (22%) used online group formats. A total of 43% 
(10/23) of studies included a bulletin board that enabled patients to interact with each 
other, as an addition to individual treatment tools.
Risk of bias in included studies
The authors’ judgments about risk of bias for each included study and presented as 
percentages across all included studies can be found in Figures 2 and 3. While the major-
ity of studies (14/23, 61%) reported adequate methods of randomization, 35% (8/23) 
of studies did not report randomization methods, and 4% (1/23) reported inadequate 
methods. The study with inadequate methods (e.g., randomization based on order of 
enrolment [47]) was excluded from primary analyses, as a randomized design was one 
of the inclusion criteria for this study. To be complete, we also report the results includ-
ing this study, in a secondary analysis. In eight studies of the 23 (35%), allocation of 
participants was adequately concealed, while allocation concealment remained unclear 
in ten of 23 studies (43%) and was at risk for inadequate concealment in 22% (5/23); for 
example, tossing a coin, picking a piece of paper, or throwing dice. None of the included 
studies reported blinding of participants, personnel, and outcome assessments, which 
led to an unclear risk of bias in 43% of studies (10/23; no information on blinding) or a 
high risk of bias in 57% of studies (13/23; information indicating that blinding did not 
take place). Over half of all studies had incomplete outcome data that led to a high risk 
of bias, which was mainly due to a lack of intent-to-treat analyses in 48% (11/23) of 
studies. The risk of selective reporting bias remained largely unclear, mainly because 
only 26% (6/23) were registered with the ClinicalTrials site and registration often took 
place after study completion.
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figure 2. Risk of bias graph.
figure 3. Risk of bias summary: review authors judgements for each included study about each risk 
of bias item. A = random sequence generation (selection bias); B = Allocation concealment (selection bias); 
C = Blinding of participants and personnel (performance bias); D = Blinding of outcome assessment (detec-
tion bias); E = Incomplete outcome data (attrition bias); F = Selective reporting (reporting bias).
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effectiveness of ICBT interventions
SMDs for the included outcomes are reported in Multimedia Appendix 2 for the 17 stud-
ies with a passive control condition, Multimedia Appendix 3 for the 3 studies with an 
active control condition, and Multimedia Appendix 4 for the 3 studies with a three-arm 
design. Pooled SMDs for the three outcome categories can be found in Table 1.
Table 1. Pooled SMDs for ICBT versus passive control conditions
Outcome category ka SMDb 95% CI z p I2 (%)
general psychological outcomes
Depressive symptoms 15 0.21 0.08-0.34 3.18 .001 29
Anxious symptoms 10 0.17 0.01-0.32 2.14 .03 0
General distress 6 0.21 0.00-0.41 1.98 .05 0
disease-related physical outcomes
IBS symptoms 2 1.19 0.82-1.57 6.25 <.001 0
Headache 3 0.49 0.21-0.77 3.41 <.001 0
Sleep quality 3 0.25 -0.02 to 0.53 1.80 .07 0
Pain 6 0.18 0.08-0.28 3.61 <.001 0
Fatigue 2 0.15 0.05-0.26 2.87 <.01 0
Tinnitus loudness 2 -0.04 -0.40 to 0.32 0.24 .81 0
Glycemic control 2 0.07 -0.17 to 0.30 0.54 .59 62
disease-related impact outcomes
Disease-specific quality of life 3 1.11 0.79-1.44 6.73 <.001 0
Disease-specific distress 6 0.17 0.03-0.31 2.41 .02 57
Note. IBS = irritable bowel syndrome.
ak = number of comparisons, b SMD =standardized mean difference.
General psychological outcomes
Sixteen of 17 studies comparing ICBT with a passive control condition included general 
psychological outcomes, 5 of which (31%) found greater improvements in the ICBT con-
dition on at least one outcome (see Multimedia Appendices 2 and 4). ICBT had similar 
effects as active treatment control conditions (see Multimedia Appendices 3 and 4). 
Pooled SMDs for depressive symptoms, anxious symptoms, and general distress yielded 
small but generally statistically significant effects (see Table 1 and Figures 4 to 6). For 
depressive symptoms, results of a sensitivity analysis excluding one outlier with a very 
large effect on depression [SMD 4.34; 56] are reported; if included, the SMD would be 
0.32 (k = 16, 95% CI 0.09 -0.55, p = .005, I2 = 78%).
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figure 4. Forest plot of standardized mean differences of the effect on depression of Internet-based cogni-
tive behavioral therapy compared with a passive control condition.
figure 5. Forest plot of standardized mean differences of the effect on anxiety of Internet-based cognitive 
behavioral therapy compared with a passive control condition.
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figure 6. Forest plot of standardized mean differences of the effect on general distress of Internet-based 
cognitive behavioral therapy compared with a passive control condition.
Disease-related physical outcomes
Seventeen studies comparing ICBT with a passive control condition included disease-
related physical outcomes, with 59% (10/17) finding effects in favor of the ICBT condition 
on at least one outcome (see Multimedia Appendices 2 and 4). Pooled SMDs for physical 
outcomes yielded varying results. Large effects were found for IBS symptoms, moderate 
effects for headache, small effects for pain and fatigue, and non-significant effects were 
found for tinnitus loudness, sleep quality, and glycaemic control (see Table 1). In the case 
of IBS symptoms, one study was excluded based on inadequate randomization proce-
dures. A secondary sensitivity analysis including this study led to very similar results as 
the primary analysis (pooled SMD 1.14, 95% CI 0.81-1.48, p < .001, I2 = 0%, k =3). Studies 
with an active control condition were not pooled due to a limited number of studies and 
comparable outcomes (see Multimedia Appendices 3 and 4 for the results of individual 
studies).
Disease-related impact on daily life
Nine studies with a passive control condition included measures of disease-related dis-
tress or quality of life, of which seven (78%) found effects in favor of the ICBT condition 
on at least one outcome (see Multimedia Appendices 2 and 4). Small but significant 
effects were found on disease-related distress, and large effects were found on disease-
specific quality of life (see Table 1 and Figures 7 and 8). In the case of disease-specific 
quality of life, one study was excluded based on inadequate randomization procedures. 
A secondary sensitivity analysis including this study led to very similar results as the 
primary analysis (pooled SMD 1.09, 95% CI 0.80-1.39, p < .001, I2 = 0%, k = 4). Results from 
studies with an active control condition were not pooled due to a limited number of 
studies and outcomes. Individual study results can be found in Multimedia Appendices 
3 and 4.
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figure 7. Forest plot of standardized mean differences of the effect on disease-specific quality of life of 
Internet-based cognitive behavioral therapy compared with a passive control condition.
figure 8. Forest plot of standardized mean differences of the effect on disease-specific distress of Internet-
based cognitive behavioral therapy compared with a passive control condition.
Role of treatment duration in intervention effectiveness
Most interventions were relatively short, with little variability in treatment duration: 4% 
(1/23) of the interventions lasted 4 weeks, 48% (11/23) lasted 6 weeks, and 48% (11/23) 
lasted 7-24 weeks (see Multimedia Appendix 2). Consequently, outcomes of the studies 
in which the intervention lasted ≤ 6 weeks and > 6 weeks were compared. Of the 5 stud-
ies finding a between-group effect on depression, 4 (80%) had an intervention duration 
of > 6 weeks. Effect sizes of the longer interventions (n = 8; SMD 0.29; 95% CI 0.13-0.46) 
were larger than those in the shorter interventions, with marginal statistical significance 
(n = 7; SMD 0.08; 95% CI -0.05 to 0.22) (χ21=3.91, p=.05). Intervention duration did not 
influence effectiveness for other outcomes.
dISCuSSIon
Principal findings
Our meta-analysis indicates that ICBT is effective for chronic somatic conditions regard-
ing both general psychological outcomes and disease-specific outcomes. Effect sizes 
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were generally small to moderate, with larger effect sizes occasionally found for disease-
related outcomes, such as self-reported headache and IBS symptoms, and for disease-
specific quality of life. These findings of larger effects on disease-specific outcomes may 
on the one hand reflect the larger sensitivity to change of these measures [62, 63] and 
on the other hand support the idea of tailoring interventions to the needs of specific 
patient groups, as disease-specific measures are likely the measures that respond well to 
more tailored, disease-specific approaches [64–67].
The three included studies that compared ICBT with an active treatment condition 
showed that ICBT can be as effective as group-based face-to-face CBT, for example. 
However, two studies also found that ICBT and an informational website without CBT 
content were similarly effective. These results indicate a need for studies in which the 
effects of specific components of ICBT are more closely investigated. The role of one 
such component of ICBT was examined in this meta-analysis −intervention length− sug-
gesting that interventions lasting longer than 6 weeks result in greater improvements 
in depression.
Overall, results of this review extend previous reviews and meta-analyses, which con-
cluded that ICBT may be a promising adjuvant treatment for psychological outcomes 
[13–16] and for patients with health problems [17–23]. Meta-analyses have typically 
reported small [18] to moderate [14, 16] pooled effect sizes for Internet-based psycho-
therapeutic interventions. The results are also comparable to meta-analyses of face-to-
face CBT, which typically find small to moderate effect sizes on a variety of outcomes [1, 
68–70], with sometimes larger disease-specific than more general mood-related effects 
[69]. Our review adds to previous findings by including all available studies in chronic 
somatic populations and by identifying differences in effectiveness for specific catego-
ries of outcome. With this approach, it was shown for the first time that guided ICBT is 
effective for various psychological and physical outcomes, with most promising results 
for disease-related outcomes, and that intervention duration might be a determinant 
of the effectiveness of ICBT for depression. These results underline the potential benefit 
of ICBT for patients with chronic somatic conditions in helping them cope with the 
consequences of their condition.
limitations
Some potential limitations should be discussed. First, there are still a limited number 
of studies on ICBT in chronic somatic conditions, and sometimes only one study was 
available for a specific condition, which precludes drawing reliable conclusions about 
specific patient groups and generalizing across conditions. Over half of the studies were 
performed in Sweden by the same authors, but post-hoc analyses did not find differ-
ences in outcomes between the Swedish and other studies (data not shown). Women 
constituted a large proportion of most study populations, reflecting the often unequal 
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gender distribution of different chronic somatic conditions. Second, studies were found 
to be of variable methodological quality, which may influence both individual study 
results and overall outcomes in meta-analysis. Although all studies had unclear or high 
risk of blinding bias, this is often unfeasible or very difficult to achieve in non-pharma-
cological behavioral interventions and thus may not be a valid indicator of study quality 
[71]. In many studies, inadequate descriptions resulted in unclear risk of bias. This may 
be resolved by using guidelines for reporting RCTs [72]. Third, the appropriateness of 
pooling studies of ICBT for various patient populations can be discussed, as pooling is 
intended for more or less homogeneous populations and outcomes. The current review 
included a relatively diverse range of chronic somatic conditions, and outcomes were 
often assessed with various different questionnaires. However, similar effects and low 
heterogeneity were found for most outcomes, supporting the idea that the included 
studies were comparable regarding their outcomes. Including these various studies in 
this meta-analytic overview provides the reader with a first indication of the overall ef-
fectiveness of ICBT for chronic somatic conditions and increases the generalizability of 
findings [73, 74]. As more trials become available in the future, meta-analyses should be 
performed for separate chronic somatic conditions. Fourth, long-term between-group 
follow-up measurements were often lacking, precluding a reliable long-term estimate. 
Fifth, there was substantial variation in description of treatment content, therapist 
contact, and dropout. For instance, not all therapist contact was with a trained therapist 
but could also include “expert” patients, nurses, physicians, occupational therapists, or 
research assistants. Dropout rates were not always adequately described and generally 
high, which is a common problem with internet interventions [75]. Sixth, publication 
bias cannot be precluded. The current review was limited to published studies, as it 
was unfeasible to obtain a complete and unbiased overview of all unpublished grey 
literature on this subject. This may have led to an overestimation of effectiveness, as 
published studies are generally more likely to include statistically significant results [76]. 
However, several studies that did not find an effect were included in the current review, 
indicating that not only studies with significant results are published on this topic.
Finally, we used the pooled standard deviation based on pre- and post-intervention 
measurements in our meta-analysis. When using change scores in meta-analysis, the 
most appropriate measure would have been the standard deviation of changes. 
However, the included studies did not report sufficient information to calculate these 
standard deviations [29], which has been recognised as a common problem when using 
change scores. Our approach can, however, be considered as a conservative approach 
since the calculated standard deviations will be slightly larger than the standard devia-
tions of changes would have been. Another alternative would have been to perform the 
meta-analysis based on post-intervention measurements, but such an approach does 
not take into account possible differences in baseline measurements. Nevertheless, we 
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also performed a meta-analysis based on post-intervention measurements results. The 
results of this meta-analysis were very similar to the change score results reported in our 
study (data not shown), and would have led to similar conclusions.
future research
Results from this review suggest several areas for future research, related to study meth-
odology and intervention design. More studies with adequate sample sizes focusing on 
a wider range of chronic somatic conditions with between-group long-term follow-up 
are needed. Only one study involved older patients [38], yet older patients are often af-
fected by chronic conditions. As dropout is common with ICBT, ways to promote engage-
ment and improve adherence should be investigated. Preliminary research suggests 
that tailoring interventions may be an effective strategy to promote engagement and 
adherence [77–79]. Strategies found to be predictive for adherence include increased 
therapist contact, more frequent website updates, and more frequent intended usage 
[80]. Also, future research is needed to examine the effects of ICBT on outcomes such as 
work-related outcomes, health behaviors, and cost-effectiveness, which were not evalu-
ated in this meta-analysis in order to narrow its scope. Last, the “active ingredients” of in-
terventions need to be identified, in order to develop effective interventions for specific 
problems. Additional control conditions including “sham” treatment websites should be 
included to assess the specific value of ICBT [81]. Analyses on computer-generated data 
about how subjects access the website may also be a worthwhile approach to examine 
engagement, usability, and active ingredients [82].
Conclusions
The current review indicates that ICBT interventions improve both psychological and 
disease-related physical outcomes in patients with chronic somatic conditions, with 
small-to-medium effect sizes. Larger improvements are occasionally found for disease-
specific outcomes related to daily-life impact of the illness, which underlines the im-
portance of tailoring interventions to specific (patient) groups. Our results also indicate 
that interventions of longer duration may be more effective for psychological outcomes 
such as depression, which implies that tailoring the duration of interventions to specific 
problems may be appropriate.
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MulTIMedIa aPPendIx 1
SeaRCh STRaTegIeS
Pubmed search strategy
(“Randomized Controlled Trial”[Publication Type] OR “Randomized Controlled Trials as 
Topic”[Mesh] OR random*[tiab] OR non-inferiority[tiab] OR equivalen*[tiab] OR rct[tiab] 
OR single blind[tiab] OR double blind[tiab] OR t r iple blind[tiab]) AND (“Internet”[Mesh] 
OR internet*[tiab] OR web*[tiab] OR online[tiab] OR “Therapy, Computer-Assisted”[Mesh] 
OR ehealth[tiab] OR e-health[tiab] OR “electronic mail”[MeSH Terms] OR “electronic 
mail”[tiab] OR “e mail”[tiab] OR email[tiab] OR cyber*[tiab] OR icbt[tiab] OR i-cbt[tiab] OR 
wcbt[tiab] OR w-cbt[tiab]) AND (“Behavior Therapy”[Mesh] OR psychotherapy[mesh] OR 
“rehabilitation”[Subheading] OR “rehabilitation”[tiab] OR “rehabilitation”[MeSH Terms] 
OR psychoeducational[tiab] OR psychoeducation[tiab] OR psycho-educational[tiab] OR 
psycho-education[tiab] OR “Counseling”[Mesh] OR counselling[tiab] OR counseling[tiab] 
OR ((therapy[tiab] OR therapies[tiab] OR treatment*[tiab]) AND (cognitive[tiab] 
OR behavior[tiab] OR behavioral[tiab] OR behaviour[tiab] OR behavioural[tiab] OR 
conditioning[tiab] OR cognition[tiab])) OR “Behavior Therapy”[Mesh] OR behavior 
modification[tiab] OR behaviour modification[tiab] OR conditioning therapy[tiab] 
OR conditioning therapies[tiab] OR conditioning treatment[tiab] OR cognition 
therapy[tiab] OR cognition therapies[tiab] OR cognitive psychotherapy[tiab] OR cogni-
tive psychotherapies[tiab] OR cognitive t reatment[tiab] OR “Self Care”[Mesh] OR self 
care[tiab] OR self help[tiab] OR self management[tiab])
PsycInfo search strategy
((internet* or web* or online* or computer* or electronic* telemedicine or websites or 
ehealth or e-health or e-mail or email or electronic mail or cyber* or icbt or i-cbt or 
wcbt). ti,ab. or (internet or online therapy or telemedicine or computer assisted therapy 
or computer mediated communication).sh.) AND ((random* or non-inferiority or equiva-
len* or rct or single blind or double blind or triple blind).ti,ab. OR ((“quantitative study” 
or “empirical study” or follow up study or “treatment outcome/clinical trial”).md. AND 
random*.af ) OR exp evidence based practice/ or clinical trials/ or treatment effectiveness 
evaluation/) AND (exp cognitive behavior therapy/ or exp behavior modification/ or exp 
behavior therapy/ or exp cognitive restructuring/ or exp cognitive therapy/ or exp dia-
lectical behavior therapy/ or (rehabilitation or psychoeducational or psychoeducation 
or psycho-educational or psycho-education or counselling or counseling or ((therapy 
or therapies or treatment*) and (cognitive or behavior or behavioral or behaviour or 
behavioural or conditioning or cognition)) or behavior modification or behaviour modi-
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fication or conditioning therapy or conditioning therapies or conditioning treatment 
or cognition therapy or cognition therapies or cognitive psychotherapy or cognitive 
psychotherapies or cognitive treatment or self care or self help or self management).
ti,ab. or self management/ or exp cognitive therapy/ or exp self monitoring/)
embase search strategy
((internet* or web* or online* or computer* or electronic* telemedicine or websites or 
ehealth or e-health or e-mail or email or electronic mail or cyber* or icbt or i-cbt or 
wcbt). ti,ab. or (internet or exp telehealth/ or computer assisted therapy or computer as-
sisted therapy).sh.) AND ((random* or non-inferiority or equivalen* or rct or single blind 
or double blind or t r iple blind).ti,ab. or (randomized controlled trial or evidence based 
practice).sh. or (therapy effect.sh. and random*.af.)) AND (exp cognitive therapy/ or exp 
behavior modification/ or exp behavior therapy/ or exp self care/ or exp self monitoring/ 
or (rehabilitation or psychoeducational or psychoeducation or psychoeducational or 
psycho-education or counselling or counseling or ((therapy or therapies or treatment*) 
and (cognitive or behavior or behavioral or behaviour or behavioural or conditioning or 
cognition)) or behavior modification or behaviour modification or conditioning therapy 
or conditioning therapies or conditioning treatment or cognition therapy or cognition 
therapies or cognitive psychotherapy or cognitive psychotherapies or cognitive treat-
ment or self care or self help or self management).ti,ab.)
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aBSTRaCT
objective: Patients with somatic conditions, such as psoriasis, frequently suffer from 
high burden of their disease in daily life and might benefit from internet-based cogni-
tive behavioral therapy (ICBT) tailored to their adjustment problems. The aim of this 
multicenter randomized controlled trial was to examine the effects of therapist-guided, 
individually tailored ICBT in a clinical sample of patients with psoriasis.
Methods: A total of 131 patients with psoriasis, who were screened for a psychological 
risk profile, were randomized to either care as usual (CAU, n = 66) or ICBT in addition to 
CAU (n = 65). Participants filled out standardized self-report questionnaires assessing 
physical and psychological functioning and impact on daily activities at baseline, post-
treatment assessment, and 6-month follow-up.
Results: In covariate-controlled linear mixed-model analyses, significantly larger im-
provements in ICBT compared to CAU were found in the primary outcomes physical 
functioning (p = .03, d = 0.36) and impact on daily activities (p = .04, d = 0.35), but not in 
psychological functioning (p = .32), up to 6 months after treatment compared to base-
line. In explorative analyses, the working alliance measured at the beginning of ICBT 
treatment predicted improved physical (p = .02) and psychological (p < .001) outcomes.
Conclusions: Results underline the promise of therapist-guided, individually tailored 
ICBT to improve physical functioning and reduce the impact of psoriasis on daily 
activities in patients with a psychological risk profile. Establishing a good therapeutic 
relationship early on may be an important factor that influences treatment outcomes in 
personalized ICBT interventions. Further research is needed to evaluate ICBT effective-
ness in additional samples and to explore its underlying mechanisms.
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InTRoduCTIon
Psoriasis is one of the most common immune-related chronic dermatological conditions 
[1] and is known for its high disease burden in daily life [2]. Patients frequently experi-
ence problems with mood, distress, and social impairments in addition to the burden of 
physical symptoms [3–6]. These problems may also negatively impact upon skin status, 
disease course, adherence, and dermatological treatment success [7–11]. Patients with 
a psychological profile of elevated levels of distress (an estimated 30–40%) are known 
to be at risk for long-term adjustment problems [3, 12] and might benefit from cogni-
tive behavioral therapy (CBT), as it has shown to improve physical and psychological 
functioning in patients with chronic somatic conditions [13–16], including dermatologi-
cal conditions [17–20]. Over the last decade, CBT has increasingly been offered online, 
which may facilitate intervention reach, increase cost-effectiveness and time-efficiency, 
and reduce possible barriers to following a psychological intervention [21, 22].
While systematic reviews show favorable effects of internet-based CBT (ICBT) for 
chronic somatic conditions [23–25], research in dermatological conditions is scarce. One 
randomized controlled trial (RCT) showed positive effects of unguided ICBT on anxiety 
and quality of life in patients with psoriasis but was limited by high dropout rates [26]. 
Therapist guidance may improve adherence [27, 28] and treatment effects [29–31], and 
patients tend to prefer guidance in ICBT [22, 32]. Furthermore, ICBT is usually based 
on standardized protocols [33], whereas recent findings underline the promise of less 
studied individually tailored interventions [34–36].
Despite the promising effects of therapist-guided, individually tailored ICBT in other 
conditions, its effects have not been examined in dermatological conditions. Possible 
predictors and correlates of treatment outcomes, including the therapeutic relationship 
[37, 38] and adherence [39], also remain unexplored in this group. Therefore, this study 
examined the effectiveness of therapist-guided, individually tailored ICBT for patients 
with psoriasis, expecting greater improvements in physical and psychological function-
ing and reduced impact on daily activities in ICBT compared to care as usual (CAU). In 
addition, sociodemographic, disease-related, and treatment-related predictors and 
correlates of treatment effects were explored.
MeThodS
Participants and procedure
Study participants were recruited through outpatient dermatology departments 
of one academic and three non-academic hospitals and through the Dutch Psoriasis 
Association (Figure 1). Inclusion criteria were a diagnosis of psoriasis, age ≥ 18 years, 
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and a positive psychological risk profile (i.e. Impact of chronic Skin Disease on Daily Life 
(ISDL) score of ≥ 5 for anxiety and/or ≥ 21 for negative mood [40, 41]). Exclusion criteria 
were psychological (i.e. diagnosis according to the Diagnostic and Statistical Manual 
of Mental Disorders (DSM) [42]) and/or physical comorbidity interfering with the study 
protocol, current psychological treatment, current photo(chemo)therapy, pregnancy, 
lack of access to a computer and/or internet, and illiteracy.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=751) 
(252 RUMC; 406 RS; 52 PVN; 26 CWZ; 15 ZGT)
Excluded (n=620)
   Did not meet inclusion criteria (n=43)
   Declined to participate (n=59)
   Did not return screening instrument (n=216)
   Did not report elevated distress levels (n=302)
Allocated to ICBT+CAU (n=65)
 Received allocated intervention (n=55)
 Non-starters (n=10, 15.4%)
 Non-completers (n=6, 9.2%)
             
 
Allocated to CAU (n=66)
Randomized (n=131)
Post-treatment
Lost to 6 month follow-up (n=28)
Analyzed: 37 (56.9%)
Lost to post-treatment assessment (n=21)
Analyzed: 44 (67.7%)
Lost to pre-treatment assessment (n=5)
Analyzed: 60 (92.3%)
Follow-Up
Lost to pre-treatment assessment (n=6)
Analyzed: 60 (90.9%)
Lost to post-treatment assessment (n=15)
Analyzed: 51 (77.3%) 
Lost to 6 month follow-up (n=21)
Analyzed: 45 (68.2%) 
Baseline
figure 1. Consort flow diagram of participants. CAU, Care as usual; CWZ, Canisius-Wilhelmina Hospital, 
Nijmegen; ICBT, internet-based cognitive behavioral treatment; PVN, Dutch Psoriasis Association; RS, Rijn-
state Hospital, Velp; RUMC, Radboud university medical center, Nijmegen; ZGT, Ziekenhuis Groep Twente, 
Almelo.
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This study had an open-label parallel-group RCT design. An independent person 
randomized the participants (allocation ratio: 1:1) using a computerized program that 
minimized on age, gender, educational level, recruitment site, self-assessed disease se-
verity, and medication use. The patients were randomized to either CAU (regular derma-
tological care) or ICBT in addition to CAU. A member of the research team informed the 
participants by phone and letter about treatment assignment. ICBT interventions took 
place between July 2010 and October 2014. Measurements were collected between June 
2010 and April 2015. Study assessments were conducted at baseline, post-treatment as-
sessment (CAU: 6 months after baseline), and 6-month follow-up (CAU: 12 months after 
baseline). The study was approved by the regional medical ethics committee, registered 
in the Dutch Trial Registry (NTR2436), and conducted in accordance with the Declaration 
of Helsinki [43]. All participants provided written informed consent.
ICBT intervention
Patients randomized to the ICBT condition received an internet-based, therapist-guided 
CBT intervention aimed to reduce the impact of psoriasis on daily life, which was based 
on previous evidence- based face-to-face interventions [41, 44]. The intervention con-
sisted of five flexible treatment modules containing a broad variety of cognitive and 
behavioral techniques focused on themes that patients often experience problems with: 
itch, pain, fatigue, negative mood, and social relationships. The participants started with 
two face-to-face intake sessions with their therapist (a psychologist), in which individual 
treatment goals were discussed. Next, patients received a telephone-based instruction 
of the intervention website by a researcher to ensure that they were capable of working 
with the program from home. The patients then started with the individually tailored 
ICBT intervention by logging on to the secure intervention website. Choice of treatment 
modules and individual assignments within these modules were determined based 
on individual patient goals, therapist’s judgment, and screening procedures [see also 
45]. The patients received personalized written feedback on their assignments from 
their therapist approximately once a week. Intervention duration and content varied 
between participants, depending on treatment goals, with a mean duration of 25 ± 12 
weeks (range 1–57 weeks). For a more detailed description of ICBT modules, therapists, 
intervention use, and adherence, see supplementary methods and results.
Instruments
Primary and secondary outcomes
The primary outcome was the impact of psoriasis on daily life, measured on three do-
mains, for which total scores were computed (composite scores: the overall average of 
normalized (z-)scores of the questionnaires included in each domain): (1) psychological 
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functioning, consisting of negative mood (ISDL) [40], anxiety (ISDL) [40], and depressive 
symptoms (Beck Depression Inventory) [46, 47]; (2) physical functioning, consisting of 
itch (ISDL) [40] and fatigue (Checklist Individual Strength) [48]; and (3) impact on daily 
activities, consisting of role limitations due to physical health problems and role limita-
tions due to emotional problems (RAND-36 Health Status Inventory) [49, 50]. Secondary 
outcomes consisted of clinician-rated (Psoriasis Area and Severity Index, PASI) [51] and 
self-reported disease severity (self-administered PASI) [52], and dermatological treat-
ment compliance.
Predictors and correlates of treatment outcome
Sociodemographic (age, sex, educational level, and marital status), disease-related 
(disease severity and duration), and treatment-related variables (working alliance 
between patient and ICBT therapist: Working Alliance Inventory - Short Form [53–55], 
ICBT adherence, website logins) were examined as possible predictors and correlates of 
treatment outcomes. Further measurement details of all study variables can be found in 
the supplementary methods and results.
data analysis
Baseline characteristics were compared with t-tests and χ2 tests. Primary analyses were 
conducted using linear mixed-effects modeling, which has superior qualities with regard 
to missing values [56] and makes use of all available data, making this a full intention-to-
treat analysis. Models were fitted with full information maximum-likelihood estimation. 
Between-group effects at post-treatment assessment and follow-up were analyzed with 
baseline scores of dependent variables as covariates. Time was operationalized as a con-
tinuous variable, and post-treatment assessment varied across participants as a result of 
different intervention lengths. Fixed linear effects of time and condition were included 
as well as random effects of intercept. Primary analyses were conducted including all 
variables included in the randomization (age, sex, educational level, recruitment site, 
systemic medication use, etanercept use, and disease severity) as covariates [57]. In 
secondary analyses, results were reported (1) without covariates (see Results) and (2) 
excluding ICBT dropouts/non-starters (see suppl. methods and results).
Between-group Cohen’s d type of effect sizes were calculated, dividing the difference 
in the estimated marginal means of the primary analyses of the two groups by their 
pooled pre-treatment SD. Within-group Cohen’s d effect sizes were calculated by divid-
ing the difference in pre- and post-treatment assessment means by pre-assessment SDs. 
Effect sizes of 0.2, 0.5, and 0.8 were considered small, moderate, and large, respectively 
[58]. Unstandardized effect sizes were defined as raw mean differences between ICBT 
and CAU.
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Pearson’s correlation coefficients were calculated between change in primary 
outcomes (residual gain scores) and selected sociodemographic, disease-related, and 
treatment-related variables [60]. All analyses were conducted in IBM SPSS v21. A power 
analysis with 80% power indicated that a sample size of two groups of 65 patients was 
needed, assuming the effect size d = 0.50 (α = .05), based on previous ICBT studies for 
physical and psychological conditions [61]. Statistical significance was accepted at 
p < .05. In explorative analyses examining correlates of treatment effects, tendencies 
towards significant effects (p < 0.10) were not reported for stringency reasons.
ReSulTS
Between June 2010 and November 2013, 751 patients were screened, and 131 patients 
were randomized to either ICBT (n = 65) or CAU (n = 66). Means and SDs of selected 
sociodemographic and disease-related variables are presented in Table 1, and baseline 
values on primary outcomes and their subcomponents, as well as secondary outcomes, 
are presented in Tables 2 and 3. These values did not differ between groups (p ≥ .10), with 
the exception of a tendency towards higher levels of fatigue (p = .08) and higher clinician-
rated disease severity (p = .03) in ICBT compared to CAU. Disease severity was generally 
mild to moderate, with 7.6% of patients having severe psoriasis (PASI > 10) [62].
Table 1. Baseline socio-demographic and disease-related characteristics of internet-based cognitive be-
havioral treatment (ICBT) and care as usual (CAU) groups
Characteristic ICBT+Cau (n = 65) Cau (n = 66)
Gender (male) 33 (50.8) 34 (51.5)
Age (years) 52.69 ± 11.27 (24-73) 53.45 ± 13.81 (19-79)
Married/ living together 46 (70.8) 53 (80.3)
Educational level
Primary 1 (1.5) 4 (6.1)
Secondary 44 (67.7) 43 (65.2)
Tertiary 20 (30.8) 19 (28.8)
Disease severity (PASI)a 5.99±5.61(1-31)c 4.20±2.87(0-13)c
Disease severity (SAPASI)a 5.27± 3.29 (1-19)c 4.48±2.41 (0-12)c
Disease duration (years) 18.03 ± 13.76 (0-59)c 15.16 ± 16.35 (0-65)c
Systemic treatmentb 25 (44.6)c 17 (29.3)c
Note. Data are presented as mean ± SD (range) or n (%), as appropriate. Abbreviations: CAU, care as usual; 
ICBT, internet-based cognitive behavioral treatment; PASI, Psoriasis Area and Severity Index; SAPASI, Self-
assessed PASI. aDue to unequal distribution of PASI and SAPASI scores, transformed variables were used 
in analyses (see Methods section). Untransformed scores are displayed in this table, bNumber of patients 
reporting use of systemic treatment, cn = 2-12 missings.
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Table 2. Means and SDs of each measurement point on primary outcome measures (i.e. total scores) and 
their subcomponents, including results of linear mixed models analyses and accompanying effect sizes
Measurement ICBT Care as usual Standardized 
effect size
unstandardized 
effect size  (95% CI)
linear mixed 
models
Mean SD n Mean SD n Effect p-value
Psychological functioning
Total score (composite)
Pre 0.02 0.87 60 -0.01 0.85 59
Post -0.51 0.74 44 -0.29 0.92 49 Time 0.22
Follow-up -0.49 0.90 37 -0.41 0.84 45 0.17 0.14 (-0.14 to 0.43) Group 0.32
negative mood (ISdl)a
Pre 5.29 3.77 60 5.39 3.72 58
Post 3.69 3.36 44 4.60 3.21 49 Time 0.35
Follow-up 3.86 3.65 37 4.11 3.53 45 0.06 0.06 (-0.28 to 0.40) Group 0.74
anxiety (ISdl)
Pre 21.85 4.61 60 22.10 4.58 60
Post 19.36 4.37 43 21.02 5.74 48 Time 0.28
Follow-up 19.45 5.38 37 20.27 5.03 45 0.24 1.09 (-0.57 to 2.74) Group 0.20
depressive symptoms (BdI)
Pre 12.78 7.50 60 11.50 6.23 58
Post 8.46 5.34 45 8.89 6.82 49 Time 0.24
Follow-up 8.53 6.72 37 8.69 6.36 45 0.15 1.01 (-1.28 to 3.30) Group 0.38
Physical functioning
Total score (composite)
Pre 0.11 0.73 60 -0.12 0.79 58
Post -0.55 0.75 43 -0.36 0.73 48 Time 0.13
Follow-up -0.48 0.77 37 -0.55 0.68 42 0.36 0.27 (0.02 to 0.52) Group 0.03
fatigue (CIS-f)
Pre 37.70 10.68 60 34.31 10.30 59
Post 30.77 12.46 44 33.58 9.19 49 Time 0.09
Follow-up 31.19 11.65 37 31.40 10.09 44 0.37 3.84 (0.09 to 7.59) Group 0.04
Itch (ISdl)
Pre 9.44 3.50 60 9.06 3.75 59
Post 7.09 3.51 44 7.44 3.67 49 Time 0.44
Follow-up 7.44 3.32 37 6.88 2.97 43 0.17 0.61 (-0.56 to 1.77) Group 0.30
Impact on daily activities
Total score (composite)
Pre 0.03 0.71 58 -0.04 0.89 57
Post 0.38 0.55 43 0.25 0.88 46 Time 0.12
Follow-up 0.37 0.69 37 0.34 0.79 43 0.35 0.28 (0.01 to 0.55) Group 0.04
emotional role functioning (Rand-36)
Pre 78.16 35.07 58 67.54 39.89 57
Post 86.36 23.09 44 76.09 38.27 46 Time 0.05
Follow-up 87.39 26.47 37 85.61 32.47 44 0.33 12.12 (0.64 to 23.61) Group 0.04
Physical role functioning (Rand-36)
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Table 2. Means and SDs of each measurement point on primary outcome measures (i.e. total scores) and 
their subcomponents, including results of linear mixed models analyses and accompanying effect sizes 
(continued)
Measurement ICBT Care as usual Standardized 
effect size
unstandardized 
effect size (95% CI)
linear mixed 
models
Pre 53.02 41.90 58 58.89 43.09 60
Post 72.09 36.68 43 73.94 40.03 47 Time 1.00
Follow-up 70.95 41.04 37 70.45 40.08 44 0.32 13.34 (0.46 to 26.22) Group 0.04
Note. All means and SDs are presented as uncorrected scores. Abbreviations: BDI, Beck Depression Inven-
tory; CI, confidence interval; CIS-f, Checklist Individual Strength - fatigue; ICBT, internet-based cognitive 
behavioral treatment; ISDL, Impact of Skin Disease on Daily Life; RAND-36, RAND-36 Health Status Inven-
tory. aDue to unequal distribution of IHDL negative mood, transformed variables were used in analyses (see 
Methods section). Untransformed scores are displayed in this table.
Table 3. Means and SDs of each measurement point on secondary outcome measures, including results of 
linear mixed models analyses and accompanying effect sizes
Measurement ICBT Care as usual Standardized 
effect size
unstandardized 
effect size (95% CI)
linear mixed 
models
Mean SD n Mean SD n Effect p-value
Clinician-assessed disease severity (PaSI)a
Pre 5.99 5.61 54 4.20 2.87 56
Post 5.04 4.59 25 3.79 2.94 42 Time .34
Follow-up 4.76 3.47 22 3.40 2.63 37 0.02 0.01 (-0.32 to 0.35) Group 0.94
Self-assessed disease-severity (SaPaSI)a
Pre 5.27 3.29 59 4.48 2.41 54
Post 4.61 5.39 44 3.95 2.26 43 Time 1.00
Follow-up 4.51 3.32 35 3.75 2.03 42 0.25 0.16 (-0.12 to 0.45) Group 0.25
dermatological treatment compliance
Pre 3.96 1.11 59 4.09 1.03 58
Post 4.02 1.21 41 4.02 0.98 44 Time 0.82
Follow-up 3.91 1.22 31 3.89 1.20 40 -0.11 -0.12 (-0.52 to 0.28) Group 0.55
Note. All means and SDs are presented as uncorrected scores. Abbreviations: ICBT, internet-based cognitive 
behavioral treatment; PASI, Psoriasis Area and Severity Index; SAPASI, self-assessed PASI. aDue to unequal 
distribution of PASI and SAPASI scores, transformed variables were used in analyses (see Methods section). 
Untransformed scores are displayed in this table.
attrition
A total of 73.3% of patients filled out post-treatment measurements, and 62.6% com-
pleted 6-month follow-up measurements (Figure 1). The ICBT intervention dropout 
rate was 26.2%: ten patients did not start treatment (nonstarters, 15.4%), six patients 
dropped out during treatment (non-completers, 9.2%), and one patient (1.5%) died dur-
ing treatment as a result of comorbidity unrelated to the treatment. Reported reasons 
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for ICBT dropout and differences between completers and dropouts can be found in the 
supplementary methods and results.
ICBT treatment satisfaction
Patients in the ICBT group who filled out post-treatment evaluation questionnaires (n = 
41) were satisfied with the ICBT intervention and gave the overall intervention a mean 
score of 7.64 ± 1.71 and user friendliness 7.72 ± 1.32 out of 10. A majority of 85.3% of 
patients would recommend the treatment to a friend or relative with a chronic somatic 
condition, and 87.7% of patients believed the treatment would have long-term posi-
tive effects (somewhat/probably/certainly); 60% of patients indicated a preference for 
internet-based treatment over other forms of treatment (phone-based: 5.0%, face to 
face: 27.5%) for future treatment, and an additional 7.5% gave internet-based treatment 
a shared first place with one or more other modalities.
Primary outcomes
Results on primary outcomes and their subcomponents, including effect sizes, are pre-
sented in Table 2 and Figure 2.
Psychological functioning
In linear mixed-model analyses controlling for previously specified covariates, no 
significant differences were found between ICBT and CAU regarding psychological 
functioning at post-treatment assessment and 6-month follow-up (p = .32) or on its 
subcomponents negative mood, anxiety, and depressive symptoms (all p ≥ .20). The 
lack of significant main effects of time (p ≥ .22) indicated that these outcomes were 
stable across post-treatment assessment and 6-month follow-up. Similar results were 
obtained in secondary analysis including no other covariates than baseline values of the 
dependent variable (p ≥ .19).
Physical functioning
Significantly larger improvements in ICBT compared to CAU were found for physical func-
tioning up to 6 months after treatment compared to baseline (F(1,76.29) = 4.60, p = .03, d 
= 0.36), with significant effects for fatigue (F(1,74.53) = 4.16, p = .04, d = 0.37) but not for 
itch (p = .30). These outcomes were stable across post-treatment assessment and 6-month 
follow-up, with the exception of fatigue, which tended to be lower at post-treatment as-
sessment than at 6-month follow-up (p = .09). In secondary analysis including no other 
covariates than baseline values of the dependent variable, a tendency towards greater 
improvement in ICBT compared to CAU was found for fatigue (p = .08) and no significant 
between-group differences for itch or total physical functioning (p ≥ .16).
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Impact on daily activities
Significantly larger improvements in ICBT compared to CAU were found for impact 
on daily activities up to 6 months after treatment compared to baseline (F(1,81.48) = 
4.18, p = .04, d = 0.35), with significant effects on both subcomponents: role limitations 
due to emotional problems (F(1,132) = 4.36, p = .04, d = 0.33) and role limitations due 
to physical health problems (F(1,81.99) = 4.25, p = .04, d = 0.32). The improvements in 
role limitations due to emotional problems at post-treatment assessment were further 
enlarged at follow-up (p = .047), while other outcomes remained stable. In secondary 
analysis including no other covariates than baseline values of the dependent variable, 
no between-group differences were found (p ≥ .17).
disease severity and compliance
Results on self-reported and clinician-assessed disease severity and dermatological 
treatment compliance, including effect sizes, are reported in Table 3. No between-group 
differences were found for any of these outcomes, with or without covariates (all p-
values ≥ .25).
within-group improvements
For primary outcome measures, ICBT within-group improvements were large for physical 
functioning (d = 0.81 - 0.90) and moderate for psychological functioning (d = 0.59 - 0.61) 
and impact on daily activities (d = 0.48 - 0.51). CAU within-group improvements were 
small to moderate for physical functioning (d = 0.30 - 0.56), psychological functioning (d 
= 0.33 - 0.47), and impact on daily activities (d = 0.33 - 0.43).
Predictors and correlates of treatment effects
To explore which patients benefitted most from treatment, treatment-related variables 
(working alliance with the therapist, treatment duration, and ICBT adherence including 
patient ratings, therapist ratings, and website logins) were correlated with change in 
primary outcomes. Results indicated that a better working alliance with the therapist 
at the beginning of treatment was associated with greater pre- to post-treatment as-
sessment improvements in psychological (r = –.66, p < .001) and physical (r = –.42, p = 
.02) functioning but not with change in impact on daily activities (r = .18, p = .34). No 
significant associations of change in primary outcomes with treatment duration, ICBT 
adherence were found, nor with the sociodemographic and disease-related variables 
age, sex, educational level, disease duration, and disease severity (all p-values ≥ .17).
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figure 2. Baseline, post-assessment, and 6-month follow-up scores on primary outcome measures 
(i.e. total scores of psychological functioning (a), physical functioning (b), and impact on daily activi-
ties (c)) for internet-based cognitive behavioral therapy (ICBT) and care as usual (Cau) groups, pre-
sented as means ± SeM. Negative scores indicate improved psychological and psychological functioning 
in (a) and (b), and positive scores indicate reduced impact on daily activities in (c).
(b)
(a)
(c)
Effectiveness of internet-based treatment 135
6
dISCuSSIon
This first trial on the effectiveness of individually tailored, therapist-guided ICBT for 
patients with psoriasis who had a psychological risk profile indicated that ICBT as an 
adjunct to CAU had more beneficial effects on physical functioning and the impact 
of psoriasis on daily activities compared to CAU alone. When analyzing who benefits 
most from ICBT, the working alliance between patient and therapist measured at the 
beginning of treatment was related to improved physical and psychological outcomes, 
suggesting that the establishment of a good patient-therapist relationship early on is of 
considerable importance in guided ICBT.
Results on primary outcomes showed significantly larger improvements in ICBT com-
pared to CAU on physical functioning and impact on daily activities. Effects on physical 
functioning were driven by improvements in fatigue, which is a frequent and disabling 
symptom in many chronic inflammatory conditions [63]. Patients often characterize 
fatigue as one of the most burdensome aspects of their condition [63], which was 
also reflected in the current trial; mean baseline scores were above the cut-off point 
for extreme fatigue [48], while means on other outcomes were comparable to norm 
groups of healthy individuals. In addition, the fatigue module was frequently chosen 
as the preferred treatment module in this trial. ICBT patients also improved more on 
impact on daily activities, indicating that patients who received ICBT felt significantly 
less limited by their physical health and emotional problems in performing their work 
or daily activities than patients who received CAU. In contrast, no significant between-
group effects were observed for psychological functioning. This is surprising, consider-
ing that patients were screened for elevated levels of distress and that negative mood 
was a frequently applied treatment module. Despite screening, baseline psychological 
functioning scores were generally comparable to healthy populations, as many patients 
scored just above cut-off values, and 22% of the sample that scored above cut-off values 
at screening did not fulfil these criteria anymore at baseline. As meta-analyses suggest 
that patients with higher distress scores demonstrate larger CBT effects [64, 65], distress 
levels may have been too low for patients to benefit sufficiently from ICBT. Low baseline 
scores were also cited as a reason for the small effects found in a recent meta-analysis on 
(I)CBT for long-term conditions (i.e. effect sizes of 0.20 - 0.21 for anxiety and depression 
[66], comparable to an earlier meta-analysis [24]).
Moderate to large ICBT effects were found for primary outcomes and their subcom-
ponents, which were comparable to similar tailored face-to-face CBT interventions [41, 
67]. However, between-group effect sizes were small, which was explained by larger 
than expected CAU effects. This may also explain why significant effects for physical 
functioning were found for fatigue but not for itch: post-treatment ICBT effect sizes were 
similar for itch and fatigue, while CAU effects were moderate for itch and small to non-
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existent for fatigue. As high standards of care are generally associated with greater CAU 
effects on physical and psychological outcomes [68], the fact that 42% of patients were 
recruited from a university medical center might have played a role in these findings. 
The timing of participant recruitment may have also contributed; patients were often 
recruited when starting dermatological treatment and many patients reported changes 
in systemic medication during the trial. In future research, differential screening proce-
dures may decrease these confounding effects and possibly optimize treatment effects 
by screening patients who experience elevated distress levels despite being on a stable 
dermatological regimen, for example.
A better therapeutic relationship (working alliance) measured early in treatment 
showed moderate to large correlations with improvements in physical and psychologi-
cal outcomes, supporting the relevance of the therapeutic relationship in ICBT. These 
findings are in line with evidence in face-to-face CBT [69–71] and expand upon scarce 
evidence from studies on internet-based interventions [38, 72–75]. Associations of 
early working alliance scores with treatment outcome were somewhat higher than 
those observed in previous studies, possibly because the therapeutic relationship is 
of greater importance in highly personalized interventions. Treatment outcomes were 
not associated with the number of logins or treatment length, partially corresponding 
with previous conflicting evidence [39, 76, 77]. While logins and treatment length have 
advantages in being objective measures, they may not adequately reflect interaction 
with treatment content and user experiences.
The characteristics of this study differed in some important ways from many previ-
ously conducted ICBT studies. ICBT was compared to CAU in a clinical sample, including 
a 6-month follow-up, while most ICBT studies have typically included community-based 
and self-referred samples, waiting-list comparisons, and post-treatment data only [for 
a summary, see 24]. While significant effects were found in this trial, the effects were 
typically small and were not all found in secondary analyses that did not include pre-
specified covariates. Consistent with our findings, recent meta-analytic evidence shows 
that the effects of ICBT are typically smaller in studies with a CAU than a waiting-list 
comparison and in clinical samples than in community-based samples, and the effects 
are often non-significant on the rare occasion that long-term follow-up results are meta-
analyzed [78–80]. This underlines the need for further in-depth research regarding the 
influence of methodological, sample, and intervention characteristics on trial results.
Both the limitations and strengths of the present study have to be considered. Firstly, 
similar to previous studies [for a summary, see 24], a substantial proportion of patients 
did not complete ICBT and/or failed to return questionnaires. In line with previous 
evidence, attrition rates were higher in ICBT than in CAU [81]. While dropout rates were 
somewhat lower than in a study of non- tailored ICBT for psoriasis [26], the fact that 
they were generally comparable to previous studies does not support the often-cited 
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idea that tailored interventions are associated with lower dropout rates. However, the 
majority of dropouts were non-starters and therefore not exposed to treatment content. 
Furthermore, the relatively long ICBT duration, i.e. a mean duration of 25 weeks com-
pared to 8 weeks in many other interventions [24], may have increased dropout rates, 
which often increase progressively with intervention duration [82]. Lower baseline dis-
ease severity was associated with higher ICBT dropout, possibly because these patients 
experienced a lower disease burden and were therefore less motivated to adhere to a 
program aimed to decrease the impact of psoriasis on daily life. The main strengths of 
the current study include the application of a unique individually tailored and therapist-
guided intervention in a target population that is generally underserved when it comes 
to psychological support. Methodological strengths include the multicenter RCT design 
comparing ICBT to CAU in a clinical sample, including a 6-month follow-up.
To conclude, individually tailored, therapist-guided ICBT led to significantly greater 
improvements compared to CAU for physical functioning and impact on daily activities 
in a clinical sample of patients with a psychological risk profile. The therapeutic relation-
ship showed moderate to large associations with better treatment effects, illustrating 
the importance of this relationship in guided ICBT. The results of this trial underline the 
promise of ICBT for dermatological conditions in a clinical setting, which is supported by 
previous studies in other conditions showing that ICBT interventions can be transferred 
to clinical practice with sustained effects and moderate to large effect sizes [83]. Future 
research should focus on the working mechanisms and provide further evidence on how 
well these interventions translate into clinical practice. Furthermore, future research in 
additional samples (e.g., higher levels of distress and disease severity) should extend 
these findings to be able to draw robust conclusions on the effectiveness of individually 
tailored, therapist-guided psychological interventions for dermatological conditions.
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SuPPleMenTaRy MeThodS and ReSulTS
1. outcome measures
Primary outcome measures
The primary outcome of this study was the impact of psoriasis on daily life, measured on 
three domains, for which total (composite) scores were computed by taking the overall 
average of standardized (z-)scores of the questionnaires included in each domain. All 
questionnaires were administered in paper-and-pencil format.
Psychological functioning
Psychological functioning was assessed with a total score of three previously validated 
measures: the Negative Mood (6 items, Cronbach’s α = .88 in the current study) and 
Anxiety (ten items, α = .79) scales of the ISDL [40], and the total score of the revised 
version of the Beck Depression Inventory [BDI-II; 46, 47] (21 items; α = .85). Higher scores 
reflect greater levels of negative mood, anxiety, and depressive symptoms, respectively. 
Higher total scores reflect worse psychological functioning.
Physical functioning
Physical functioning was assessed with a total score of two frequently reported symp-
toms in psoriasis: fatigue and itch. Fatigue was assessed with the 8-item fatigue subscale 
of the Checklist Individual Strength [CIS; 48], with higher scores reflecting higher levels 
of fatigue (α = .92). Intensity and duration of itch was assessed with a 4-item subscale of 
the ISDL [40], with higher scores reflecting greater itch intensity and duration (α = .81). 
Higher total scores reflect lower physical functioning.
Impact on daily activities
Impact on daily activities was assessed with a total score of two subscales of the previ-
ously validated RAND-36 Health Status Inventory [49, 50], assessing the extent of role 
limitations due to physical health problems (four items, α = .88) and role limitations due 
to emotional problems (three items, α = .81), with higher scores reflecting fewer role 
limitations in each of the two domains. Higher total scores reflect lower impact on daily 
activities.
Secondary outcome measures: disease severity and compliance
Patient-rated disease severity was assessed with the widely used and validated Self-
Administered Psoriasis Area and Severity Index (SAPASI; [52]), consisting of silhouettes 
of the front and back of a body on which patients can mark their affected body areas, 
as well as three visual analogue scales to assess the erythema, induration, and scaliness 
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of the average lesion. Scores on the SAPASI can range from 0 to 72, with higher scores 
indicating more severe psoriasis.
Clinician-rated disease severity was assessed with the Psoriasis Area and Severity 
Index (PASI), in which a clinician (i.e. a dermatology research nurse) assigned a numerical 
value of 0 to 6 to the area of involvement for four body regions, and rated erythema, 
desquamation, and induration of the plaques for each region on 5-point scale, with 
higher overall scores (range 0 - 72) signifying greater disease severity [51].
Dermatological treatment compliance was assessed with a 5-item questionnaire (α = 
.94), asking how often patients adhered to treatment prescriptions/recommendations 
regarding hormone ointments, other ointments, medications, other professional care, 
and other prescriptions/recommendations. Each question could be answered on a 
scale from 1 to 5, ranging from less than once a week to seven days a week, or could be 
answered as ‘not applicable’. Total scores were constructed by calculating the mean of 
applicable items, with higher scores indicating greater compliance.
ICBT treatment satisfaction
Patients’ satisfaction with the ICBT intervention, and their evaluation of its user-friendli-
ness, was rated on a 10-point scale with higher scores reflecting higher satisfaction and 
greater user-friendliness. Patients were also asked to rate to which degree they though 
the intervention would have a sustained positive effect and whether they would recom-
mend the intervention to a friend or family member with a chronic somatic condition, 
on a four-point scale ranging from ‘no’ to ‘certainly’.
Sociodemographic and disease-related predictors of treatment outcome
Sociodemographic variables were assessed with a general checklist assessing patients’ 
gender, age, educational level, and marital status. Disease severity was assessed with the 
SAPASI [52] and PASI [51] described above. Disease duration was assessed with an item 
asking how old the patient was when the psoriasis diagnosis was given, which was then 
subtracted from the age of the patient.
Treatment-related predictors and correlates of treatment outcome
The working alliance between patient and ICBT therapist (i.e. the mutual agreement 
on the goals and tasks of a therapeutic intervention, in the context of a positive affec-
tive bond [55]) was assessed at the beginning of treatment (after face-to-face intakes, 
but before starting the internet-based treatment) by the client version of the 12-item 
(short version) Working Alliance Inventory [WAI-S; 53, 54], using the overall alliance 
score. Treatment duration was defined as the number of weeks patients spent on ICBT 
treatment, excluding mutually agreed upon weeks of non-activity (e.g., vacation). Ad-
herence to ICBT was assessed from three perspectives: 1) patient evaluation of their own 
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adherence, 2) therapist rating of patient’s adherence, and 3) intervention website usage. 
Patient-rated adherence was assessed at post-treatment with the following four items: 
“During treatment, I have fully completed all assignments”, “During treatment, I have 
worked intensively on my treatment goals”, “During treatment, I have often practiced 
and applied what I have learned in daily life”, and “During treatment, the internet-based 
treatment was a regular part of my daily life”. Therapist-rated adherence was based on 
the same 4 items, in which the therapist rated the patient on these items. Both ratings 
were found to be reliable (patient rating: α = .67; therapist rating: α = .94). Intervention 
website usage was defined as the total number of website logins during treatment and 
average number of logins per week, assessed by monitoring https-server requests.
2. data analysis: normal distribution
All continuous variables were checked for normality (skewness and kurtosis < 1.5) and 
adjusted if necessary and possible. A skewed distribution on the physical role limitations 
rank score was observed at baseline. As data transformations did not lead to signifi-
cant improvements, unadjusted scores were used for analyses. SAPASI and PASI scores 
showed substantial skewness and kurtosis, which was corrected for by square root 
transformation and replacing two (PASI) or four (SAPASI) outlying cases with the next 
highest scores (skewness and kurtosis < 1.5 after transformation) [59].
3. ICBT intervention, dropout, and sensitivity analysis
ICBT modules
An overview of the frequency of the ICBT treatment modules that were applied is pre-
sented in Table S1. The modules negative mood (58%), itch (51%), and fatigue (45%) 
were applied most often, while the modules pain (11%) and social relationships (17%) 
were applied in a minority of cases. The majority of patients (n = 30; 55%) worked on two 
treatment modules during treatment, while 16 patients worked on one module (29%) 
and 8 patients (15%) worked on three modules.
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Table S1. Internet-based cognitive behavioral treatment: overview of treatment modules, in patients who 
started treatment (n = 55)
Treatment module
negative mood fatigue Itch Pain Social relationships
Primary modulea 17 (31%) 14 (25%) 16 (29%) 4 (7%) 2 (4%)
Secondary moduleb 14 (25%) 11 (20%) 10 (18%) 1 (2%) 2 (4%)
Tertiary modulec 1 (2%) 0 (0%) 2 (4%) 1 (2%) 5 (9%)
Not applied 23 (42%) 30 (55%) 27 (49%) 49 (89%) 46 (83%)
Note. n = 1 patient started ICBT but dropped out after the first few messages, prior to commencing any 
modules.. a Module that patients have worked on for the longest time, compared to the other modules, b 
Module that patients have worked on for a shorter amount of time than the primary module, c Module that 
patients have worked on for a shorter amount of time than the secondary module.
ICBT therapists
Therapist guidance in ICBT was given by a total of six female therapists (mean age = 
29.67 ± 8.76), all having at least a Master’s degree in Clinical and/or Health Psychology, 
with previous therapist experience ranging from 0 to 7 years (mean = 2.17 ± 2.79). Three 
therapists had finished further postgraduate training as healthcare psychologists (i.e. 
‘GZ psychologists’). All therapists were supervised by a senior clinical psychologist with 
post-academic training in cognitive behavioral treatment.
ICBT duration
Mean intervention duration (excluding non-starters) was 25 weeks (± 12 weeks), ranging 
from 1-57 weeks. During the intervention, a period of ≥ 4 weeks of no contact with the 
therapist was observed in 20% of patients (n = 13) and ICBT treatment was temporarily 
put on hold due to personal circumstances in 34% of patients (n = 22). ICBT duration was 
calculated excluding the mutually agreed upon weeks of inactivity.
ICBT dropout
Overall intervention dropout was 26.2%, consisting of ten non-starters (15.4%) and 
seven dropouts (10.8%). The ten non-starters did not start treatment for various reasons: 
personal or familial circumstances (n = 3), lack of time (n = 2), physical comorbidity (n 
= 1), psychological comorbidity (n = 1), not wanting to come for intake sessions (n = 
1), lack of computer skills (n = 1), or unknown reasons (n = 1). The 6 non-completers 
reported the following reasons: alleviated symptoms/complaints (n = 1), deteriorated 
symptoms (n = 1), personal or familial circumstances (n = 1), physical/psychological 
comorbidity (n = 1), lack of computer skills (n = 1) or unknown reasons (n = 1). Lastly, one 
of the dropouts was a patient who died during the treatment as a result of comorbidity 
unrelated to the treatment.
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Differences between completers and dropouts
Intervention completers had higher baseline self-reported disease severity (p = .03) 
than non-starters/non-completers. Measurement completers were significantly older (p 
= .04) and showed a tendency towards a greater impact of psoriasis on daily activities (p 
= .09) than measurement dropouts.
ICBT completers: Sensitivity analysis
In sensitivity analyses excluding ICBT dropouts/non-starters (n = 16), tendencies towards 
larger effects in ICBT compared to CAU were found for the primary outcomes physical 
functioning (p = .051) and impact on daily activities (p = .097). In subcomponents of 
these primary outcomes, significant between-group effects were found for fatigue (p = 
.04) and trends on role limitations due to physical (p = .06) and emotional (p = .09) health 
problems.
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aBSTRaCT
objective: Internet-based cognitive behavioral treatment (ICBT) has shown to be (cost-) 
effective for patients with chronic somatic conditions. However, ICBT (cost-)effective-
ness studies in psoriasis, a chronic inflammatory skin disease associated with impaired 
physical and psychological functioning, are lacking. In this study, the cost-effectiveness 
of individually-tailored therapist-guided ICBT was examined in patients with psoriasis.
Methods: An economic evaluation from a societal perspective was performed along-
side a randomized controlled trial (Trial Registry Number NTR2436). Patients who were 
screened for a psychological risk profile were randomized to regular dermatological care 
(CAU; n = 66) or ICBT added to CAU (n = 65). Outcomes were assessed up to 6 months 
post-treatment and included patient utilities, healthcare costs, productivity losses, and 
incremental costs per quality-adjusted life year (QALY) gained. Cost-effectiveness was 
analyzed in bootstrapped samples using 1) incremental cost-effectiveness ratios (ICERs) 
and 2) incremental net monetary benefit (INMB) analyses correcting for baseline values 
and confounders.
Results: No significant between-group differences were found in QALYs and costs at 
post-treatment and 6-months follow-up in ICER and INMB analyses. However, in post-
hoc subgroup analyses, ICBT was found to be cost-effective specifically for patients 
with: 1) higher self-assessed disease severity (60% of ICERs in dominant quadrant; 78% 
chance of being cost-effective at a willingness to pay [WTP] of €20,000), and 2) higher 
self-perceived impact of psoriasis on daily life (78% of ICERs in dominant quadrant; 95% 
chance of cost-effectiveness at WTP of €20,000).
Conclusion: Offering ICBT to psoriasis patients was only cost-effective for patients 
with relatively high self-assessed disease severity and patients who experience a rela-
tively high self-perceived impact of psoriasis on daily life. These results suggest that it 
is clinically relevant to screen for these characteristics prior to ICBT, in order to offer 
cost-effective care.
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InTRoduCTIon
Psoriasis is a common immune-mediated chronic inflammatory condition in which patients 
experience scaly skin lesions that may itch or bleed [1]. The lifelong care associated with 
having psoriasis leads to substantial societal costs, including ongoing direct costs of medi-
cation and health care use, but also substantial indirect costs including productivity losses 
[e.g., 2-5]. Furthermore, impairments in health-related quality of life (HRQoL) in patients 
with psoriasis have been found to be comparable to other chronic diseases such as cardio-
vascular diseases, cancer, and diabetes [6]. The high prevalence (approximately 2-3% of the 
population) and the substantial physical, psychological, and economic burden of psoriasis 
emphasizes the need for (cost-)effective treatment options [7–9]. Growing evidence sug-
gests that psychological interventions should be part of these treatment options and may 
decrease physical and psychological symptoms in chronic skin conditions [e.g., 10–12].
Scarce previous studies have shown that interventions based on cognitive behavioral 
therapy (CBT) can be effective in reducing physical and psychological symptoms in patients 
with chronic skin conditions [10–12]. The central idea behind CBT is that the way people 
make sense of the world affects their feelings and behavior. In this relatively short-term 
and goal-oriented treatment form, cognitive distortions and dysfunctional beliefs are 
challenged in order to improve psychological complaints [13]. In order to improve access 
to care and potentially enhance its cost-effectiveness, CBT interventions are increasingly 
being offered online: internet-based CBT (ICBT). Systematic reviews have demonstrated 
the effectiveness of ICBT in other patient samples [e.g., 14–16] and evidence on ICBT cost-
effectiveness is accumulating [17–21], even though studies in patients with dermatological 
conditions are lacking. Thus far, only one study has examined the effectiveness of unguided 
ICBT in patients with psoriasis, and demonstrated that this intervention was able to improve 
anxiety and quality of life [22]. The effectiveness of therapist-guided ICBT for patients with 
psoriasis has thus far only been examined in our recent randomized controlled trial (RCT), 
which demonstrated significant improvements in physical functioning and decreased 
disease impact on daily activities, as compared to regular dermatological care [23].
Regarding cost-effectiveness, two studies have provided preliminary support for the 
idea that distance-delivered psychological interventions may decrease costs in patients 
with skin conditions: adding internet-based or phone-based self-management to 
regular dermatological care had similar effects and decreased societal costs compared 
to regular care alone in patients with psoriasis [24] and atopic dermatitis [25]. Thera-
pist guidance may be an important factor influencing cost-effectiveness, as a recent 
systematic review showed that particularly guided internet-based interventions were 
more cost-effective than a variety of comparison conditions, including care as usual, 
face-to-face CBT, telephone counseling, and unguided ICBT [26]. However, no studies 
to date have examined the cost-effectiveness of guided ICBT in patients with psoriasis.
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In the current study, the cost-effectiveness of an individually-tailored, therapist-
guided ICBT intervention is examined. In a multicenter randomized controlled trial 
(RCT), this intervention has been shown to significantly improve physical functioning 
and decrease disease impact on daily activities as compared to regular dermatological 
care [23]. However, it remains unknown to what extent these clinical benefits outweigh 
the costs from a societal perspective. Therefore, an economic evaluation was performed 
alongside the RCT, with the hypothesis that ICBT in addition to regular dermatological 
care is cost-effective from a societal perspective.
MaTeRIalS and MeThodS
design
This economic evaluation from a societal perspective was conducted alongside an open-
label parallel-group randomized controlled trial (RCT; allocation ratio: 1:1) examining 
the effects of an Internet-based cognitive behavioral treatment offered in addition to 
care as usual (ICBT+CAU; intervention group) as compared to care as usual alone (CAU, 
consisting of regular dermatological care; control group). The methodological details of 
the study have been described elsewhere [23] and will be briefly summarized here. The 
study was approved by the regional medical ethics committee (i.e. Commissie Mensge-
bonden Onderzoek regio Arnhem – Nijmegen) and registered in the Dutch Trial Registry 
(NTR2436). The study was conducted in accordance with the Declaration of Helsinki [27] 
and all participants gave written informed consent before entering the study.
Participants
Study participants were patients with psoriasis recruited through four outpatient derma-
tology departments and through the Dutch Psoriasis Association. Inclusion criteria were a 
diagnosis of psoriasis, age ≥ 18 years, and a positive psychological risk profile (i.e. Impact 
of chronic Skin Disease on Daily Life (ISDL) score of ≥ 5 for anxiety and/or ≥ 21 for negative 
mood [23, 28]). Exclusion criteria were psychological and/or physical comorbidity inter-
fering with the study protocol, current psychological treatment, current photo(chemo)
therapy, pregnancy, lack of access to a computer and/or internet, and illiteracy.
ICBT intervention
Patients randomized to the intervention condition participated in individually-tailored, 
therapist-guided ICBT aimed at reducing the impact of psoriasis on daily life. The inter-
vention consisted of five flexible treatment modules focused on the following themes: 
itch, pain, fatigue, negative mood, and social relationships. Participants started with two 
face-to-face intake sessions with a psychologist, in which individual treatment goals 
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were mutually determined. Choice of treatment modules and individual assignments 
within these modules were determined based on treatment goals, therapist judgment, 
and screening procedures. Patients received personalized written feedback on their 
assignments from their therapist, approximately once a week. Intervention duration 
and content varied between participants, depending on treatment goals, with a mean 
duration of 25 weeks (± 12 weeks, range = 1-57 weeks). For more details regarding inter-
vention content, see our paper on the effectiveness of this intervention [23].
outcomes
To assess cost-effectiveness from a societal perspective, the below mentioned measures 
of costs and effects were administered at baseline, post-treatment (ICBT: end of treat-
ment, CAU: 6 months after baseline), and 6 months post-treatment (ICBT: 6 months after 
end of treatment, CAU: 12 months after baseline).
Utilities and quality-adjusted life years
Quality of life from a health perspective was measured by the EuroQol questionnaire 
[EQ-5D-3L; 29]. This generic self-report questionnaire consists of 5 domains: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. Respondents rate 
their state of health on each of these domains on one of three levels (no problems = 1; 
some problems = 2; extreme problems = 3). Based on this questionnaire, utility scores 
were calculated, using the Dutch tariff, as a preference-based measure of quality of life 
anchored at 0 (death) and 1 (perfect health) [30]. Quality-Adjusted Life Years (QALYs) 
area under the curve was calculated using the trapezium rule [31]. In order to examine 
the percentage of participants who reached a stable clinically significant improvement 
in health-related quality of life, the difference between pre-treatment scores and the 
mean of post-treatment and 6 months follow-up scores on the EQ-5D utility values were 
calculated. The cut-off score for minimal clinically important difference (MCID) was set 
at 0.05, based on a recent systematic review on use of quality of life instruments in RCTs 
of psoriasis [32].
Cost evaluation
Societal costs included in this study were 1) healthcare sector costs (i.e. self-reported 
healthcare and medication use), 2) patient travel costs for healthcare use, 3) costs as-
sociated with loss of productivity in paid self-reported labour (i.e. absenteeism and 
presenteeism), and 4) ICBT intervention costs.
Healthcare costs were calculated based on the Trimbos and iMTA questionnaire on 
Costs associated with Psychiatric illness (TIC-P) [33] and included psoriasis-related 
healthcare use (i.e. care provided by dermatologists and dermatology nurses), care by 
the general practitioner and company doctor, psychological/psychosocial care (e.g., 
154 Chapter 7
care provided by a psychologist, psychiatrist, or social worker), and care provided by 
alternative medicine practitioners. Healthcare use costs were calculated by multiplying 
the healthcare use with unit prices that were estimated based on the TIC-P [33] and the 
Dutch manual for cost analysis in healthcare [34].
Medication costs were calculated by multiplying the daily defined doses by the prices for 
medication retrieved from the Dutch national tariff list (www.medicijnkosten.nl). Taken into 
account were dermatological treatment-related systemic medication and medication pre-
scribed for psychological conditions. Costs of topical treatments were excluded, as reliable 
information on topical treatment use could not be obtained based on the included self-
report questionnaires. Furthermore, as these costs are much lower than other (systemic) 
medication costs, topical treatments were not the expected cost drivers in this study.
Patient travel costs for healthcare use were calculated by multiplying a price of €0,19 
per kilometre with the average distance in kilometres from the patients’ houses to the 
reported healthcare facilities used (i.e. hospitals, GPs, pharmacies), in accordance with 
general guidelines from the Dutch manual for cost analysis in healthcare [34].
Loss of productivity costs (i.e. absenteeism and presenteeism) were calculated using 
the friction cost method, and were based on modules of the PROductivity and Disease 
Questionnaire [PRODISQ; 35]. Productivity costs were calculated by multiplying the 
overall average costs of productivity loss per hour [i.e. €34.97; 34] by the amount of 
hours that patients were absent or experienced a suboptimal work performance be-
cause of their illness.
ICBT intervention costs were calculated based on 1) IT costs for intervention develop-
ment, hosting, and technical support, 2) ICBT therapist salary costs, based on time spent 
on intake sessions and online/telephone guidance of participants, 3) patient travelling 
expenses for face-to-face intake sessions, and 4) salary costs of a research assistant for 
an instruction session of the intervention website by telephone. As having a computer 
with Internet access was part of the inclusion criteria, costs for computer and internet 
access were considered sunk costs and were, therefore, not included in the analysis.
In accordance with the Dutch manual for cost analysis in healthcare [34], the time that 
patients spent on this intervention was assumed to be adequately reflected in estimates 
of their QoL, and were therefore not monetarily rated, to prevent double counting. It 
was estimated that 30% of the population of psoriasis patients would be eligible for the 
ICBT treatment and 10% of these patients would be reached. Therefore, costs of ICBT 
use per patient were calculated by dividing the total intervention costs by the number 
of patients corresponding to this 10% that would be treated using the ICBT intervention. 
For intervention development costs, an amortization period of 5 years was assumed. All 
costs were updated to 2015 by applying Dutch price indices when needed. Missing data 
on costs and effects were imputed using the last-observation-carried-forward (LOCF) 
method to correct for possibly selective non-response.
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Statistical analysis
Between-group differences in costs at baseline and follow-up were calculated using 
independent-samples t-tests based on bootstrapped samples (1000 replications), as a 
non-parametric way to incorporate uncertainty. Cost-effectiveness results were analyzed 
according to intention-to-treat principles and were also based on bootstrapped samples. 
Differences in costs and QALYs between ICBT and CAU were analyzed for the study period 
of 12 months. An incremental cost-effectiveness ratio (ICER) was calculated by dividing 
the difference in costs between ICBT and CAU by the difference in their effects (i.e. QALYs).
As correcting for confounders was not possible in the analysis based on ICERs the net 
monetary benefit (NMB) was used as a dependent variable in regression analyses. In 
these analyses we examined the influence of 1) potential differences in baseline costs 
and 2) potential confounders. Corresponding with the analytic strategy of the previ-
ous RCT, the baseline dependent variable and the confounders age, sex, educational 
level, work status, recruitment site, self-reported systemic antipsoriatic medication use, 
and self-assessed (Self-Administered Psoriasis Area and Severity Index [SAPASI; 36]) 
and clinician-assessed disease severity (Psoriasis Area and Severity Index [PASI; 37]) 
were included as covariates [23]. When needed, covariates were log-transformed and 
winsorized in order to reduce the influence of outliers and reach a normal distribution 
(i.e. for baseline costs and self-assessed and clinician-assessed disease severity). The 
confounder work status, operationalized as currently having a paid job (0 = no, 1 = yes), 
was added in this study due to its specific relevance for costs of productivity losses. 
NMB was calculated as follows: NBM = (WTP x Effects) – Costs, where WTP is short for 
willingness to pay (in Euros). Incremental NBM (INBM) can be defined as the difference 
between two NBMs and a positive INBM in this study can be interpreted as the added 
value in Euros of the ICBT intervention versus CAU. Results were based on a general 
linear model that was bootstrapped 1000 times.
In case no main cost-effectiveness would be shown, post-hoc secondary analyses 
would be conducted by conducting the ICER-based analyses described above separately 
for high and low-scorers on clinically relevant constructs, in order to examine whether 
the intervention was cost-effective specifically for clinically relevant subgroups. In our 
previous publication reporting the effectiveness of this intervention [23], patients in this 
sample were shown to have relatively low levels of disease severity and psychological 
distress. Resultantly, we hypothesized that results may be more pronounced when 
patients had experienced a greater disease burden, corresponding with the overall goal 
of the intervention to reduce the impact of psoriasis on daily life (e.g., greater disease 
severity, higher levels of distress, larger impact of the condition on daily life). Therefore, 
we explored this idea further in the current study in four post-hoc subgroup analyses. 
Subgroups were constructed by applying a median split on baseline values, resulting in 
a group of high-scorers versus low-scorers on the following constructs: 1) self-assessed 
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disease severity [SAPASI; 36]; 2) clinician-assessed disease severity [PASI; 37]; 3) psycho-
logical distress (Impact of chronic Skin disease on Daily Life [ISDL] composite z-score of 
anxiety and negative mood subscales [ISDL; 28]), in line with screening of the psycho-
logical risk profile in the RCT; and 4) self-perceived impact of psoriasis on daily life [ISDL; 
28]. For measurement details, see [23, 38].
ReSulTS
Sample characteristics
Baseline sociodemographic and disease-related characteristics of the study sample, 
consisting of 131 participants, can be found in Table 1, and a flow diagram of study par-
ticipants is presented in Figure 1. Sociodemographic and disease-related characteristics 
did not significantly differ between the intervention and control group (p ≥ .10), with the 
exception of a higher clinician-rated disease severity in the intervention group (p = .03) 
and a trend indicating that patients in the intervention group used systemic antipsori-
atic medication more often (p = .07). A small number of patients reported a co-morbid 
psoriatic arthritis diagnosis (ICBT: n = 11; CAU: n = 5, p = .12); this number was too small 
to compare cost-effectiveness outcomes for patients with and without this diagnosis.
Table 1. Baseline characteristics of internet-based cognitive behavioral treatment plus care as usual 
(ICBT+CAU) and care as usual (CAU) groups
Characteristic ICBT+Cau (n = 65)a Cau (n = 66)a
Gender (male) 33 (50.8) 34 (51.5)
Age (years) 52.69 ± 11.27 (24-73) 53.45 ± 13.81 (19-79)
Married/ living together 46 (70.8) 53 (80.3)
Educational level
Primary 1 (1.5) 4 (6.1)
Secondary 44 (67.7) 43 (65.2)
Tertiary 20 (30.8) 19 (28.8)
Work status
 Employed (paid job) 35 (53.8%) 26 (48.5%)
Unemployed 25 (38.5%) 32 (39.4%)
Missing 5 (7.7%) 8 (12.1%)
Disease duration (years) 18.03 ± 13.76 (0-59)b 15.16 ± 16.35 (0-65)b
Disease severity (PASI) 5.99 ± 5.61(1-31)b 4.20 ± 2.87(0-13)b
Disease severity (SAPASI) 5.27 ± 3.29 (1-19)b 4.48 ± 2.41 (0-12)b
Systemic treatmentc 25 (44.6)b 17 (29.3)b
HRQoL utility (EQ-5D) 0.75 (0.21)b 0.76 (0.20)b
Note. CAU = care as usual; EQ-5D = European Quality of Life-5 Dimensions Questionnaire; HRQoL = health-
related quality of life; ICBT = internet-based cognitive behavioral treatment; PASI = Psoriasis Area Severity 
Index; SAPASI = Self-assessed PASI. amean ± SD (range) or n (%), bn = 2-12 missings, cnumber of patients 
reporting use of systemic antipsoriatic medication.
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Assessed for eligibility (n=751) 
(252 RUMC; 406 RS; 52 PVN; 26 CWZ; 15 ZGT)
Excluded (n=620)
   Did not meet inclusion criteria (n=43)
   Declined to participate (n=59)
   Did not return screening instrument (n=216)
   Did not report elevated distress levels (n=302)
Allocated to ICBT+CAU (n=65)
 Received allocated intervention (n=55)
 Non-starters (n=10, 15.4%)
 Non-completers (n=6, 9.2%)
             
 
Allocated to CAU (n=66)
Randomized (n=131)
Post-treatment
Lost to 6 month follow-up (n=28)
Analyzed: 37 (56.9%)
Lost to post-treatment assessment (n=21)
Analyzed: 44 (67.7%)
Lost to pre-treatment assessment (n=5)
Analyzed: 60 (92.3%)
Follow-Up
Lost to pre-treatment assessment (n=6)
Analyzed: 60 (90.9%)
Lost to post-treatment assessment (n=15)
Analyzed: 51 (77.3%) 
Lost to 6 month follow-up (n=21)
Analyzed: 45 (68.2%) 
Baseline
figure. 1. ConSoRT flow diagram of study participants. CWZ = Canisius-Wilhelmina Hospital, Nijme-
gen; PVN = Dutch Psoriasis Association; RS = Rijnstate Hospital, Velp; RUMC = Radboud university medical 
center, Nijmegen; ZGT = Ziekenhuis Groep Twente, Almelo.
Cost-effectiveness
At baseline, patients reported an average EQ-5D utility score of 0.75 (SD = 0.20); this 
value did not differ between groups (p = .58). A clinically significant improvement on the 
EQ-5D (i.e. MCID ≥ 0.05) was observed in 20 out of 59 intervention participants (33.9%) 
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and in 16 out of 60 control group participants (26.7%); this percentage did not differ 
between groups (χ2(1) = 0.74, p = .39). Baseline societal costs in the intervention group 
were €3,984 (SD = €5,824) compared to €2,843 (SD = €4,506) in the control group, which 
did not significantly differ between groups (p = .22). Mean costs in the intervention 
and control groups, based on the 6-months follow-up period (i.e. post-treatment and 
6 month follow-up measurements), are presented in Table 2. None of these costs (i.e. 
for healthcare use, medication use, patient travel, absenteeism, presenteeism, and total 
costs) differed between the two groups (p ≥ .16).
Table 2. Mean (±SD) costs in Euros for the internet-based cognitive behavioral treatment plus care as usual 
(ICBT+CAU) and care as usual (CAU) groups, based on the six months follow-up period, indexed to the year 
2015
Cost category ICBT+Cau Cau
Health care use €1,032 (1525) €1,431 (2405)
Medication use €1,409 (3958) €1,109 (3917)
Patient travel costs €237 (265) €252 (382)
Absenteeism €1,279 (3799) €906 (2952)
Presenteeism €2,251 (7225) €1,731 (4748)
ICBT intervention €497 n.a.
Note. CAU = care as usual; ICBT = internet-based cognitive behavioral treatment, n.a. = not applicable.
ICeR analysis
Results from the 1000 bootstrapped replications of mean QALYs and total costs for the 
12-month study period are presented in Table 3. In a base case analysis, no differences 
between groups were found on effectiveness (mean QALY difference = -0.014; 2.5 to 
97.5 percentile = -0.062 to 0.038) or costs from a societal perspective (mean difference 
= €1,295; 2.5 to 97.5 percentile = -€1,502 to €4,176) at both post-treatment and 6 
months follow-up (p ≥ .45). Figure 2 presents the cost-effectiveness plane containing a 
scatterplot of the simulated ICERs. The majority of ICERs (58%) appear in the northwest 
quadrant, suggesting that ICBT+CAU was inferior to CAU alone (i.e. larger societal costs 
and smaller HRQoL gains in the intervention group). There was a 24% probability that 
the intervention resulted in greater HRQoL improvements, but at higher societal costs 
(northeast quadrant). Eleven percent of ICERs were located in the southwest quadrant, 
indicating reduced societal costs in ICBT+CAU compared to CAU alone, but also inferior 
gains in HRQoL. Lastly, 7% of the ICERs were located in the southeast quadrant, indi-
cating that ICBT was associated with greater improvements in HRQoL and less societal 
costs, compared to CAU.
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Table 3. Mean QALYs and costs for the internet-based cognitive behavioral treatment plus care as usual 
(ICBT+CAU) and care as usual (CAU) groups as a result of 1000 bootstrapped replications
ICBT+Cau Care as usual Δ Qaly Δ Costs
QALY costs QALY costs
Average 0.78 €6,641 0.79 €5,346 -0.014 €1,295
2.5 percentile 0.75 €4,849 0.76 €3,604 -0.062 -€1,502
97.5 percentile 0.81 €8,789 0.83 €7,339 0.038 €4,176
Note. CAU = care as usual; ICBT = internet-based cognitive behavioural treatment; QALY = quality adjusted 
life years.
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figure 2. Cost-effectiveness plane: Base case analysis.
InMB analyses: correcting for relevant confounders
In uncorrected analyses, the incremental net monetary benefit (INMB) value at a WTP of 
0 was -€1,305 (95% CI = -€4,573 to €1,985), indicating non-significantly larger societal 
costs in the intervention group than in the control group at post-treatment and 6 months 
follow-up (p = .46). Considering that a statistically non-significant lower improvement 
on the EQ-5D in the intervention group compared to the control group was found, a 
WTP acceptability curve would be irrelevant. Therefore, upcoming analyses focused 
on the INMB at a WTP of 0, thereby essentially analysing between-group differences in 
costs. When correcting for baseline costs, the INMB became positive (€268; 95% CI = -2686 
- 3047), which increased when including previously specified confounders (€1,335; 95% 
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CI = - €2,261 - €4,660); however, group differences remained non-significant (p = .84 and 
.47, respectively).
Subgroup analyses
Because the intervention group did not show overall cost-effectiveness, subgroup anal-
yses on clinically relevant subgroups were conducted. All subgroups were constructed 
using median split procedures. Main outcomes concerning costs and QALYs, as well as 
the percentage of ICERs in the dominant quadrant (i.e. ICBT is associated with lower 
costs and higher effects than CAU), are presented in Table 4.
Table 4. Results of the base case and subgroup analyses concerning costs and QALYs for the internet-
based cognitive behavioral treatment plus care as usual (ICBT+CAU) and care as usual (CAU) groups, and 
the % of dominant ICERS based on 1000 simulations
ICBT+Cau Care as usual
Subgroups Costs QALY Costs QALY % southeast 
(dominant)
Self-assessed disease severity (SAPASI) high €8,152 0.81 €8,746 0.76 60
low €5,181 0.74 €3,308 0.80 0
Clinician-assessed disease severity (PASI) high €8,902 0.79 €7,008 0.85 0
low €4,619 0.79 €4,515 0.79 28
Distress (ISDL) high €8,704 0.75 €3,850 0.76 0
low €4,535 0.81 €6,829 0.84 14
Impact of disease on daily life (ISDL) high €7,294 0.74 €9,856 0.71 78
low €4,935 0.80 €2,948 0.85 0
Note. CAU = care as usual; ICBT = internet-based cognitive behavioural treatment PASI = Psoriasis Area and 
Severity Index; QALY = quality adjusted life years; SAPASI = Self-Administered PASI.
1. Self-assessed disease severity
Figure 3 presents the cost-effectiveness plane for patients with a) high self-assessed 
disease severity (i.e. SAPASI ≥ 4.76, n = 56), and b) low self-assessed disease severity 
(i.e. SAPASI ≥ 4.76, n = 57). In patients with high SAPASI scores, the majority of ICERs (i.e. 
60%) were located in the southeast (dominant) quadrant. A further 35% of ICERs were 
located in the northeast quadrant. In contrast, in patients with low SAPASI scores, nearly 
all ICERs (i.e. 98%) were located in the northwest (inferior) quadrant. Figure 4 shows the 
cost-effectiveness acceptability curve (CEAC) for patients with high self-assessed disease 
severity, which illustrates that, given a WTP of €20,000 per QALY gained, the probability 
that ICBT is cost-effective compared to CAU is 78%, rising to 92% given a WTP of €80,000.
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figure 3. Cost-effectiveness plane subgroups: Self-assessed disease severity (Self-assessed Psoria-
sis area and Severity Index). a = high self-assessed disease severity, b = low self-assessed disease severity.
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figure 4. Cost-effectiveness acceptability curve comparing for the internet-based cognitive behavioural 
treatment in addition to CAU (ICBT+CAU) to care as usual alone (CAU), for patients with high self-assessed 
disease severity (Self-assessed Psoriasis Area and Severity Index).
2. Clinician-assessed disease severity
Figure S1 presents the cost-effectiveness plane for patients with 1) high clinician-assessed 
disease severity (i.e. PASI ≥ 3.9, n = 53), and 2) low clinician-assessed disease severity (i.e. 
PASI ≥ 3.9, n = 56). In patients with high clinician-assessed disease severity (i.e. PASI ≥ 3.9, n 
= 53), ICBT generally resulted in lower costs and lower effects compared to CAU (i.e. 86% 
of ICERs in northwest inferior quadrant). In patients with low clinician-assessed disease 
severity (i.e. PASI ≥ 3.9, n = 56), 31% of ICERs were in the northeast quadrant and 28% 
of ICERS were in the southeast quadrant. The mean bootstrapped ICER was €21,430 per 
QALY gained, and given a WTP of €20,000 per QALY gained, the probability that ICBT is 
cost-effective compared to CAU is 52%, rising to 57% at a WTP of €80,000.
3. Psychological distress
Figure S2 presents the cost-effectiveness plane for patients with a) high psychological 
distress (i.e. IHDL composite z-score ≥ -.10, n = 59, and b) low psychological distress (i.e. 
IHDL composite z-score ≥ -.10, n = 59). In patients with high psychological distress, 78% 
of ICERs were located in the northwest (inferior) quadrant. The remaining 22% of ICERs 
were located in the northeast quadrant. In patients with low psychological distress, most 
ICERs (i.e. 82%) were in the southwest quadrant. The mean bootstrapped ICER for low 
psychological distress was €91,278 per QALY gained.
4. Impact of psoriasis on daily life
Figure 5 presents the cost-effectiveness plane for patients with a) high self-perceived 
impact of psoriasis on daily life (i.e. IHDL impact ≥ 16, n = 56), and b) low self-perceived 
impact of psoriasis on daily life (i.e. IHDL impact ≥ 16, n = 59). In patients with high 
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self-perceived impact on daily life, 78% of ICERS were located in the southeast (dominant) 
quadrant. In patients with low self-perceived impact on daily life, 97% of ICERs were in 
the northwest (inferior) quadrant. Figure 6 shows the CEAC for patients with high self-
perceived impact on daily life, which illustrates that, at a WTP of €20,000 per QALY gained, 
the probability that ICBT is cost-effective compared to CAU is 95%, rising to 96% at a 
WTP of €80,000.
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figure 5. Cost-effectiveness plane subgroups: Impact of psoriasis on daily life (Impact of chronic 
Skin disease on daily life - disease-related impact subscale). a = high impact on daily life, b = low 
impact on daily life.
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figure 6. Cost-effectiveness acceptability curve comparing for the internet-based cognitive behavioural 
treatment in addition to CAU (ICBT+CAU) to care as usual alone (CAU), for patients with high self-perceived 
impact of the disease on daily life (Impact of chronic Skin disease on Daily Life - disease-related impact 
subscale).
dISCuSSIon
In this study, the cost-effectiveness of individually-tailored therapist-guided ICBT for 
patients with psoriasis and a psychological risk profile was examined from a societal 
perspective. Previous RCT results showed that this intervention significantly decreased 
the impact of psoriasis on daily activities and improved physical functioning [23]. In the 
current cost-effectiveness analysis, ICBT in addition to CAU was found to have similar 
effects on HRQoL as CAU alone and led to similar costs to society during a follow-up 
period of 6 months. Post-hoc subgroup analyses demonstrated that the intervention 
was cost-effective specifically for patients with higher self-assessed disease severity and 
higher self-perceived impact of psoriasis on daily life, which suggests that targeting the 
intervention specifically at those groups may be a cost-effective approach.
The finding that ICBT could not be considered cost-effective in comparison to CAU 
in the overall sample is not in line with previous cost-effectiveness studies in various 
conditions [26], nor with preliminary evidence of reduced costs following distance-
delivered psychological interventions in patients with chronic skin conditions [24, 25]. 
These findings may be partly explained by a  baseline imbalance in costs and the generic 
measurement of HRQoL in a dermatological patient sample. First, costs in the ICBT group 
were already higher than in the CAU group at baseline, although the difference was not 
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statistically significant. This likely explains why costs at post-treatment and 6-months 
follow-up were also statistically non-significantly higher in the ICBT condition and sug-
gests that this cost difference may not be attributable to the ICBT intervention. Instead, 
it may have been related to the fact that patients in the ICBT group had significantly 
higher disease severity, more often had a paid job (i.e. more possibilities of productivity 
losses), and were more often using systemic antipsoriatic medication (i.e. higher medi-
cal costs), although the last two differences were not statistically significant. In fact, the 
negative cost difference disappeared when baseline costs were controlled for in INMB 
analyses, illustrating the confounding effect of baseline costs. Moreover, the generic 
measure of HRQoL that was used to quantify effects (i.e. EQ-5D) may not have sufficiently 
captured intervention effects in patients with psoriasis, as it may not be specific enough 
to detect important aspects of HRQoL in dermatological samples [39, 40]. Furthermore, 
previous reviews demonstrated that the EQ-5D-3L showed limited responsiveness to 
change, especially for small to moderate changes in health status, as well as ceiling 
effects, across a range of conditions [41–44]. A ceiling effect was also observed in this 
study, with 22% of participants having the highest possible score at baseline, increasing 
to 28% at post-treatment and 6-month follow-up. Last, responsiveness in patients with 
psoriasis may be specifically impaired in the upper limits of the EQ-5D [45], which may 
have caused problems in the current trial in which EQ-5D utility values were on the high 
end of what is typically observed in psoriasis patients [46].
Subgroup analyses clearly showed that ICBT was cost-effective for two specific patient 
groups: those with higher self-assessed disease severity and those who experience a 
larger impact of psoriasis on daily life. ICBT was considered most cost-effective for pa-
tients who experienced a relatively high impact of psoriasis on daily life, corresponding 
with the overall therapeutic goal of the intervention: to reduce the burden of psoriasis in 
daily life. This may also be a reason why we did not find that ICBT was more cost-effective 
for patients with higher levels of psychological distress; perhaps its operationalization 
(i.e. elevated levels of anxiety and negative mood) was too generic to capture the spe-
cific impact of psoriasis in daily life. A possible explanation for the fact that we did not 
find ICBT to be cost-effective for patients with higher clinician-assessed disease sever-
ity may be that self-assessed disease severity reflects more subjective components of 
the disease experience, including not only objective disease severity, but also patient 
burden. This more subjective disease burden may be more relevant for psychological 
interventions than objective disease severity, which may explain their differential re-
sults. Alternatively, clinician-assessed disease severity may have been less reliable in the 
current study, as it was not always measured at the same time as other measures (i.e. 
questionnaires) that were filled out at home for logistic reasons.
The findings that ICBT was considered cost-effective for subgroups of patients with 
higher levels of self-assessed disease severity and a larger impact of psoriasis on daily 
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life are highly clinically relevant. They give a clear indication of who might benefit most 
from this intervention and suggest that offering ICBT specifically to these groups may 
be the most cost-effective approach. Furthermore, for both subgroups, societal costs 
in the ICBT+CAU group were actually lower than in the CAU group at post-treatment 
and 6-months follow-up. This indicates that intervention costs are offset by societal cost 
reductions, and suggests that even at a willingness to pay of 0, the intervention would 
most likely be cost-effective for these subgroups. This is a relevant consideration for 
implementation, as usually new health interventions are associated with increased costs 
compared with regular care.
To our knowledge, this is the first empirical study reporting on the cost-effectiveness 
of ICBT in patients with chronic skin conditions. Methodological strengths include the 
high internal validity by the RCT design, the use of validated outcome measures, and the 
6-month follow-up allowing an evaluation of the longer-term cost-effectiveness from 
a societal perspective. Furthermore, the study was conducted as an open-label trial in 
outpatient departments of several academic and non-academic hospitals, and was thus 
a good reflection of daily clinical practice. This is important for the generalizability of 
cost-effectiveness results. The fact that we were able to show that ICBT was cost-effective 
for relevant subgroups of this relatively well-treated sample (i.e. low PASI scores) can be 
considered a strength of the intervention, which further underlines its clinical relevance. 
Lastly, this cost-effectiveness analysis was one of the few to date that took into account 
indirect costs (i.e. productivity losses), which increases the generalizability of results. 
A recent review of health economic analyses of psoriasis showed that only 9 of the 60 
included articles took indirect costs into account [47], despite cost-of-illness studies that 
illustrate the large impact that psoriasis has on occupational disability [48–51].
This study had a number of possible limitations, which give rise to several sugges-
tions for future research. First, costs and QALY estimates were based on a relatively short 
follow-up of 6 months. A longer duration with more measurements might have led to 
more accurate estimates and would have increased the ability to capture late effects. 
Second, despite screening for elevated levels of distress, mean distress and disease se-
verity levels of the study sample were relatively low. This raises the question whether the 
intervention would have been more (cost-)effective in a different sample. Furthermore, 
it has important consequences for the interpretation of subgroup analyses, as the ma-
jority of patients in the subgroups had at most moderate disease severity and distress 
levels. Therefore, further studies should be conducted in samples with higher disease 
severity and distress, and they should also focus on samples screened for relatively 
high levels of perceived impact of the condition on daily life and self-assessed disease 
severity, as results of our study suggest that the intervention may be considered cost-
effective in these groups. Third, the current study used a non-disease-specific measure 
(EQ-5D) to calculate QALYs for the cost-effectiveness analysis, which might have been 
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too generic to assess clinically relevant improvements in dermatology patients and may 
not adequately measure disease-specific aspects of HRQoL in patients with psoriasis 
[40]. Therefore, it is recommended that dermatology-specific measurements to reliably 
assess improvements brought about by psychological interventions are developed to 
aid future cost-effectiveness research in these groups. Fourth, like most internet-based 
interventions, the study suffered from a number of missing data, which were handled 
by applying the conservative LOCF method. Last, like most economic evaluations con-
ducted alongside RCTs, the current study was powered to detect differences in primary 
outcomes and not differences in costs. Similarly, post-hoc subgroup analyses were based 
on small samples, and therefore results should be replicated in larger samples.
In conclusion, while the ICBT intervention was not considered cost-effective in com-
parison to regular dermatological care in the overall study sample, subgroup analyses 
suggested that it was cost-effective for two specific patient groups: those patients who 
experience high self-assessed disease severity and those who experience a high impact 
of the condition in daily life. Considering that these are typical target groups for whom 
psychological interventions are commonly indicated, screening for these characteristics 
prior to offering ICBT may be both cost-effective and clinically relevant.
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figure S1. Cost-effectiveness planes subgroups: Clinician-assessed disease severity (Psoriasis area 
and Severity Index). a = high clinician-assessed disease severity, b = low clinician-assessed disease sever-
ity.
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figure S2. Cost-effectiveness planes subgroups: Psychological distress (Impact of chronic Skin dis-
ease on daily life - anxiety and negative mood subscales). a = high psychological distress, b = low 
psychological distress.
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Chronic skin conditions are common and associated with a significant psychosocial 
impact on daily life, including impairments in psychological and physical functioning. 
This impact is not only a consequence of living with a chronic skin condition; it can 
also play a significant role in disease exacerbation, as increased psychological distress 
can result in disease flares in inflammatory skin conditions. Although the psychosocial 
impact of chronic skin conditions is increasingly recognized, research on psychological 
factors influencing chronic skin conditions, and evidence-based psychological treat-
ments for these groups, are relatively scarce. The field of research and medicine that 
involves this complex interaction between psychological factors and the skin is termed 
psychodermatology; a field that is considered upcoming. This thesis aimed to expand 
the current literature in psychodermatology by presenting the results of studies focused 
on 1) new concepts in psychodermatology, specifically aspects of body awareness; 2) 
new methods in psychodermatology to assess existing concepts of relevance, specifi-
cally both direct and indirect methods to assess predictors of perceived stigmatization 
and implicit stigmatization-related bias; and 3) new psychological treatment methods in 
psychodermatology, specifically the effectiveness and cost-effectiveness of individually-
tailored therapist-guided internet-based cognitive behavioural treatment (ICBT). The 
majority of the studies presented in this thesis have been conducted in patients with 
psoriasis, as an illustrative example of a common chronic skin condition.
PaRT I. ConCePTS 2.0: The Role of Body awaReneSS In ChRonIC SkIn 
CondITIonS
In Chapter 2, we examined the potential role of body awareness in patients with pso-
riasis. Because the treatment of psoriasis often relies heavily on self-care, patients are 
typically required to play an active role in managing their skin condition. This suggests 
that body awareness may be particularly relevant in psoriasis; however this had not 
been researched before. We developed a new questionnaire to assess body awareness: 
the Body Attention, Ignorance and Awareness Scale (BAIAS). Results showed that this 
questionnaire reliably measures three aspects of body awareness: 1) being aware of and 
paying mindful attention to bodily signals (attention); 2) self-perceived importance of, 
and general attitude towards, body awareness (awareness); and 3) not recognizing and/
or ignoring bodily signals (ignorance). When examining associations with physical and 
psychological functioning, especially the ignorance subscale was found to be related to 
reduced functioning. Given the association between body ignorance and worse psycho-
logical functioning, and the negative influence of impaired psychological functioning 
on treatment outcomes, it may be clinically important to screen for aspects of body 
awareness in patients with chronic skin conditions.
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PaRT II. MeThodS 2.0: exPlICIT and IMPlICIT MeaSuReS of PeRCeIVed 
STIgMaTIzaTIon
In Chapters 3 and 4, the concept of stigmatization was examined using two different 
approaches: administering a validated self-report questionnaire to examine predictors 
of perceived stigmatization (Chapter 3), and using computerized reaction time tasks 
to examine implicit cognitive and behavioral biases to stigmatization-related stimuli 
(Chapter 4).
In Chapter 3, predictors of self-reported perceived stigmatization were examined in 
patients with psoriasis. In this cross-sectional study, patients filled out self-report ques-
tionnaires to assess perceived stigmatization, as well as potential sociodemographic, 
disease-related, personality, illness cognition, and social support predictor variables. We 
found that 73% of patients experienced stigmatization to some degree, and that per-
ceived stigmatization correlated with all five categories of potential predictor variables. 
Perceived stigmatization was found to be particularly predicted by sociodemographic, 
disease-related, and personality variables in multiple regression models. These results 
may provide input for effective screening and intervention development, as they 
provide indications on which patients are especially vulnerable regarding perceived 
stigmatization.
In Chapter 4, we examined implicit cognitive and behavioral bias to disease-related 
and social threat-related stigmatization stimuli in patients with alopecia and psoriasis, as 
well as in their significant others. Indirect tasks were used to measure reaction times to 
stimuli related to skin conditions and social threat. We found that patients with alopecia 
were significantly slower than healthy controls to name the colors of disease-related 
words in a modified Stroop task. This attentional bias to disease-related stimuli was also 
found in their significant others. In patients with psoriasis and their significant others, no 
attentional bias was found on the Stroop task. Instead, a behavioral bias was found when 
they were asked to respond to pictures of disgusted faces in an approach-avoidance 
task. It was shown that patients with psoriasis showed increased behavioral avoidance 
of these faces compared with controls. This behavioral bias was also found in their 
significant others. These results suggest that implicit stigmatization-related processes 
may differ across skin conditions, with people with psoriasis being more affected by 
social reactions (i.e. disgusted faces) and people with alopecia by disease-related cues. 
Furthermore, the results suggest that these biases may extend to patients’ significant 
others.
Summary 179
8
PaRT III. TReaTMenT 2.0: InTeRneT-BaSed CognITIVe BehaVIoRal TReaTMenT
In Chapters 5, 6, and 7 of this thesis, we focused on the effectiveness and cost-effective-
ness of internet-based cognitive behavioral treatment (ICBT) to reduce the psychosocial 
impact of chronic somatic conditions (and particularly psoriasis) in daily life.
In Chapter 5, we examined the current state of the art of ICBT in adult patients with 
chronic somatic conditions. In a review and meta-analysis, we described and evaluated 
the effectiveness of guided ICBT. A total of 23 randomized controlled trials were included 
and standardized mean differences between the intervention and control conditions 
were calculated and pooled for three outcome categories: general psychological out-
comes, disease-related physical outcomes, and outcomes related to the impact of the 
condition on daily life. Results showed that guided ICBT can be an effective treatment 
for general psychological outcomes (small effects), disease-related physical outcomes 
(small to large effects), and outcomes related to the impact of the condition on daily life 
(small to large effects). Furthermore, explorative analyses revealed that longer treatment 
duration was associated with larger effects on depressive symptoms. Future research in 
separate chronic somatic conditions is needed to corroborate these results, as analyses 
were based on a relatively small number of comparisons.
In Chapter 6, we described the results of a multicenter randomized controlled trial 
on the effectiveness of individually-tailored and therapist-guided ICBT in patients with 
psoriasis who were screened for a psychological risk profile of elevated levels of distress. 
Patients were randomized to either ICBT in addition to regular dermatological care or 
regular care alone. Controlling for relevant covariates, the ICBT group showed signifi-
cantly greater improvements in physical functioning (consisting of itch and fatigue) and 
impact on daily activities (consisting of physical and emotional role functioning). No 
differences were observed in psychological functioning (consisting of depressive and 
anxious symptoms), nor in the secondary outcomes disease severity and dermatological 
treatment compliance. The relationship between therapist and patient measured at the 
beginning of treatment was found to be predictive of improvements in physical and 
psychological outcomes, underlining the importance of a good therapeutic relationship 
in personalized ICBT interventions.
Last, in Chapter 7, the cost-effectiveness of individually-tailored and therapist-
guided ICBT for patients with psoriasis was examined, by conducting an economic 
evaluation alongside the randomized controlled trial. Outcomes were assessed up to 
6 months post-treatment and included patient utilities, healthcare costs, productivity 
losses, and incremental costs per quality-adjusted life year gained. Cost-effectiveness 
was analyzed in bootstrapped samples using 1) incremental cost-effectiveness ratios 
and 2) incremental net monetary benefit analyses correcting for baseline values and 
confounders. Results demonstrated that offering ICBT to patients with psoriasis was not 
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considered cost-effective in the overall sample, but was cost-effective for two specific 
patient groups: patients with relatively high self-assessed disease severity and patients 
who experience a relatively high self-perceived impact of psoriasis on daily life. These 
results suggest that it may be clinically relevant to screen for these characteristics prior 
to ICBT, in order to offer cost-effective care.
The results of this thesis underline psychological aspects related to chronic skin condi-
tions that have remained relatively unexplored to date, such as the relevance of body 
awareness and non-conscious processes associated with perceived stigmatization. Fur-
thermore, this thesis showed for the first time that individually-tailored and therapist-
guided ICBT can be effective in reducing the impact of chronic skin conditions in daily 
life, and cost-effective for subgroups of patients with relatively high self-assessed disease 
severity and a relatively large self-perceived impact of the condition on daily life. Future 
research may build upon the findings of this thesis to further enlarge our knowledge on 
explicit and implicit aspects of the psychosocial burden of chronic skin conditions, and 
how this burden may be decreased by optimizing psychodermatological interventions 
and implementing them in clinical practice.
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The substantial psychosocial impact of chronic skin conditions is increasingly recognized, 
with psychodermatological research to date focusing mainly on showing that patients 
with chronic skin conditions are at increased risk for psychological problems, including 
elevated levels of distress, anxiety and depressive symptoms [e.g., 1, 2]. Far less is known 
about potential risk and resilience factors for impaired physical and psychological func-
tioning in this patient group. Furthermore, evidence-based psychological interventions 
to improve physical and psychological functioning are scarce. The studies in this thesis 
were designed to help fill these gaps in the current literature, by examining 1) new con-
cepts in psychodermatology that are possible predictors of relevant disease outcomes 
(i.e. aspects of body awareness in Chapter 2), 2) new methods in psychodermatology 
to assess existing concepts of relevance (i.e. both direct and indirect methods to assess 
predictors of perceived stigmatization (Chapter 3) and implicit stigmatization-related 
bias (Chapter 4)), and 3) new psychological treatment methods in psychodermatology 
to reduce the impact of psoriasis in daily life (i.e. effectiveness and cost-effectiveness 
of individually-tailored therapist-guided internet-based cognitive behavioral treatment 
[ICBT] in Chapters 5, 6, and 7). The results of these studies are summarized in Chapter 8. 
In this final chapter, the findings of these studies will be discussed, including method-
ological considerations, recommendations for future research, implications for clinical 
practice, and an overall conclusion.
ConCePTS 2.0: The Role of Body awaReneSS In ChRonIC SkIn CondITIonS
Dermatological disease management, such as treatment adherence, has long been 
recognized as an important issue in the management of psoriasis, as the literature to 
date shows that adherence to topical and systemic treatment is generally poor [3−5]. 
Patients are required to take an active role in their own treatment regimen, as they need 
to take time to apply topical treatments on a regular basis. Therefore, body awareness in 
patients with skin conditions may be adaptive, as it leads to patients paying adequate 
attention to bodily symptoms such as dry skin and responding with appropriate self-
care behavior. Consequently, a lack of body awareness may be a risk factor for adverse 
outcomes. However, body awareness had not been examined in patients with chronic 
skin conditions, nor had instruments been developed to assess specifically the aspect 
of not recognizing bodily signals and/or of ignoring them. In Chapter 2, we introduced 
the Body Attention, Awareness and Ignorance Scale (BAIAS) as a new measure to assess 
body awareness in people with a dermatological condition, and showed that it could 
reliably measure three aspects of body awareness: body ignorance, body attention, and 
general body awareness. Particularly the aspect of not recognizing bodily signals and/or 
ignoring them, as reflected in body ignorance, was found to be related to impairments 
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in physical and psychological functioning. This suggests that it may be relevant to assess 
body awareness in this patient group and to pay special attention in clinical practice to 
those patients who do not recognize or ignore bodily signals in clinical practice, as this 
may be an indicator for adverse outcomes.
As this was the first study to examine body awareness in patients with chronic skin 
conditions, many questions remain for future research. First, the properties of the con-
cept of body awareness, and how each of its components relates to relevant outcomes 
and mechanisms, should be further examined. For example, a lack of body awareness 
may be related to a lack of emotional awareness as is seen in alexithymia, as physical 
and emotional sensations often co-occur; emotions are often associated with physical 
sensations and emotional awareness partly relies on the perception of internal bodily 
signals [6-8]. The difficulty in distinguishing feelings from bodily sensations is one of 
the characteristics of alexithymia [9], and a lack of body awareness as well as emotion 
awareness has been found in individuals suffering from pain disorders such as lower 
back pain [8]. Second, it may be relevant to examine indirect methods for assessing body 
awareness. It could be hypothesized that aspects of impaired body awareness may be 
captured by implicit measures, in light of the potential lack of awareness in afflicted in-
dividuals. Third, norm scores for the BAIAS should be established for patient and healthy 
samples, as it remains unknown how our sample compares to other groups and whether 
patients with psoriasis and healthy controls differ with regard to levels of body aware-
ness. Fourth, the BAIAS should be compared with other measures of body awareness 
[e.g., 10] to further assess its psychometric properties, including its convergent validity. 
Fifth, prospective studies are needed to examine causal relationships between aspects 
of body awareness and physical and psychological functioning, to study whether body 
ignorance is indeed a risk factor for impaired functioning.
If prospective studies confirm that body ignorance is indeed a risk factor, interven-
tions may be developed to target this factor in clinical practice. In order to increase 
body awareness in patients with skin conditions, a possible intervention component 
that might be further examined is mindfulness. In other populations, mindfulness in-
terventions have been found to improve aspects of body awareness [e.g., 11, 12, 13]. 
Furthermore, increased body awareness is suggested to be one of the core working 
mechanisms of mindfulness interventions [14, 15], and several of the few studies avail-
able have already shown promising effects of mindfulness for chronic skin conditions 
[16-19]. In addition, an aspect of body awareness similar to our operationalization of 
body ignorance was recently found to mediate the effect of a mindfulness interven-
tion in patients with chronic pain and co-morbid depression [14]. The meditation 
components of mindfulness interventions may help to improve body awareness, given 
that meditation procedures commonly emphasize body awareness by instructing indi-
viduals to notice subtle changes in the body. Future research should focus on working 
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mechanisms and explore the potential mediating role of aspects of body awareness in 
psychological interventions.
MeThodS 2.0: exPlICIT and IMPlICIT MeaSuReS of PeRCeIVed STIgMaTIzaTIon
Having a visible skin conditions such as psoriasis is often accompanied by an altered 
appearance. This can have substantial psychosocial consequences, as others may stare, 
make negative remarks or even avoid the individual afflicted with the condition. Per-
ceived stigmatization is recognized as an important aspect of the psychosocial burden of 
psoriasis; it is associated with significant distress and has been found to be an important 
predictor of disability [e.g., 20, 21-23]. Its widespread impact was underlined in Chapter 
3 of this thesis, which showed that the vast majority of patients with psoriasis (73%) had 
experienced stigmatization to some degree. Furthermore, it was found that perceived 
stigmatization could be predicted by sociodemographic, disease-related and personal-
ity variables. Although prospective studies are needed to disentangle cause and effect, 
the predictors found in this study increase our understanding of which patients may be 
especially vulnerable to stigmatization-related problems. This may aid further develop-
ment of screening and intervention procedures.
In this study, in line with other studies, perceived stigmatization was assessed with a 
self-report questionnaire [24]. While self-report measures provide valuable information 
in reflecting patients’ conscious experience as they perceive it in hindsight, they prob-
ably do not capture the rapid and reflexive responses associated with initial reactions. 
These have been theorized to be at least as important in influencing behavior, but have 
remained largely unexplored in previous research in psychodermatology [25]. Therefore, 
in Chapter 4, we examined these rapid and reflexive responses to stigmatization-related 
stimuli using computer-based reaction time tasks: Approach-Avoidance Tasks [26] and a 
modified version of the Emotional Stroop Task [27]. Stigmatization can be accompanied 
by reflexive disgust reactions of others, which can be considered a defensive response: 
disgust initiates avoidance in order to prevent potential contamination [28, 29]. As 
stigmatization is commonly experienced by patients with psoriasis, they may fear or 
actually be confronted with disgust reactions [30, 31]. Therefore, patients may process 
disgusted facial expressions differently than  healthy controls, and we hypothesized that 
this would be reflected in implicit reflexive processes in the form of an avoidance bias. 
This was found in Chapter 4: in an Approach-Avoidance Task consisting of pictures of 
emotional facial expressions, both patients with psoriasis and their significant others 
showed greater behavioral avoidance of disgusted faces than controls. A similar bias 
was not observed in patients with alopecia (i.e. a dermatological condition characterized 
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by hair loss), who instead were characterized by an attentional bias to disease-related 
words.
The fact that biases were also observed in patients’ significant others, is consistent 
with the idea of courtesy stigma, also known as stigma by association [32, 33]: this idea 
suggests that people associated with stigmatized individuals may be the targets of 
stigma as well, simply by being connected to a stigmatized person [34-36]. Furthermore, 
significant others may experience a substantial burden due to a patient’s condition, 
and this burden may also be reflected in these biases [37]. The differences in response 
latencies of patients and their significant others versus controls are still open to various 
interpretations, as the tasks that were used to assess attentional and behavioral bias 
were specifically designed for this study and their psychometric properties need to be 
further examined. Furthermore, the results should be interpreted with caution, as they 
were based on a relatively small between-group effect and groups differed on various 
characteristics. However, the avoidance effect we found in psoriasis was specific for 
disgust and was not found for other negative and positive facial expressions included, 
and disgust is a prominent feature in stigmatization responses [e.g., 38]. Therefore, the 
tentative conclusion can be drawn that this effect may be attributed to an automatic 
stigmatization-related avoidance reaction, probably stemming from a coping reaction 
to perceived negative responses to the skin condition. Similarly, the fact that people 
with alopecia were significantly slower to name the color of the ink of hair-related 
words than the ink color of other word categories suggests that they might suffer from 
a disease-related attentional bias.
The task we used to assess behavioral avoidance consisted of a symbolic form of 
approach-avoidance behavior, operationalized as joystick movements towards or away 
from the screen. This approach may be viewed by some as too artificial to represent 
real-life behavior; however previous research has shown that important cognitive and 
affective components of approach-avoidance behavior can be captured in how people 
respond to stimuli in computer-based tasks. Furthermore, these tasks have the advan-
tage of allowing more precise reaction time measurements of very fast processes that 
probably cannot be captured in real-world settings [39]. A research design incorporating 
virtual reality may be promising for future research, as it combines the ability to measure 
reactions precisely with an increased ‘real world’ experience [39].
The stigmatization-related biases found in patients with chronic skin conditions 
may have important clinical implications. Given that previous studies in other samples 
show that attention and avoidance biases may be successfully retrained [40-44], future 
research may examine paradigms in which patients with chronic skin conditions who 
experience high levels of perceived stigmatization and an avoidance bias towards dis-
gusted faces are trained to redirect their attention towards neutral or positive stimuli. 
A similar approach may be used to retrain an attention bias to disease-related words, 
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for example by using attention bias modification paradigms [45]. Future research 
should explore whether retraining these attention and avoidance biases is feasible, and 
whether this would subsequently lead to a reduction in perceived stigmatization and 
fear of negative evaluation.
TReaTMenT 2.0: InTeRneT-BaSed CognITIVe BehaVIoRal TReaTMenT
In light of the substantial psychological and psychosocial impact of chronic skin condi-
tions, psychological interventions that help patients with adjustment problems to cope 
with their condition and its consequences in daily life may be a valuable addition to 
regular dermatological care. However, research on psychological interventions for 
chronic skin conditions is scarce, and evidence-based interventions that have been 
implemented in clinical practice are largely unavailable. In order to help fill this gap in 
current literature, this thesis studied the potential of an innovative individually-tailored 
therapist-guided internet-based cognitive behavioral treatment (ICBT). A system-
atic evaluation of the overall effectiveness of previous studies on ICBT in patients with 
chronic somatic conditions is provided in Chapter 5, followed by an evaluation of the 
effectiveness (Chapter 6), and cost-effectiveness (Chapter 7) of an individually-tailored, 
therapist-guided ICBT intervention designed to reduce the impact of psoriasis in daily 
life.
effectiveness of guided ICBT for chronic somatic conditions: a meta-analysis
In order to assess the overall effectiveness of ICBT for patients with chronic somatic 
conditions, a meta-analysis was conducted of previous studies of guided ICBT interven-
tions. This was the first meta-analytic review providing a disease-transcending overview, 
examining overall effectiveness on broad domains of functioning of relevance to the 
majority of patients. The results showed that guided ICBT had overall small effects on 
generic psychological outcomes and small to large effects on disease-specific physical 
outcomes and outcomes relating to the impact of the condition on daily life. The gener-
ally low heterogeneity observed between studies for the outcomes included provided 
support for the validity of this overarching approach of examining broad domains of 
functioning in various patient populations. However, several limitations warrant discus-
sion. For example, as only 23 studies could be included and not all studies used the 
same outcomes, the number of comparisons contained in each analysis was typically 
small. As the analyses compared effect sizes based on various outcome measures (e.g., 
standardized scores on various measures of depressive symptoms), and were based on 
different samples (e.g., various somatic conditions), we emphasize that these are broad 
estimates that should be further consolidated in future research.
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Individually-tailored and guided ICBT for psoriasis: a randomized controlled 
trial
The overall beneficial effects of guided ICBT for patients with chronic somatic conditions 
suggest that this may also be a feasible approach for patients with chronic skin condi-
tions. However, no studies have been conducted in this patient group. We therefore con-
ducted a multicenter randomized controlled trial to examine the effectiveness (Chapter 
6), and cost-effectiveness (Chapter 7) of ICBT in patients with psoriasis. An important 
strength of these studies was that they were largely conducted in a clinical setting. This 
has the benefit of allowing an evaluation of whether a treatment works in real-world 
settings in routine daily practice. Given that randomized controlled trials (RCTs) are 
generally considered as the ‘gold standard’ providing the highest level of evidence, this 
trial design significantly contributes towards the establishment of evidence-based in-
terventions in patients with psoriasis, especially in light of the paucity of previous trials. 
Furthermore, the primary analyses included both post-treatment and 6-months follow-
up measurements, allowing a longer term evaluation of intervention effects. Lastly, as 
the effectiveness and cost-effectiveness of guided ICBT for patients with chronic skin 
conditions to date has not been examined, the economic evaluation had considerable 
added value. In the sections below, the effectiveness and cost-effectiveness of the inter-
vention will be discussed, as well as several aspects of the intervention.
effectiveness of tailored and guided ICBT for patients with psoriasis
Results of the RCT showed that individually-tailored therapist-guided ICBT was effective 
in improving physical functioning and reducing the impact of psoriasis on activities 
in daily life, but not in improving  psychological functioning, in patients with psoriasis 
screened for elevated levels of distress. Moderate to large within-group improvements 
were found on primary outcomes in the ICBT condition. However, the magnitude of 
between-group effects of ICBT compared to regular dermatological care was small. This 
was in line with our previous meta-analysis on effects of guided ICBT for chronic somatic 
conditions (Chapter 5), but contrasted with our expectation that tailored treatment 
might increase effect sizes. Several factors may have contributed to these findings. First 
and foremost, the fact that patients’ distress levels were relatively low, which is more 
elaborately discussed below, may have meant that there was limited room for improve-
ment. Second, patients in the care as usual (CAU) condition improved more than was 
expected, possibly due to regression to the mean and/or to the effects of dermatological 
treatment. Alternatively, the fact that patients received extra appointments for study 
assessments conducted by care professionals may have also played a role in terms of 
an attention effect that may explain improvements in the control group. Third, meth-
odological characteristics such as the clinical setting, the care as usual comparison 
condition, and the statistical analysis that included both post-treatment and 6 months 
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follow-up measurement in the same analysis have been associated with smaller effect 
sizes in previous literature [e.g., 46]. However, these study characteristics improve eco-
logical validity by representing longer-term effects in a real-world setting with a relevant 
comparison condition; therefore we consider these to be strengths of our study. Given 
these results, we conclude that ICBT may be beneficial for patients with psoriasis in 
terms of improving physical functioning and reducing the impact of the condition on 
daily activities.
Screening for elevated levels of distress
In order to select the target group for individually-tailored and therapist-guided ICBT, 
prior to trial inclusion patients were screened for heightened levels of distress [47-53]. 
As elevated baseline distress levels were shown to be associated with better psychologi-
cal treatment outcomes in other studies [54, 55], this group may benefit most from ICBT. 
Screening for distress in clinical practice and offering a tailored intervention to patients 
with elevated distress levels has the potential benefit of enhancing the timely identifica-
tion of both patients at risk and those with existing psychological problems. However, 
several aspects of the screening procedures applied warrant some more discussion.
First, although cut-off scores for elevated distress levels were based on previous 
research [50-52], there remains a risk that patients who score close to the cut-off scores 
may be classified incorrectly. This risk may have increased due to the fact that patients 
with a psychiatric diagnosis according to the Diagnostic and Statistical Manual of Mental 
Disorders [DSM-IV-TR; 56], and patients in current psychological treatment (i.e. patients 
generally characterized by high distress levels), were excluded prior to filling out screen-
ing questionnaires. Consequently, the majority of patients scored just above the cut-off 
boundaries and the selected target group for ICBT was relatively narrow and arguably 
limited in its generalizability. Second, in line with previous literature [57, 58], a subgroup 
of patients who screened positive at screening no longer fulfilled these criteria at base-
line. Third, despite their elevated levels of distress, the patients included had not sought 
prior psychological treatment. This subgroup of patients not previously identified except 
through current screening may be less adherent to treatment [58]. In a recent study, one 
third of patients with skin cancer were identified as in need of psychological care, but 
only 11.5% requested such support [47]; this illustrates that the need for support and 
desire for support do not necessarily correspond. It is likely that this, together with the 
relatively low levels of distress, dampened intervention effects, which were generally 
small in the current trial. It is therefore recommended that the results from this study 
be further substantiated in future research on the effects of tailored and guided ICBT 
in patients screened for higher levels of distress, taking into account patient needs and 
motivation. Conducting semi-structured interviews prior to study inclusion might help 
to ensure that ICBT is the best treatment choice for participants [59].
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Tailoring and therapist guidance in ICBT
Two important characteristics of our ICBT intervention were individual tailoring and 
therapist-guidance. Based on previous research, it was expected that adherence rates 
and effectiveness would benefit from both of these characteristics. In systematic reviews 
comparing guided and unguided ICBT interventions, both between and within stud-
ies, guided interventions typically show greater treatment effects [60-62] and greater 
adherence rates [61]. In our trial, in the evaluation questionnaires filled out by ICBT 
participants, personal contact with the therapist was consistently rated as one of the 
most positive elements of the intervention. Furthermore, the importance of therapist 
guidance was reflected in the association between the patient-therapist relationship 
and treatment results: a better working alliance at the beginning of treatment showed 
moderate associations with greater effects of treatment on physical and psychological 
functioning. Given that previous literature generally shows that working alliance ratings 
are very similar for online and face-to-face treatments [63, 64], the concern often raised 
by therapists that a therapeutic alliance may not develop well in online interventions 
seems unfounded. However, taking into account the mixed results of previous research 
regarding the predictive value of the working alliance for therapeutic outcomes [63, 64], 
it may be important for future research to identify moderators of alliance-outcome as-
sociations and further explore the specific aspects of the patient-therapist relationship 
that facilitate positive outcomes. The fact that the intervention was individually tailored 
sets it apart from most other, typically standardized, ICBT interventions.
The therapist in consultation with the patient chose one or more of five possible treat-
ment modules, based on the mutually determined treatment goals, and each module 
could be further tailored as the therapist selected those assignments most suitable 
for the individual patient. This offers important advantages, as it acknowledges and 
meets patient preferences, and treatment can be adapted according to each patient’s 
characteristics [59]. An individually-tailored therapist-guided intervention may fit well 
into a stepped care model of ICBT, starting with unguided ICBT for patients with mild 
adjustment problems, standardized guided ICBT for patients with moderate problems, 
and individually-tailored guided ICBT for patients with moderate, more complex, 
problems [59, 65], in which patients experience multiple problems in daily life and/
or comorbidity [66]. A tailored approach, including the ability to work on multiple 
individually-determined treatment goals, may be specifically relevant for patients with 
chronic somatic conditions, since these conditions typically affect multiple aspects of 
patients’ lives, including both physical and psychological functioning.
A recent review found moderate to large effects for tailored ICBT for anxiety and de-
pression [67], underlining the potential effectiveness of this approach. Our trial showed 
beneficial effects of individually-tailored ICBT compared to care as usual in patients 
with psoriasis, and a similar trial from our research group also showed beneficial effects 
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compared to care as usual in patients with rheumatoid arthritis [68]. These findings 
demonstrate the feasibility and potential effectiveness of this approach for patients with 
chronic somatic conditions. Future studies may focus on expanding the evidence base 
for individually-tailored treatments in these groups, for example by directly comparing 
the effectiveness of individually-tailored versus standardized treatments in order to 
show the added value of tailored treatments. Furthermore, the role of patient and thera-
pist preferences regarding the order of modules/assignments may be further explored, 
as well as the effects of different orders and combinations of modules in individually-
tailored ICBT in general, in order to optimize treatment procedures [69].
dropout in ICBT
Despite individual tailoring and therapist-guidance, ICBT adherence rates were not 
higher than what has been on average found in previous trials. A total of 26.2% of pa-
tients dropped out of the ICBT condition, compared to a median of 29% in our previous 
meta-analysis of ICBT for chronic somatic conditions (Chapter 5). This may be related 
to the relatively long intervention duration (i.e. an average of 25 weeks, compared to 6 
weeks in many other interventions [70]): longer interventions are typically associated 
with higher dropout rates [71]. Furthermore, the fact that participant recruitment was 
based on screening in regular dermatological care as compared to recruitment based on 
advertising in the community in many other studies may have led to a less intrinsically 
motivated sample. The majority of dropouts (i.e. 15.4% of patients) were non-starters. 
These patients dropped out before having seen the intervention; therefore, their 
decision to drop out could not have been related to intervention content. Reported 
reasons for dropout were largely unrelated to the intervention, such as occurrence of 
comorbidity. Future research should aim to find strategies to further reduce dropout 
rates in internet-based interventions, which show somewhat higher dropout rates than 
face-to-face interventions [72]. Therefore, it remains important to further investigate 
factors that are associated with adherence and outcomes. Results of our randomized 
controlled trial (Chapter 6) suggest that the degree to which patient and therapist agree 
on the tasks and goals of the treatment, as well as the affective bond between patient 
and therapist, are predictors of treatment outcomes in ICBT. Recent research further 
suggests that treatment credibility and intrinsic motivation are important factors in in-
creasing adherence [73]. In line with what is seen in studies of placebo effects, patients’ 
belief in the effectiveness of the treatment may have a strong effect on outcomes [74, 
75], and therefore it may be relevant to enhance treatment credibility and strengthen 
expectancy effects. Furthermore, we recommend focusing on what makes patients en-
gage in an ICBT intervention and which features best suit patient needs and preferences.
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Timing of ICBT
Recruitment strategies for the RCT in most centers entailed patients who attended the 
outpatient dermatology department being invited to participate. Consequently, pa-
tients were often selected when a dermatological treatment regimen was either started 
or adapted. Furthermore, as the typical duration of our study was one year, changes 
in medication use (e.g., switching from topical to systemic or biological medication) 
occurred frequently. New biological treatments, for example, can greatly reduce the 
severity of the condition and offer benefits beyond the skin, in terms of a reduction 
in psychological morbidity [76]. While the fact that average disease severity remained 
stable over the course of post-treatment and follow-up suggests that intervention 
effects were not related to decreases in disease severity, it may be recommended for 
future research and clinical practice to employ a strategy in which an ICBT interven-
tion is offered to patients who consistently display elevated levels of distress over time 
despite multiple visits to a dermatologist.
Cost-effectiveness of ICBT for patients with psoriasis
An economic evaluation from a societal perspective was conducted alongside the RCT. 
Results showed that the ICBT and CAU groups had similar costs and effects at post-treat-
ment and 6 month follow-up. Thus, in the overall study sample, in contrast to previous 
reviews showing that ICBT is cost-effective in a range of conditions [77-79], the ICBT in-
tervention could not be considered cost-effective in comparison to regular dermatologi-
cal care. Previously mentioned factors such as low baseline levels of distress and disease 
severity, intervention timing, care as usual comparison, and recruitment procedures, 
may have played a role in these findings. Another potential explanation may lie in the 
fact that the effects were assessed with the EQ-5D-3L. This generic questionnaire is the 
most frequently used measure in cost-effectiveness analysis, and its advantages include 
the calculation of quality-adjusted life years (QALYs) that can be compared across trials 
and patient populations. However, this generic measure consists of broad dimensions, 
and with three answer categories per question, leaves limited room for nuance. Previous 
reviews suggest that it may not adequately measure disease-specific aspects of quality 
of life in patients with psoriasis [80] and that it shows limited responsiveness to change 
and ceiling effects across a range of conditions [81]. Considering that a ceiling effect was 
also observed in our study, and EQ-5D scores were already relatively high at baseline, 
there may have been limited room for improvement.
Subgroup analyses showed that ICBT may be cost-effective for two specific patient 
groups: those who experience relatively high self-assessed disease severity, and those 
who experience a relatively high burden of psoriasis in daily life. This gives a clear indica-
tion of patients for whom ICBT would be a cost-effective treatment strategy, suggesting 
that it may be clinically relevant to screen for higher levels of self-reported disease sever-
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ity and impact of psoriasis on daily life prior to ICBT, in order to offer cost-effective care. 
Both can be measured with brief self-report questionnaires [24, 82], which increases the 
feasibility of screening for these characteristics in clinical practice.
Clinical implications and implementation of ICBT
The positive results of the multicenter randomized controlled trial suggest that it may 
be beneficial to implement ICBT in clinical practice. The conditions for effective imple-
mentation of ICBT in the Netherlands are favorable: the Dutch government actively 
stimulates the implementation of internet-based interventions [83], and 94% of the 
Dutch adult population in general, and 82% of Dutch chronically ill individuals, report 
using the Internet [84]. The feasibility of offering ICBT to patients with chronic somatic 
conditions is supported by the results of one of our previous studies, which showed 
that patients with psoriasis and rheumatoid arthritis perceived more benefits than 
disadvantages of ICBT [85]. The relatively small number of non-completers (excluding 
non-starters) and overall positive intervention evaluations from ICBT participants in our 
RCT further illustrates that the intervention is feasible from the patient perspective. Fur-
thermore, use of internet-based interventions in primary care facilities is relatively high 
in the Netherlands: a recent study showed that online psychological self-management 
interventions are currently used by 49% of the mental health counselors in general 
practice [86].
Although future research should further evaluate the cost-effectiveness of ICBT in 
different samples, the current intervention was shown to be relatively inexpensive, and 
offering ICBT as an addition to regular care did not lead to significantly higher costs 
from a societal perspective. Future research may examine the effectiveness of this ICBT 
intervention in patients with a co-morbid mood disorder, representing a substantial 
proportion of the patient population, who were excluded from the current trial [e.g., 
1, 2, 87]. Various trials have shown that ICBT can be effective for patients with various 
DSM diagnoses [excluding severe cases; 59]. As tailored interventions may be especially 
suited for patients with more severe complaints [65], it seems feasible to develop an 
alternative screening procedure in which patients with co-morbid mood or anxiety 
disorders can participate. Furthermore, based on the findings of our cost-effectiveness 
study, focusing the ICBT intervention on a target population of patients who experience 
a relatively large burden of the skin condition on daily life, and/or who have a relatively 
high self-assessed disease severity may be both clinically relevant and cost-effective.
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fuTuRe dIReCTIonS In PSyChodeRMaTology
The aim of the studies presented in this thesis was to advance current knowledge on 
the assessment and treatment of the psychosocial impact of chronic skin conditions. 
Several remaining gaps in the literature that may be addressed in future research are 
highlighted in this section.
First, there is a relative lack of literature on potential risk and resilience factors for im-
paired physical and psychological functioning in patients with chronic skin conditions. 
Previous psychodermatological studies have mainly focused on examining the level of 
impaired psychological functioning in patients with chronic skin conditions [e.g., 1, 2, 
87-91]. However, it remains unclear which characteristics are associated with greater risk 
for impaired psychological and physical functioning in this patient group. In this thesis, 
aspects of body awareness and stigmatization were found to be related to impairments 
in physical and psychological functioning; this suggests that the presence of these 
aspects (e.g., not recognizing bodily signals and/or ignoring them, or high levels of 
perceived stigmatization) may be a risk factor for impaired functioning in patients with 
psoriasis. These and other possible risk factors, such as dysfunctional coping strategies, 
maladaptive illness cognitions, and disease-related implicit biases, should be explored 
further in longitudinal studies in diverse chronic skin conditions, in order to shed more 
light on potential risk groups and develop evidence-based tailored interventions that 
take these characteristics into account.
Second, future research could further explore the assessment and clinical relevance 
of implicit biases in chronic skin conditions. In our study on implicit stigmatization-
related biases in chronic skin conditions, we focused on two types of cognitive biases: 
attention and approach-avoidance biases. However, cognitive bias can also occur for 
memory and interpretation, and it may be hypothesized that stigmatized groups such 
as patients with chronic skin conditions show memory and interpretation biases for 
socially threatening stimuli. For example, stigmatized patients may recall stimuli related 
to social threat more easily than other stimuli, and may interpret ambiguous stimuli 
as socially threatening. These and other potential biases in patients with chronic skin 
conditions could be further explored. Furthermore, possibilities for clinical applications 
to target these cognitive biases should be examined. Potentially, ICBT interventions 
may be augmented with online cognitive bias modification modules [CBM; 92, 93] to 
target the implicit biases in patients with chronic skin conditions that were observed in 
Chapter 4. Promising effects of CBM programs on reducing implicit bias and improving 
physical and psychological wellbeing have already been observed in other populations, 
including individuals suffering from pain and social anxiety [40-44]. However, remaining 
questions about the methodological quality of some of the earlier studies on cognitive 
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bias modification [94, 95] highlight the need to examine how these interventions may 
be optimized and for whom and under which circumstances they may be effective.
Third, the overall effectiveness of psychodermatological treatments should be further 
examined. Although the first studies to examine the effects of psychological interven-
tions in chronic skin conditions date from over three decades ago [for an overview see: 
96], current evidence of the effects of such interventions is still thin due to the very 
small number of studies [e.g., 97]. Our RCT advances knowledge in this field by, for the 
first time, examining the effectiveness of individually-tailored and therapist-guided ICBT 
in patients with psoriasis, and showing that it can be effective in improving physical 
functioning and reducing the impact of psoriasis on daily activities. Given that the 
intervention was found to be cost-effective specifically in patients who experience a 
larger impact of the condition on daily life and those with higher self-reported disease 
severity, the results may be further substantiated by trials that examine the effects for 
these subgroups in particular. Furthermore, future research may examine the effects of 
individually-tailored guided ICBT in patients with more elevated levels of distress, since 
distress levels were relatively low in our sample. Last, it may be interesting to directly 
compare the effects for patients with a recent compared to a long-standing diagnosis, 
as well as for individually-tailored versus standardized treatments.
A potential way to augment (I)CBT interventions is to combine them with elements 
of serious gaming. In light of previous research indicating the potential and effective-
ness of serious games to promote health and showing that interest and enjoyment are 
important factors in increasing use of online interventions [e.g., 98, 99-101], the addition 
of serious gaming elements may promote both the adherence to and the effectiveness 
of internet-based interventions. Furthermore, based on research on dual-process mod-
els [102], there may be much to gain by combining interventions directed at changing 
cognitions and behavior on an explicit level (e.g., CBT-based interventions) with serious 
gaming intervention elements designed to influence implicit processes by incorporat-
ing principles of attention bias modification and approach-avoidance training. Future 
research could examine whether these innovative multimodal intervention combina-
tions may result in synergistic treatment effects.
Furthermore, effectiveness of current psychodermatological interventions may 
be further enhanced by exploring new fields of application. While current interven-
tions typically aim to improve physical and psychological outcomes, the potential of 
psychodermatological interventions to improve pharmacological outcomes remains 
relatively unexplored. A considerable number of patients with psoriasis are on systemic 
treatments, which can be highly expensive (e.g., biological treatments) and can  cause 
significant side effects [103]. Psychodermatological (internet-based) interventions may 
be developed that incorporate pharmacological conditioning combined with expec-
tancy training with the aim of enhancing pharmacological effects. Previous research in 
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relation to other conditions has suggested that a combination of automatic (e.g., con-
ditioning) and conscious (e.g., verbal or written suggestions) expectancy training may 
be able to decrease pharmacological doses while maintaining treatment effects [e.g., 
104-107]. These applications remain relatively unexplored in patients with dermatologi-
cal conditions and may hold considerable promise for reducing medication costs and 
improving patient wellbeing.
Last, several focus points for research on ICBT in general can be identified. While 
the efficacy and effectiveness of ICBT has been shown across a range of mental and 
physical health conditions [e.g., 59], the evidence  for cost-effectiveness of ICBT is much 
more scarce [77-79] and needs to be further established. Furthermore, relatively little 
is known about predictors, moderators, and mediators of treatment outcomes. In the 
current study, the therapeutic alliance at the beginning of treatment was associated 
with change in two out of the three primary outcomes, suggesting that this alliance 
may be a predictor of treatment success in tailored and guided ICBT. The specific cogni-
tive behavioral mechanisms causing therapeutic changes in health outcomes need to 
be further explored. Most ICBT interventions consist of a broad range of intervention 
elements, which complicates the study of working mechanisms and effective interven-
tion ingredients. Dismantling studies may shed more light on specific mechanisms 
of change, for example by comparing the effects of interventions with and without 
selected key characteristics. Once more has been learned about the mechanisms of 
change and moderating factors, it will become possible to better predict treatment 
success and provide a clear answer to the question of which clients are most suitable 
for internet-based treatment and what works for whom. A final focus point for research 
could be to conduct studies on the effects of integrating ICBT into routine care, given 
that there is substantial and accumulating evidence for its effects in various physical and 
mental health populations [e.g., 70, 108, 109-112].
ConCluSIonS
The overall results of this thesis highlight aspects of the psychosocial burden of chronic 
skin conditions such as psoriasis that have remained relatively unexplored to date. Fur-
thermore, they demonstrate that guided ICBT can be effective in reducing this burden 
as well as cost-effective for specific patient groups. Future studies may build upon these 
findings to further enlarge our understanding of implicit and explicit processes related 
to the psychosocial burden of dermatological conditions, and of how this burden may 
be decreased by optimizing current psychodermatological interventions and imple-
menting them in clinical practice. Three main conclusions can be drawn from this thesis:
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1. New concepts in psychodermatology, in particular aspects of body awareness, are 
of relevance for physical and psychological functioning in patients with chronic skin 
conditions. Specifically the aspect of not recognizing or ignoring bodily signals is 
related to impaired physical and psychological functioning in patients with psoriasis.
2. A large proportion of patients with psoriasis feels stigmatized, the extent of which 
can be predicted by sociodemographic, disease-related, and personality characteris-
tics. New assessment methods in psychodermatology demonstrated that the experi-
ence of stigmatization may also affect patients with chronic skin conditions (and 
their significant others) on an automatic, non-conscious level, as demonstrated by 
the specific implicit attentional and behavioral stigmatization-related biases found 
in these groups.
3. New psychological treatments, specifically therapist-guided ICBT, were found to be 
effective for patients with chronic somatic conditions. Individually-tailored therapist-
guided ICBT was shown to be effective in improving the physical functioning and 
reducing the impact of psoriasis on the daily activities of patients with the condition. 
Despite a general lack of cost-effectiveness of this intervention, it was found to be 
cost-effective for clinically relevant subgroups of patients with higher self-reported 
disease severity and a greater experienced impact of the skin condition on daily life.
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Chronische huidaandoeningen komen veel voor en gaan regelmatig gepaard met een 
grote invloed op het dagelijks leven van patiënten, zoals beperkingen in het psycholo-
gisch en lichamelijk functioneren. Deze gevolgen van een chronische huidaandoening 
kunnen ook een belangrijke rol spelen in de verergering van de huidaandoening. 
Hoewel de rol van psychologische factoren bij chronische huidaandoeningen steeds 
meer erkend wordt, is er tot nu toe nog maar relatief weinig onderzoek verricht naar 
psychologische factoren die van invloed zijn op chronische huidaandoeningen. Ook 
zijn er nog maar weinig psychologische behandelingen voor deze patiëntgroepen 
onderzocht. Het vakgebied binnen het wetenschappelijk onderzoek en de klinische 
praktijk dat zich bezighoudt met het complexe samenspel van psychologische factoren 
en de huid wordt psychodermatologie genoemd. Dit proefschrift heeft als doel om een 
bijdrage te leveren aan het vakgebied van de psychodermatologie, door wetenschap-
pelijk onderzoek gericht op 1) nieuwe concepten binnen de psychodermatologie, zoals 
lichaamsbewustzijn; 2) nieuwe methoden binnen de psychodermatologie, zoals het 
gebruik van zowel directe en indirecte methoden bij het meten van stigmatisatie en 3) 
nieuwe psychologische behandelmethoden binnen de psychodermatologie, zoals de 
(kosten)effectiviteit van een door een coach begeleide online cognitief gedragsthera-
peutische behandeling. Het overgrote deel van de studies in dit proefschrift is uitge-
voerd bij patiënten met psoriasis, als illustratief voorbeeld van een veelvoorkomende 
chronische inflammatoire huidaandoening.
deel I. ConCePTen 2.0: de Rol Van lIChaaMSBewuSTzIjn BIj 
ChRonISChe huIdaandoenIngen
In hoofdstuk 2 onderzochten we de potentiële rol van lichaamsbewustzijn bij patiënten 
met psoriasis. Omdat zelfzorg van groot belang is bij de behandeling van veel huidaan-
doeningen, zoals psoriasis, wordt over het algemeen van patiënten verwacht dat zij een 
actieve rol spelen bij de behandeling van hun aandoening. Dit zou erop kunnen duiden 
dat lichaamsbewustzijn met name van belang kan zijn bij psoriasis, wat nog niet was 
onderzocht. We ontwikkelden een nieuwe vragenlijst om lichaamsbewustzijn te meten: 
de Body Attention, Ignorance and Awareness Scale (BAIAS). De resultaten lieten zien dat 
deze vragenlijst op een betrouwbare wijze drie aspecten van lichaamsbewustzijn kan 
meten: 1) het zich bewust zijn van lichamelijke signalen en hier aandacht aan schenken 
(Aandacht); 2) het door de persoon ervaren belang en attitude ten aanzien van lichaams-
bewustzijn (Bewustzijn); 3) het niet herkennen en/of negeren van lichamelijke signalen 
(Ignoreren). Het onderzoek naar verbanden van lichaamsbewustzijn met lichamelijk 
en psychologisch functioneren liet zien dat met name de subschaal Ignoreren samen-
hing met verminderd functioneren. Omdat verminderd psychologisch functioneren 
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een negatieve invloed kan hebben op behandeluitkomsten, kan het daarom klinisch 
relevant zijn om lichaamsbewustzijn in kaart te brengen bij patiënten met chronische 
huidaandoeningen.
deel II. MeThoden 2.0: exPlICIeTe en IMPlICIeTe MeThoden oM eRVaRen 
STIgMaTISaTIe Te MeTen
In hoofdstuk 3 en 4 werd stigmatisatie onderzocht door verschillende expliciete en 
impliciete methoden via vragenlijsten (hoofdstuk 3) en computertaken (hoofdstuk 4).
In hoofdstuk 3 werden voorspellers van ervaren stigmatisatie onderzocht via zelf-
rapportagevragenlijsten bij patiënten met psoriasis. In dit onderzoek vulden patiënten 
vragenlijsten in waarmee ervaren stigmatisatie gemeten werd, naast vragenlijsten over 
5 soorten mogelijke voorspellers van ervaren stigmatisatie: sociaal-demografische va-
riabelen (bijv. leeftijd en geslacht), ziekte-gerelateerde variabelen (bijv. ziekte-ernst en 
ziekteduur), persoonlijkheidsvariabelen (bijv. een hogere score op aspecten van de type 
D persoonlijkheid, waarbij mensen de neiging hebben om negatieve emoties te ervaren 
en emoties niet gemakkelijk kunnen uiten in hun sociale omgeving), ziektecognities 
(bijv. acceptatie van de aandoening en hulpeloosheid ten opzichte van de aandoening) 
en sociale steun variabelen (bijv. het aantal goede vrienden dat iemand aangeeft te heb-
ben en de mate waarin iemand sociale steun ervaart). De resultaten lieten zien dat 73% 
van de patiënten zich in meer of mindere mate gestigmatiseerd voelde. Ervaren stig-
matisatie werd met name voorspeld door sociaal-demografische, ziekte-gerelateerde 
en persoonlijkheidsvariabelen. Deze resultaten kunnen mogelijk gebruikt worden voor 
de ontwikkeling van screeningsinstrumenten en effectieve interventies, aangezien 
hiermee aanwijzingen kunnen worden verkregen over welke patiënten kwetsbaar zijn 
voor ervaren stigmatisatie.
In hoofdstuk 4 werd onderzocht in hoeverre patiënten met huidaandoeningen, en 
hun naasten, vertekeningen laten zien in hoe ze reageren op stimuli die met ervaren 
stigmatisatie te maken hebben. We maakten gebruik van computertaken om reactietij-
den te meten terwijl patiënten met alopecia en psoriasis reageerden op stimuli die te 
maken hadden met huidaandoeningen en sociale dreiging. In een aangepaste Stroop 
taak werden deelnemers onder andere ziekte-gerelateerde woorden (bijv. schilfers of 
haaruitval) en neutrale woorden (bijv. deurknop of fluitketel) aangeboden, waarbij de 
woorden in verschillende kleuren werden weergegeven. Uit de resultaten bleek dat pa-
tiënten met alopecia langzamer reageerden dan mensen zonder huidaandoeningen in 
het benoemen van de kleuren van ziekte-gerelateerde woorden dan in het benoemen 
van de kleuren van neutrale woorden. Deze vertekening in de aandacht voor ziekte-
gerelateerde stimuli werd ook gevonden bij hun naasten. Bij patiënten met psoriasis en 
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hun naasten werd dit niet gevonden. Bij deze groepen werd echter wel een vertekening 
in hun reacties gevonden met behulp van een computertaak waarbij zij werden ge-
vraagd om met een joystick foto’s van gezichten met verschillende gezichtsuitdrukkin-
gen te benaderen of te vermijden. De resultaten lieten zien dat patiënten met psoriasis 
vooral de foto’s van gezichten met een walgende gezichtsuitdrukking sneller vermeden, 
vergeleken met mensen zonder huidaandoening. Deze vertekening werd ook gevonden 
in hun naasten. De resultaten duiden erop dat impliciete ervaringen van stigmatisatie 
mogelijk verschillen tussen huidaandoeningen, waarbij mensen met psoriasis meer 
beïnvloed worden door sociale reacties (met name walgende gezichtsuitdrukkingen) 
en mensen met alopecia door ziekte-gerelateerde signalen. Daarnaast suggereerden 
de resultaten dat deze vertekeningen ook van toepassing zijn op de naasten van deze 
patiënten.
deel III. BehandelIng 2.0: CognITIeVe gedRagSTheRaPIe aangeBoden 
VIa InTeRneT
In Hoofdstuk 5, 6 en 7 van dit proefschrift werd de effectiviteit en kosteneffectiviteit van 
cognitieve gedragstherapie aangeboden via het internet (eCGT) onderzocht met be-
trekking tot het verminderen van de invloed van chronische lichamelijke aandoeningen 
(in het bijzonder psoriasis) op het dagelijks leven.
In hoofdstuk 5 werd een overzicht gegeven van de huidige stand van zaken in het on-
derzoek naar de effectiviteit van begeleide eCGT behandelingen bij volwassen patiënten 
met een chronische lichamelijke aandoening. In totaal werden er 23 gerandomiseerde 
gecontroleerde studies opgenomen in deze review en meta-analyse. Op basis van de 
samengevoegde resultaten van deze individuele studies werd de overkoepelende effec-
tiviteit berekend voor drie soorten uitkomstmaten: algemene psychologische uitkomst-
maten (bijv. angstklachten en depressieve klachten), lichamelijke uitkomstmaten (bijv. 
pijn en vermoeidheid) en uitkomstmaten ten aanzien van de invloed van de aandoening 
op het dagelijks leven (bijv. ziekte-gerelateerde kwaliteit van leven). De resultaten lieten 
zien dat begeleide eCGT kleine effecten had op de algemene psychologische uitkomst-
maten en kleine tot grote effecten had op lichamelijke uitkostmaten en de invloed 
van de aandoening op het dagelijks leven. Daarnaast lieten de resultaten zien dat een 
langere eCGT behandelduur samenhing met grotere effecten op depressieve klachten. 
Toekomstig onderzoek in afzonderlijke chronische lichamelijke aandoeningen is nodig 
om deze resultaten verder te ondersteunen, gezien dit overzichtsartikel gebaseerd was 
op een relatief klein aantal studies.
In hoofdstuk 6 werden de resultaten beschreven van een studie waarin de effectivi-
teit van een begeleide eCGT behandeling op maat werd onderzocht bij patiënten met 
212 Samenvatting
psoriasis. Bij deze patiënten was met behulp van vragenlijsten vastgesteld dat zij een 
psychologisch risicoprofiel hadden, bestaand uit een verhoogd distress niveau. De deel-
nemende patiënten werden op basis van kans toegewezen aan ofwel de groep die eGCT 
ontving als aanvulling op de normale dermatologische zorg, ofwel aan de groep die al-
leen de normale dermatologische zorg ontving. Nadat er gecontroleerd werd voor rele-
vante variabelen (bijv. ziekte-ernst en medicatiegebruik) liet de eCGT groep een grotere 
verbetering zien in het lichamelijke functioneren (jeuk en vermoeidheid) en de invloed 
van de aandoening op het dagelijks leven (rolbeperkingen ten gevolge van emotionele 
en lichamelijke problemen). Er werden geen verschillen tussen de twee groepen ge-
vonden op het gebied van psychologisch functioneren (angstklachten en depressieve 
klachten), noch in de secundaire uitkomstmaten ziekte-ernst en therapietrouw bij de 
dermatologische behandeling. De relatie tussen therapeut en patiënt, gemeten aan het 
begin van de eCGT behandeling, bleek voorspellend te zijn voor verbeteringen in het 
lichamelijk en psychologisch functioneren. Dit onderstreept het belang van een goede 
therapeutische relatie in gepersonaliseerde eCGT behandelingen.
Als laatste werd in hoofdstuk 7 de kosteneffectiviteit van begeleide eCGT behande-
ling op maat onderzocht bij patiënten met psoriasis, door middel van een economische 
evaluatie die gelijktijdig werd uitgevoerd met de effectstudie. In deze economische eva-
luatie werden de maatschappelijke kosten van de twee onderzoeksgroepen (begeleide 
eCGT behandeling op maat versus alleen de normale dermatologische zorg) afgezet 
tegen de verkregen verbetering in ziekte-gerelateerde kwaliteit van leven in beide groe-
pen gemeten tot 6 maanden na de eCGT behandeling. De kosten die in dit onderzoek 
in kaart werden gebracht waren bijvoorbeeld de kosten voor de ontwikkeling en het 
onderhoud van de eCGT behandeling, de kosten voor zorgverbruik van de deelnemers 
en de kosten door ziekteverzuim. De resultaten lieten zien dat begeleide eCGT op maat 
voor patiënten met psoriasis niet kosteneffectief bleek te zijn in de gehele steekproef, 
maar wel kosteneffectief was voor twee specifieke patiëntgroepen: patiënten met rela-
tief hoge zelf-gerapporteerde ziekte-ernst en patiënten die een relatief hoge invloed 
van de aandoening op het dagelijks leven ervaren. Deze resultaten geven aan dat het 
mogelijk klinisch relevant kan zijn om deze kenmerken bij patiënten in kaart te brengen 
voorafgaand aan de eCGT behandeling, om kosteneffectieve zorg aan te kunnen bieden 
aan deze groepen.
De studies uit dit proefschrift onderstrepen het belang van nog niet eerder onder-
zochte psychologische concepten bij chronische huidaandoeningen, zoals de relevantie 
van lichaamsbewustzijn en van impliciete processen gerelateerd aan stigmatisatie. 
Bovendien liet dit proefschrift voor het eerst zien dat begeleide eCGT op maat effectief 
kan zijn in het verminderen van de invloed van chronische huidaandoeningen op het 
dagelijks leven, en kosteneffectief kan zijn voor subgroepen van patiënten met een rela-
tief hoge zelf gerapporteerde ziekte-ernst en hoge ervaren invloed van de aandoening 
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op het dagelijks leven. Toekomstig onderzoek kan voortbouwen op de resultaten uit dit 
proefschrift om de psychodermatologische kennis te vergroten en hieraan gerelateerde 
interventies te optimaliseren voor implementatie in de klinische praktijk.
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2012-present
2013-present
2010-2012
2011-2012
2016
2016
1.0
1.0
0.2
1.0
1.0
0.1
0.1
TEACHING ACTIVITIES
e) Lecturing
-  Leiden University: Bachelor course ‘Perspective on Career Planning (POCP) – seminar 
teacher
-  Master course ‘Innovations in eHealth care’ – Lecture on eHealth in cognitive rehabilitation
2015-2017
2015-2017
15.0
1.0
f) Supervision of internships / other
-  Thesis supervisor Master Health Psychology, Radboud University. Thesis: The role of Type D 
personality in patients with psoriasis
-  Thesis supervisor Master Health Psychology, Radboud University. Thesis: De rol van 
automatische processen bij patiënten met psoriasis: een exploratief onderzoek.
-  Minor research Project supervisor Research Master Behavioral Science, Radboud University 
(3 students). Topic: implicit processes in patients with chronic skin conditions.
-  Thesis supervisor Master Clinical Neuropsychology (CNP), Leiden University. Thesis: Source 
monitoring and hallucinations in Parkinson’s disease
-  Thesis supervisor Master Clinical Neuropsychology (CNP), Leiden University (5 students). 
Thesis: The effect of watching masticatory videos on masticatory function, quality of life 
and cognitive ability of elderly people with dementia
-  Thesis supervisor Master Clinical Neuropsychology (CNP), Leiden University. Thesis: 
Exploring associations between attention bias and interpretation bias with anxiety in 
clinically anxious youth
-  Thesis supervisor Master Clinical Neuropsychology (CNP), Leiden University. Thesis: Will 
cerebellar transcranial direct current stimulation improve cognitive function?
2011
2012
2012
2015
2015-2016
2016
2016
1.0
1.0
1.5
1.0
5.0
1.0
1.0
TOTAL 64.25
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In de jaren waarin ik aan mijn proefschrift heb gewerkt zijn er vele mensen geweest die 
ik dankbaar ben voor hun bijdragen aan dit onderzoek en hun steun op wetenschap-
pelijk en op persoonlijk vlak.
Allereerst natuurlijk alle mensen met huidaandoeningen die geheel belangeloos 
hebben meegewerkt aan de onderzoeken die beschreven staan in dit proefschrift. Dit 
proefschrift was nooit tot stand gekomen als zij niet de moeite hadden genomen om de 
vele vragenlijsten in te vullen en de tijd hadden genomen voor extra bezoeken op de 
polikliniek en voor deelname aan de eHealth interventie.
Mijn speciale dank gaat uit naar mijn promoteren, Andrea Evers en Peter van de Kerk-
hof. Andrea, veel dank voor het vertrouwen dat je in me hebt gesteld, voor je betrokken-
heid, voor je inspirerende drive voor de wetenschap, voor je kritische blik, en voor alle 
kansen die je mij gegeven hebt. Ik ben erg dankbaar dat ik me onder jouw begeleiding 
heb kunnen ontwikkelen tot de onderzoeker die ik nu ben en ik heb in de afgelopen 
jaren ontzettend veel van je geleerd. Peter, veel dank voor jouw betrokkenheid bij dit 
onderzoek vanuit de dermatologie. Ik heb je immer aanwezige en aanstekelijke enthou-
siasme voor de psychodermatologie en voor dit onderzoek enorm gewaardeerd; zonder 
jouw inzet was dit onderzoek niet mogelijk geweest.
Mijn dank gaat tevens uit naar mijn copromotor, Henriët van Middendorp. Henriët, 
als begeleider was jij er altijd voor me, of het nu ging om grote of kleine dingen. Ik 
kwam steeds weer met hernieuwde energie uit een overleg met jou en jij leek overal een 
oplossing voor te hebben. Jouw humor, betrokkenheid, positiviteit, nauwkeurigheid, 
oplossingsgerichtheid en kritische blik heb ik de afgelopen jaren enorm gewaardeerd. 
Ik had me echt geen betere copromotor kunnen wensen, heel veel dank daarvoor!
Naast mijn promotoren en copromotor zijn er door de jaren heen veel mensen be-
trokken geweest bij de verschillende onderzoeken uit dit proefschrift. Naast de mensen 
die vanuit hun ervaring als patiënt hebben meegedaan als deelnemer in de studies be-
schreven in dit proefschrift, zijn er vier patiënten in het bijzonder die ik graag zou willen 
bedanken: Hen Ros, Mariëtte Tomas, Henk van Duijn en Ilse van Ee. Jullie hebben in je 
rol als patiënt-onderzoekspartner mijn onderzoek verrijkt door vanuit jullie perspectief 
als patiënt heel actief en betrokken mee te denken met verschillende aspecten van het 
onderzoek. Als onderzoeker zal ik nooit precies weten hoe het is om een aandoening als 
psoriasis of reumatoïde artritis te hebben, en jullie input is voor mij daarom van grote 
waarde geweest.
Graag wil ik mijn fijne collega’s uit Nijmegen bedanken die als eCoach-therapeuten 
onvermoeibaar en enthousiast alle patiënten uit mijn onderzoek online hebben bege-
leid in het kader van de eHealth behandelingen: Irene Vermeulen, Saskia Spillekom-van 
Koulil, Tamara Bremer, Els Garritsen, Alicia Wijnakker en Lieke Wirken. Ik ben jullie stuk 
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voor stuk erg dankbaar voor de goede therapeutische begeleiding van de patiënten in 
mijn onderzoek en voor de tijd die jullie gestoken hebben in de eindeloze registraties 
voor het onderzoek. Irene Vermeulen, als eCoach psychologe van het eerste uur, en 
Saskia Spillekom-van Koulil, die met haar passie voor de psychodermatologie en aan-
stekelijke enthousiasme onmisbaar is geweest binnen dit project, wil ik graag speciaal 
bedanken.
De werving van deelnemers voor de studie naar de (kosten-)effectiviteit van de 
eHealth interventie bij patiënten met psoriasis heeft plaatsgevonden in vier verschil-
lende ziekenhuizen, en dit was niet mogelijk geweest zonder de dermatologen en 
medewerkers die bereid waren om zich voor dit onderzoek in te zetten. Daarom wil 
ik graag de afdelingen Dermatologie van het Radboudumc, het Rijnstate ziekenhuis, 
ZGT Almelo en het Canisius-Wilhelmina Ziekenhuis bedanken voor hun medewerking. 
In het bijzonder wil ik Peter van de Kerkhof en Elke de Jong van het Radboudumc, 
Jurgen Smit en Tilly Ten Broeke van het Rijnstate ziekenhuis, Ilse Kroft van ZGT Almelo, 
en Manon Zeeuwen-Franssen van het Canisius-Wilhelmina Ziekenhuis bedanken, wiens 
inzet het voor mij mogelijk hebben gemaakt om deelnemers te includeren op deze 
vier afdelingen. Ook wil ik graag de Psoriasis Vereniging Nederland bedanken voor hun 
medewerking aan dit onderzoek.
Mijn dank gaat uit naar de onderzoeksverpleegkundigen van de afdeling Derma-
tologie van het Radboudumc, die alle patiënten die meededen aan de studie over de 
effectiviteit van eCGT meerdere keren gezien hebben om de ziekte-ernst te beoordelen: 
Marisol Kooijmans-Otero, Jessica Terwindt-Slob en Lisa Jacobs. De PASI metingen voor 
mijn onderzoek waren vaak een logistieke uitdaging, bedankt dat jullie dit alles mogelijk 
hebben gemaakt!
Er komt veel logistiek kijken bij het jarenlang verzamelen van data voor wetenschap-
pelijk onderzoek, en ik had dat niet alleen kunnen doen. Ik wil bij dezen dan ook graag 
alle studenten en onderzoeksassistenten bedanken die in de loop der jaren betrokken 
zijn geweest bij mijn onderzoeken, in het bijzonder Nina Koch, Milou Looijmans, en 
Kirsten Luizink, die eindeloos bezig zijn geweest met het telefonisch te woord staan van 
(mogelijke) deelnemers van mijn onderzoeken en het invoeren van vragenlijstboekjes. 
Veel dank daarvoor, dames! Verder wil ik graag Michiel Vogelaar bedanken voor de 
randomisatie van mijn onderzoekspatiënten, en Ria te Winkel-Slotboom voor haar 
ondersteuning en hulp bij het samenstellen van de vragenlijstboekjes.
Gedurende de jaren heb ik daarnaast van verschillende mensen waardevol advies 
gekregen dat bij heeft gedragen aan de studies in dit proefschrift. Ik wil Wietske Kievit 
graag bedanken voor haar fijne, nuchtere en praktische advies en hulp bij het doen van 
de kosten-effectiviteitsanalyses en Rogier Donders voor zijn enthousiaste uitleg over 
statistische analyses. Graag wil ik ook Joyce Maas, Eni Becker en Mike Rinck bedanken 
voor de fijne samenwerking en hun deskundige advies bij de studie naar impliciete 
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processen bij huidaandoeningen, en Tessel Galesloot voor haar hulp bij de werving van 
de gezonde controlegroep bij deze studie. Voor de dataverzameling in deze studie ben 
ik dank verschuldigd aan Elke Schoneveld, Hannah Niermann, Tijn Mommers, Anne de 
Bruijn, Nina Koch en Nina Zuurveen. Ook wil ik graag de Alopecia Vereniging bedanken 
voor hun medewerking aan dit onderzoek.
Graag wil ik Pfizer bedanken, die dit onderzoek financieel mede mogelijk heeft ge-
maakt, en met name Grietje Bruinsma als fijne en betrokken contactpersoon in de loop 
der jaren. Ik vond het een hele prettige samenwerking.
Frank, Joris en Daan van IPPZ/Karify, dankzij de samenwerking met jullie is de eCoach 
behandeling uitgegroeid tot het platform dat het nu geworden is, en nog steeds gaat de 
ontwikkeling van de eCoach door. Veel dank voor de fijne samenwerking.
Natuurlijk wil ik ook graag alle collega’s van de afdeling Medische Psychologie van 
het Radboudumc bedanken voor de leuke en gezellige jaren in Nijmegen, waar ik mijn 
proefschrift en onderzoekscarrière begon. Ik heb met veel plezier op MP gewerkt en 
kijk met positieve herinneringen terug op de vele gezellige uitjes, koffiepauzes, ESC 
overleggen, onderzoeksmeetings en congressen. In het bijzonder wil ik natuurlijk mijn 
collega-onderzoekers en kamergenootjes bedanken, voor de gezelligheid en het delen 
van alle grote en kleine dagelijkse ups en downs die het schrijven van een proefschrift 
met zich meebrengt. Ook de dames van het secretariaat, Helma, Nancy, Jacintha en 
Brenda, wil ik graag bedanken voor alle praktische ondersteuning door de jaren heen.
In 2013 maakte ik met enkele andere onderzoekers de overstap van het Radboudumc 
naar de Universiteit Leiden. Een spannende stap, maar gelukkig belandden we in een 
warm bad. Graag wil ik alle collega’s van de sectie Gezondheids-, Medische en Neuro-
psychologie bedanken, die ons destijds als ‘wijzen uit het oosten’ ontvangen hebben 
en gezamenlijk de nieuwe sectie vorm hebben gegeven tot een gezellige afdeling met 
een prettige sfeer waar ik me zeer thuis voel. In het bijzonder wil ik mijn roomie Yvette 
bedanken voor de gezelligheid op onze kamer, en natuurlijk de betreffende ‘wijzen uit 
het oosten’ waarmee ik vanaf de eerste jaren in Nijmegen tot de laatste jaren in Leiden 
dit hele promotieproces heb doorlopen. Ook alle collega-onderzoekers op mijn gang en 
daarbuiten wil ik bedanken voor de gezelligheid door de jaren heen.
Graag wil ik ook mijn lieve paranimfen bedanken, Maaike Ferwerda en Roos van der 
Vaart. Maaike, wij zijn in 2010 als partners in crime samen begonnen aan dit promotie-
avontuur. Omdat ons onderzoek heel soortgelijk begon en onze werkplekken tegenover 
elkaar waren, hebben we alle dagelijkse ups en downs met elkaar meegemaakt en ook 
veel voor elkaar betekend in de praktische uitvoering van onze projecten. Er is veel 
veranderd in de loop der jaren en inmiddels zien we elkaar helaas veel minder vaak. Des-
ondanks heb ik me altijd gesteund gevoeld door jou en hoop ik oprecht dat de toekomst 
je vele mooie dingen gaat brengen. Ik kijk uit naar de dag dat we ook jouw promotie 
gaan vieren! Roos, in de afgelopen jaren ben je uitgegroeid van een fijne collega naar 
222 Dankwoord
een lieve vriendin. Bedankt dat je er altijd bent om de grote en kleine dingen mee te de-
len. Van onderzoeksfrustraties tot dertigersdillema’s, na een gezellige en relativerende 
lunchwandeling met jou kon ik altijd weer met frisse moed aan de slag. Dankjewel voor 
je support de afgelopen jaren!
Ik wil natuurlijk ook mijn vrienden en (schoon)familie bedanken voor de interesse en 
steun die zij hebben getoond tijdens mijn promotieonderzoek, en ook vooral voor de 
broodnodige afleiding en balans, omdat er meer in het leven is dan een promotie. Zon-
der anderen te kort te willen doen wil ik een aantal mensen bij naam bedanken. Joyce en 
Susanne, voor alle theekransjes die wij in de loop der jaren met z’n drieën hebben gehad 
en alles wat we samen hebben gedeeld. Heerlijk om vriendinnen te hebben die als geen 
ander weten hoe het is om te promoveren en waarmee ik ook op persoonlijk vlak alles 
kan delen. Saskia en Melisa, veel dank voor 20 jaar vriendschap en elkaar steeds weer 
vinden, waar het leven ons ook brengt. Dames van de leesclub, bedankt dat jullie er 
tijdens de laatste loodjes van mijn proefschrift voor zorgden dat ik ook nog eens iets 
anders las dan onderzoeksartikelen. Papa, mama en Paul, wat ben ik blij met zulke fijne 
ouders en broer. Het betekent enorm veel voor mij dat jullie altijd voor me klaarstaan en 
me altijd zullen steunen in alles wat ik doe. Jullie hebben me mede gevormd tot hoe ik 
nu ben, en ik ben heel dankbaar voor alles wat jullie voor me hebben gedaan.
Mijn laatste woord van dank gaat natuurlijk uit naar jou, lieve Ruud. Een proefschrift 
schrijven kost veel tijd en van een partner soms veel geduld. Bedankt dat jij er altijd voor 
me bent en dat je me steunt in alles wat ik doe. Wat mijn dag ook brengt, de wetenschap 
dat ik elke avond bij jou thuis mag komen is voor mij het fijnste gevoel dat er is. Dit 
proefschrift markeert het einde van een belangrijk hoofdstuk in mijn leven en wij gaan 
nu samen een heel bijzonder nieuw hoofdstuk schrijven. Ik ben ontzettend trots op jou 
en prijs mezelf gelukkig dat ik mijn leven samen met jou mag delen.
Sylvia
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CuRRICuluM VITae
Sylvia van Beugen werd op 11 maart 1984 geboren te 
’s-Hertogenbosch. Zij groeide op in Hedel, een dorp 
nabij ’s-Hertogenbosch. Na het behalen van haar 
VWO diploma aan het ds. Pierson college in ’s-Herto-
genbosch, begon zij aan de studie psychologie aan 
de Universiteit van Tilburg. Ze koos voor de richting 
Psychologie en Gezondheid en behaalde in 2006 haar 
Bachelordiploma. Vervolgens rondde zij in 2009 twee 
Masteropleidingen aan de Universiteit van Tilburg af: 
de Master Psychologie en Geestelijke Gezondheid en 
de Research Master in de Medische Psychologie. Na 
voltooiing van haar opleiding werd zij in 2010 als juni-
or onderzoeker aangesteld op de afdeling Medische Psychologie van het Radboudumc. 
Daar verzamelde zij de data die ten grondslag lagen aan de hoofdstukken in dit proef-
schrift. In 2013 volgde zij haar promotor Professor Andrea Evers naar de Universiteit Lei-
den, alwaar zij als onderzoeker en docent werd aangesteld bij de sectie Gezondheids-, 
Medische en Neuropsychologie. Aan de Universiteit Leiden rondde zij haar proefschrift 
af en gaf zij onderwijs in de Bachelor- en Masteropleiding Psychologie. Gedurende haar 
promotieonderzoek maakte zij deel uit van het dagelijks bestuur van de Netherlands 
Society for Research on Internet Interventions (NSRII) en de Werkgroep eHealth in 
Behavioral Medicine (eHBM). Zij heeft tijdens haar promotieonderzoek verschillende 
presentaties (o.a. op uitnodiging) verzorgd op nationale en internationale congressen. 
In 2013 ontving zij tijdens het congres van de European Society for Dermatology and 
Psychiatry de Essay Prize voor haar onderzoek over impliciete stigmatisatie-gerelateerde 
processen bij patiënten met huidaandoeningen (Hoofdstuk 4 van dit proefschrift) en in 
2016 ontving zij de Herman Musaph Stichting Literatuurprijs voor haar publicatie over 
lichaamsbewustzijn bij patiënten met psoriasis (Hoofdstuk 2 van dit proefschrift). Haar 
promotieonderzoek maakte deel uit van de Nederlands-Vlaamse onderzoeksschool 
Experimentele Psychopathologie (EPP) en van de onderzoeksschool Radboud Institute 
for Health Sciences (RIHS). Momenteel werkt Sylvia van Beugen als onderzoeker bij de 
sectie Gezondheids-, Medische en Neuropsychologie van de Universiteit Leiden aan een 
onderzoeksproject gericht op de doorontwikkeling van een serious gaming en eHealth 
interventie voor zowel gezonde als chronisch zieke populaties (ERC Proof of Concept 
Grant). Ook is zij docent in de Bachelor- en Masteropleiding Psychologie bij de sectie 
Gezondheids-, Medische en Neuropsychologie aan de Universiteit Leiden.
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